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Abstract
Glaucoma is the second leading cause of vision loss in the world. In the commonest 
form of the disease, chronic open angle glaucoma, increased intraocular pressure 
(IOP) is associated with accelerated death of retinal ganglion cells (RGCs) and 
consequent loss of visual field. Currently, there is no treatment to recover lost vision. 
If surviving tissue could be regenerated on the basis of its plasticity in glaucomatous 
eye, visual impairment associated with glaucoma might be potentially reversed. The 
project was to determine if RGC remodelling in glaucoma might be driven by 
combined IOP reduction and manipulation of retinal perineuronal nets to form a 
neural substrate for the recovery of vision loss in glaucoma
The purpose of the initial part of the study was to establish an in vitro model of
glaucoma such as retinal explant culture to analyse morphological changes of RGCs 
over a period of time. Biolistic transfection of retinal explant culture has been 
optimised to study remodelling of adult RGCs in vitro. Broad-spectrum caspase 
inhibitor enhanced RGC survival and axonal regrowth while exogenous BDNF 
enhanced the number of growth cones on the axons of RGCs.
The main part of the project was conducted using two rat glaucoma models, induced
by either injection of hypertonic saline into the episcleral veins to sclerose the 
trabecular meshwork or paramagnetic microbeads into the anterior chamber (a novel 
technique). Optical coherence tomography (OCT) imaging enabled the observation of 
progressive glaucomatous changes in vivo and estimation of retinal nerve fibre layer 
thickness (RNFL). A significant reduction in RNFL thickness 17-32 days following 
induction of intraocular pressure was observed.
To investigate the possibility that the dendritic changes of RGCs in glaucoma could 
be reversed, chondroitinase ABC was injected into the rats’ eyes to promote RGCs 
regeneration in glaucoma by enzymatic digestion of PNN. The treatment of 
glaucomatous retinas with chondroitinase ABC resulted in a significant change in 
morphological parameters of RGCs compared to RGCs of non-treated glaucomatous 
eyes, suggesting that chABC promoted recovery of RGC dendritic tree in adult 
glaucomatous eyes.
Our study confirmed the existence of a perineuronal net in the rat retina and indicated 
that molecular weight distribution and immunohistochemical tissue localisation of 
glycosaminoglycans varied in young, old and glaucomatous rat retinas. 
Chondroitinase sulphate proteoglycans were mainly localised to the photoreceptor 
layer, while aggrecan core protein to the inner retina. Aggrecan was highly degraded 
in young, old and glaucomatous retinas.
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Chapter 1: Introduction
1.1. Glaucoma
1.1.1. Background
Glaucoma is a gradually progressive neuropathy that involves excavation of the optic 
disc and loss of retinal ganglion cells (RGCs) (Pease et al., 2000), leading to visual 
impairment and blindness. The disease is a leading clinical problem worldwide, being 
the second most common cause of blindness (Quigley, 1996; Thylefors et al., 1995). 
According to the World Health Organization (WHO), about 37 million people 
worldwide in 2002 were blind, with more than 82% of all blind people being 50 years 
or older (Resnikoff et al., 2004). Risk factors for glaucoma are usually associated with 
relatively high intraocular pressure (IOP), age and a genetic predisposition. Although 
lowering IOP often slows the development and the progression of the disease, it is not 
always possible to lower IOP to a harmless level (Libby et al., 2005). Furthermore, 
even lowering IOP does not always prevent the progression of the disease (AGIS- 
Investigators, 2000).
In the normal eye, aqueous humour is produced by the ciliary body and then flows 
into the posterior chamber and through the pupil into the anterior chamber. Aqueous 
leaves the eye through the trabecular meshwork, flowing into Schlemm’s canal and 
into episcleral veins. The balance between aqueous production inside the eye and its 
drainage out of the eye determines the intraocular pressure, which normally falls 
within a range of 10-21mmHg. However, it can be as low as OmmHg in hypotomy 
and can be over 70mmHg in severe glaucoma. A pressure of 20-30mmHg generally 
leads to progressive damage over many years, while a pressure of 40-50mmHg 
contributes to a rapid loss of vision (Khaw et al., 2004a).
1.1.2. Forms of glaucoma
The clinical forms of glaucoma have been classified as primary and secondary 
glaucomas. In primary glaucomas, the initiating event begins in the anterior chamber 
angle or conventional outflow pathway, without an apparent impact from other 
disorders. These types of glaucoma are bilateral and usually have a genetic basis 
(Ritch et al., 1989). The secondary glaucomas occur as an effect of a recognised
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predisposing condition. These conditions can be unilateral or bilateral, acquired or 
with a genetic basis (Ritch et al., 1989).
The primary glaucomas include primary open-angle glaucoma, primary-angle closure 
glaucoma, and primary congenital glaucoma. In primary open-angle glaucoma, there 
is an increased resistance to aqueous humour outflow in the trabecular meshwork or 
Schlemm’s canal (Ritch et al., 1989). Primary-angle closure glaucoma is characterised 
by apposition of the lens to the back of the iris which prevents the flow of aqueous 
from the posterior chamber to the anterior chamber (Khaw et al., 2004a). Primary 
congenital glaucoma is caused by incomplete development of the anterior chamber 
angle (Ritch et al., 1989).
The aetiologic classification of secondary glaucoma is based on the underlying factors 
that cause the elevated intraocular pressure. According to this classification, 
secondary glaucomas can be divided into conditions associated with: developmental 
disorders, ocular disease, systemic diseases and drugs, inflammation and trauma, and 
ocular surgery (Ritch et al., 1989).
1.1.3. Diagnostic aspects
The basic diagnostic evaluation of glaucoma consists of intraocular pressure 
measurement (tonometry) as well as morphological and functional studies of the eye. 
The main pathological findings in glaucoma are neuroretinal rim loss (which reflects 
loss of retinal ganglion cells), increased excavation of the papilla, nasal displacement 
of the vessels of the papilla, sharp bending of the vessels, and haemorrhages at the 
periphery of the papilla (Dietlein et al., 2009).
1.1.4. Research approaches to treatment
Current treatment for glaucoma is focussed on the reduction of IOP, which has been 
shown to be effective in preventing disease progression in ocular hypertension, 
primary open angle glaucoma and normal tension glaucoma. Glaucoma can be treated 
using pharmacological, laser and surgical intervention (Khaw et al., 2004b). Although 
there are treatments for lowering IOP, a lot of damage can occur before a patient
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presents and, in some cases, damage can be so extensive that the patients’ ability to 
carry out everyday activities are compromised. To date, treatments can only arrest 
glaucoma, although some groups are investigating ways to repair the damage. Present 
research in glaucoma management is focussed on three approaches: the development 
of new strategies to lower IOP, the administration of agents that can rescue damaged 
RGCs (neuroprotection) and optic nerve regeneration (Dahlmann-Noor et al., 2010).
Neuroprotection has been defined as treating disease by preventing neuronal death or 
deterioration (Levin 1999). With reference to glaucoma, neuroprotection is an 
intervention aimed at preventing the optic nerve damage and RGC death. This can be 
achieved by affecting cellular factors derived from the optic nerve itself or by 
eliminating extracellular risk factors (for instance, reducing IOP). However, the 
effectiveness of neuroprotective agents in the treatment of glaucoma has not been 
demonstrated (Sena et al., 2010). Recent clinical trials examining the safety and 
efficacy of oral memantine (Allergan) for glaucoma treatment did not show any 
significant benefit when compared to placebo-treated patients (Bessero, 2010).
Stem cell transplantation is currently being investigated as a potential therapeutic 
approach. An adult retinal explant organotypic tissue culture system has been studied 
as an in vitro intraocular stem cell transplantation model (Johnson and Martin, 2008). 
The transplantation of oligodendrocyte precursor cells and mesenchymal stem cells 
was shown to have a neuroprotective effect in a rat glaucoma model (Bull et al., 2009; 
Johnson et al., 2010). Apart from stem cell treatments that aim at prolonging RGC 
survival by providing neurotrophic factors, some stem and precursor cell studies 
investigate whether transplanted cells differentiate into RGC-like phenotypes, raising 
the possibility of improving vision. Similarly to stem cells, a spontaneously 
immortalised Muller cell line can migrate and differentiate into various retinal cell 
types (Lawrence et al., 2007; Limb et al., 2002). The migration of Muller cells into 
the RGC layer, following their transplantation into glaucomatous eyes, was promoted 
by modulating extracellular matrix with chondroitinase ABC and by controlling 
microglial reactivity with anti-inflammatory therapy (Bull et al., 2008; Singhal et al.,
2008).
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Another potential treatment approach is endogenous expression of neurotrophic 
factors. Transfection of growth factor genes into RGCs using viral vectors leads to a 
sustained increase in the endogenous expression of neurotrophic factors. Adeno- 
associated virus mediated expression of brain-derived neurotrophic factor (BDNF) 
(Martin et al., 2003) and ciliary neurotrophic factor (CNTF) (Leaver et al., 2006; 
Pease et al., 2009) demonstrated a protective effect of neurotrophic factor gene 
therapy in a model of glaucoma. Intravitreal injection of BDNF and glial cell line- 
derived neurotrophic factor (GDNF), followed by electroporation, also enhanced 
survival of RGCs (Ishikawa et al., 2005; Mo et al., 2002).
Direct injection of neurotrophic factors, such as BDNF, CNTF, NT-4, fibroblast 
growth factor (FGF-2) and neurturin, into the vitreous or optic nerve lesion sites 
prolonged RGC survival in vivo, and their exogenous application prolonged RGC 
survival in vitro (Parrilla-Reverter et al., 2009). Neuroprotectants, including nipradilol 
and T-588, were also effective against RGC damage in a glaucoma model (Karim et 
al., 2009; Maeda et al., 2004).
In addition to enhancing RGC survival, several growth factors have also been shown 
to promote axonal regrowth. Intravitreal injections of CNTF in vivo stimulated axonal 
regeneration (Cui and Harvey, 2000). Intravitreal injections of AAV to deliver FGF-2 
to RGCs enhanced axonal regrowth after axotomy (Sapieha et al., 2003). Neural-tube- 
derived embryonic stem cells from chicken supported regeneration of RGC axons 
within the rat optic nerve, involving astrocytic expression of the matrix 
metalloproteases (MMP)-2 and -14, digestion of chondroitin sulphate proteoglycans 
and secretion of trophic factors (Charalambous et al., 2008).
1.1.5. Current treatments
1.1.5.1. Effect of IOP reduction
The Early Manifest Glaucoma Trial (Leske et al., 2003), Ocular Hypertension 
Treatment Study (Kass et al., 2002) and Advanced Glaucoma Intervention Study 
(AGIS-Investigators, 2000) imply that there is a positive association between IOP 
level and the severity of glaucomatous injury. Moreover, they support the therapeutic
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efficacy of lowering IOP in reducing the rate of progression of glaucomatous field 
loss (AGIS-Investigators, 2000; Collaborative Normal-Tension Glaucoma Study, 
1998; Gordon et al., 2002; Kass et al., 2002; Leske et al., 2003; Nouri-Mahdavi et al., 
2004). Nevertheless, lowering of IOP by either surgery or drug therapy might not 
thoroughly prevent progression of visual field loss in all patients, which can even 
progress more rapidly in those with greater initial injury (Harbin et al., 1976; Leske et 
al., 2003; Schwartz et al., 2004).
1.1.5.2. Pharmacotherapy
There are two approaches to the medical reduction of intraocular pressure. The first 
approach is a reduction of the production of aqueous humor using beta-blockers 
(inhibition of the beta-mediated stimulation of Na+/K+-ATPase), carbonic anhydrase 
inhibitors or sympathomimetic drugs (activation of the alpha-mediated inhibition of 
Na+/K+-ATPase). Another method to reduce IOP is by increasing the outflow of 
aqueous humor with cholinergic/parasympathomimetic drugs and prostaglandin 
derivatives (trabecular meshwork), sympathomimetic drugs (uveoscleral outflow) or 
prostaglandin derivatives (uveoscleral outflow). According to the European Glaucoma 
Society (EGS) guidelines, prostaglandin analogs, beta-blockers, alpha-2 agonists, and 
topical carbonic anhydrase inhibitors are the recommended drugs (Dietlein et al.,
2009). Topical prostaglandin analogs (PGA) are among the more effective 
medications for lowering intraocular pressure, with reductions of 33% (van der Valk 
et al., 2005) and a 15% to 20% failure rate (Hedman et al., 2002).
Many types of treatment for glaucoma that do not lower the intraocular pressure are 
being investigated for prospective use mostly in patients with normal-pressure 
glaucoma. However, there is not sufficient evidence to support their use (Sycha et al.,
2003). Potential treatments include calcium antagonists (nimodipine, nifedipine) 
administered in low doses to patients with vasospastic manifestations (Tomita et al.,
1999) and mineralocorticosteroids (fludrocortisone) given in low doses to patients 
with marked arterial hypotension (Gugleta et al., 1999).
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1.1.5.3. Surgery and laser techniques
Indications for surgical intervention include a progression of optic neuropathy or 
visual field defects in a patient with chronic open-angle glaucoma despite the 
administration of two or three topical treatments (Burr et al., 2005). A surgery might 
also be recommended if local therapy is required immediately but is not tolerated due 
to systemic or local side effects, or if the regular use of eye drops is not possible. 
Surgical procedures for glaucoma include trabeculectomy, goniotomy, implant 
surgery and iridectomy (Dietlein et al., 2009).
The purpose of cyclophotocoagulation is to decrease the inflow of aqueous humor by 
destroying the non-pigmented epithelial cells of the ciliary body that produce it. The 
ciliary body is coagulated with a laser, either from inside the eye, under endoscopic 
visualisation, or through the sclera without opening the globe (Dietlein et al., 2009). 
There are conflicting opinions about the value of this treatment among surgical 
ophthalmologists (Becker and Funk, 2001; Krott et al., 1997).
1.1.6. Mechanisms of RGC death in glaucoma
Previous evidence identifies apoptosis as a potential final pathway of RGC death in 
glaucoma (Kerrigan et al., 1997; Quigley, 1999; Quigley et al., 1995) and indicates 
that both pro- and anti-apoptotic (pro-survival) pathways are activated in experimental 
glaucoma (Levkovitch-Verbin et al., 2007). Apoptosis is a programmed cell death, 
characterised by chromatin condensation, cellular shrinkage, blebbing of the plasma 
membrane, DNA fragmentation, and ultimately intracellular fragmentation associated 
with the formation of apoptotic bodies (Kerr et al., 1972; Wyllie et al., 1984). Finally, 
cells undergo phagocytosis without inflammation, mediated by macrophages or 
surrounding tissue (Quigley et al., 1995). A number of mechanisms have been 
suggested to initiate RGC apoptosis in glaucoma, including neurotrophic factor 
deprivation, hypoperfusion, glial cell activation, glutamate excitoxicity and an 
abnormal immune response (Kuehn et al., 2005).
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1.1.6.1. Neurotrophic factor deprivation
Since axonal transport is essential to the normal functioning of neurons, retrograde 
transport of neurotrophins produced in the target organ may be necessary for RGC 
survival (Kuehn et al., 2005). According to the present hypothesis, the retrograde 
delivery of neurotrophic substances to RGCs is inhibited by pressure-induced axonal 
transport obstruction at the optic nerve head, resulting in apoptosis (Johnson et al.,
2000). However, it has been shown that neurotrophic factors such as BDNF can also 
be produced by RGCs, and their local intraretinal release influences the survival of 
RGCs in the rat (Spalding et al., 2005; von Bartheld et al., 1996; Wang et al., 2002). 
Neurotrophins involved in developmental apoptosis include: BDNF, nerve growth 
factor (NGF), neurotrophin-3, neurotrophin-4/5, neurotrophin-6 and neurotrophin-7. 
These neurotrophic factors can bind to two transmembrane receptor families, which 
may directly interact with each other. These include the Trk receptors within the 
tyrosine kinase family and the extracellular domain of the p75 neurotrophin receptor 
(Guerin et al., 2006).
A number of studies support the idea that neurotrophic deprivation is a cause of RGC 
death. BDNF delivery into the retina is significantly reduced in animal models of 
glaucoma (Kuehn et al., 2005; Pease et al., 2000; Quigley et al., 2000), while 
administration of BDNF into the rat eye with experimentally elevated IOP has been 
found to increase the number of rescued RGCs (Ko et al., 2001; Kuehn et al., 2005). 
In addition, the injection of ciliary neurotrophic factor (CNTF) in axotomised adult rat 
optic nerves caused partial survival of RGCs (Ji et al., 2004; van Adel et al., 2003).
1.1.6.2. Hypoperfusion
Two theories explaining glaucomatous optic neuropathy (GON) have been described: 
the mechanical and the vascular (Fechtner and Weinreb, 1994). The mechanical 
theory suggests that GON is a direct consequence of elevated IOP, causing damage to 
the lamina cribrosa and neural axons (Yan et al., 1994). According to the vascular 
theory of glaucoma, GON is caused by an insufficient blood supply to the optic nerve 
head due to vascular risk factors reducing ocular blood flow (OBL), including 
elevated IOP (Flammer et al., 2002). Since blood flow to the anterior optic nerve
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depends on perfusion pressure, increased IOP might obstruct the vascular supply to 
the optic nerve by contributing to elevated pressure in the optic nerve. Optic nerve 
ischaemia might also occur due to insufficient autoregulation of blood flow within the 
optic nerve in glaucoma (Flammer et al., 2002).
1.1.6.3. Glial cell activation
Another important factor contributing to RGC death in glaucoma is activation of glial 
cells. There are three types of glial cells in the mammalian retina including astrocytes, 
microglia and Muller cells (Kuehn et al., 2005). Retinal glial cells become activated in 
glaucoma, leading to the increased retinal expression of glial fibrillar acidic protein, 
an early event in the pathogenesis of glaucoma (Elizabeth et al., 2004; Wang et al., 
2000; Woldemussie et al., 2004). Since glial cells support neuronal functions, it is 
suggested that RGC death caused by the activation of glial cells might occur due to 
the reduced levels of glial support. Nevertheless, it might be possible that the 
activation of glial cells leads to the release of substances detrimental to RGCs, 
including cytokines, reactive oxygen species or nitric oxide (Tezel and Wax, 2000). It 
has been shown that mixed retinal glia cultures exposed to increased hydrostatic 
pressure release tumour necrosis factor alpha (TNF-a) (Tezel and Wax, 2000), an 
inducer of apoptotic cell death through TNF-a receptor-1 (p55) occupancy in a 
caspase-mediated pathway (Tezel et al., 2001; Tezel and Wax, 2000). According to 
the results obtained from immunohistochemical studies, TNF-a is produced by retinal 
glia in glaucoma and its receptor is present on RGCs (Tezel et al., 2001).
Apoptosis mediated by glial cells could also be caused by the enhanced synthesis of 
nitric oxide which affects synaptic plasticity, neurotransmitter release and regulation 
of vascular tone. Increased amounts of nitric oxide can cause cell death in RGCs and 
other various cell types (Dawson and Dawson, 1996; Morgan et al., 1999). In a rat 
model of experimentally induced glaucoma, excessive levels of the enzymes 
responsible for the production of nitric oxide have been observed in the optic nerve 
head (Shareef et al., 1999). RGC damage seemed to be reduced by the inhibited 
synthesis of nitric oxide in this model (Neufeld et al., 1999). However, in a different 
rat model, induced by hypertonic saline injection into the episcleral veins, inhibition 
of these enzymes did not protect RGCs (Morrison et al., 2005; Pang et al., 2005).
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There is evidence from immunohistochemical studies that elevated levels of nitric 
oxide synthase are present in the human glaucomatous nerve head (Neufeld et al., 
1997).
1.1.6.4. Glutamate toxicity
Glutamate is a main excitatory neurotransmitter in the retina, produced by presynaptic 
cells. The release of large amounts of glutamate leads to neuronal death in the process 
of excitotoxicity (Caprioli et al., 1996). Although increased glutamate levels have 
been observed in human patients suffering from glaucoma as well as in a primate 
model of glaucoma (Dreyer, 1998), it has not been confirmed by some other studies 
(Honkanen et al., 2003; Wamsley et al., 2005). Therefore, the role of glutamate 
toxicity in glaucoma remains uncertain. Recent studies have demonstrated resistance 
of RGCs to glutamate toxicity in the presence of neurotrophic factors (Ullian et al.,
2004), in contrast to the sensitivity of retinal amacrine cells to increased glutamate 
levels. It was suggested that the reduced numbers of RGCs followed by the glutamate 
administration might have been caused by a loss of amacrine cells and a lack of 
neurotrophic support for RGCs (Kuehn et al., 2005).
1.1.6.5. Abnormal immune response
A number of studies have suggested a role for humoral immune response in the 
pathogenesis of glaucoma (Schori et al., 2001; Wax, 2000). Autoantibodies directed 
against retinal antigens as well as optic nerve head proteoglycans have been observed 
in the sera of glaucoma patients (Tezel et al., 1999). Since one of the functions of 
proteoglycans is the creation of a spatial network for the support of the optic nerve 
and blood vessels, an immune response to proteoglycans might weaken the 
extracellular matrix supporting the lamina cribrosa, inducing or enhancing cupping of 
optic nerve head (Kuehn et al., 2005).
There are also reports that immunisation with copolymer-1 (COP-1) enhanced activity 
of T lymphocytes, which had neuroprotective effects on RGCs in animals subjected to 
optic nerve injury, glutamate excitotoxicity, and chronically elevated IOP (Kipnis et 
al., 2000; Schori et al., 2001; Schori et al., 2002). COP-1, a synthetic amino acid
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polymer, was shown to suppress autoimmune encephalomyelitis (EAE) induced by 
myelin basic protein (MBP) (Teitelbaum et al., 1971). Although the precise 
mechanism of neuroprotection induced by T cells is unknown, it has been suggested 
that an immune response to the degeneration of the optic nerve leads to the secondary 
degeneration of additional RGCs. However, the survival of surrounding cells could be 
caused by the presence of neurotrophins at the site of injury. Neurotrophic factors 
such as nerve growth factor, BDNF, neurotrophins 3, 4, and 5, are released by T cells 
accumulated at the site of injury and presented with specific antigen (Schwartz and 
Budenz, 2004). In addition, T cells activated by the use of low-dosage y-irradiation 
were found to have neuroprotective effects after glutamate excitotoxicity or optic 
nerve injury (Kipnis et al., 2004). Ultimately neuroprotection, caused possibly by the 
T cell-mediated immune response was observed after bone marrow transplantation 
and high-dose irradiation in a mouse model of hereditary pigmentary glaucoma 
(Anderson et al., 2005).
1.1.7. Morphology and function of RGCs
Several types of RGCs have been identified based on soma size and the architecture 
of the dendritic field in the primate retina: midget, parasol, small bistratified and 
wide-field cells (Dacey, 1993; Dacey and Petersen, 1992; Kolb et al., 1992; Perry and 
Cowey, 1981; Rodieck et al., 1985; Watanabe and Rodieck, 1989; Weber et al., 1998; 
Yamada et al., 2005).
Midget cells represent approximately 80% of the total population of ganglion cells in 
the primate retina. They are characterised by medium-sized somas and small- or 
medium-sized dendritic trees that are frequently formed from a single dendrite, which 
then forms a solid, bushy dendritic arbour (Figure 1.1 A). Midget cells project to the 
four dorsal, parvocellular layers of the lateral geniculate nucleus (LGN) (Dacey, 1993; 
Watanabe and Rodieck, 1989; Rodieck et al., 1985; Dacey & Petersen, 1992; Weber 
et al., 1998).
Parasol cells represent approximately 10% of the ganglion cells in the primate retina, 
with the largest somas and dendritic fields in the ganglion cell layer (Figure 1.1B).
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Their dendritic trees are frequently comprised of three or four thick primary dendrites 
forming an extremely symmetrical arbour. The axons of these neurons are generally 
larger compared to the axons of midget cells and project to the two ventral 
magnocellular layers of the LGN. In contrast to midget cells, parasol cells are 
characterised by large receptive fields with rapidly conducting axons, and they are 
most responsive to achromatic stimuli of high temporal and low spatial frequency 
(Rodieck et al., 1985; Dacey & Petersen, 1992; Weber et al., 1998).
Bistratified cells, similarly to midget cells, project to the parvocellular geniculate 
layers (Dacey, 1994) (Figure 1.2.A). Wide-field cells, heterogeneous cells with large 
dendritic arbours (Peterson and Dacey, 2000) (Figure 1.2B), project to the lateral 
geniculate nucleus, the superior colliculus, or the pretectum (Dacey et al., 2003).
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Figure 1.1. Confocal image showing the morphologic features (small soma and dendritic 
arbour) that characterize the normal midget cell, with arrowhead indicating intraretinal 
axon segment (A). Morphologic features that characterize the soma, dendritic field, and 
intraretinal axon segment (arrowhead) of a parasol cell in the normal retina (B). Scale bar: 
10 pm (A), 25 pm (B) (Weber et al., 1998).
Figure 1.2. Small bistratified cell (A). Wide field ganglion cell, classified as diffuse 
because their dendrites branch throughout the inner plexiform layer (IPL) (B). Scale bar: 
100 pm (Yamada et al., 2004).
1.1.7.1. Morphology and function of RGC in glaucoma
Weber et al. (1998) have observed that the earliest structural signs of glaucomatous 
neuropathy in RGCs, induced by the elevated IOP, involved changes at the level of 
the dendritic arbour, including a thinning of the proximal and distal dendrites, sudden 
reductions in dendritic process diameter at branch points, and reduced complexity of 
the cell’s dendritic tree (Figure 1.3). The changes at the level of the dendritic arbour 
preceded the reduction in axon diameter, while soma size was reduced simultaneously 
or later. These data clearly indicate a progressive process of RGC degeneration in 
glaucoma (Weber et al., 1998).
Some studies examining changes in axon diameter (Quigley et al., 1988), soma size 
(Glovinsky et al., 1991; Glovinsky et al., 1993) and neurofilament content (Vickers et 
al., 1995) in ganglion cells from glaucomatous eyes suggested that the most 
detrimental changes occur in large ganglion cells compared to other cell types. Data 
demonstrating the differential effects of chronically elevated IOP on neurons in the 
magnocellular and parvocellular layers of the LGN suggest that these large cells could 
be primarily parasol cells (Chaturvedi et al., 1993). This supports the hypothesis that 
the P- and M-pathways of the primate visual system are affected differentially by the 
disease, which might significantly contribute to the development of more sensitive 
psychophysical tests for the early detection of glaucoma (Ruiz-Ederra and Verkman,
2006). However, Weber et al. (1998) observed only subtle differences in the patterns 
and degrees of degenerative changes between midget and parasol cells in response to 
chronic elevation in IOP.
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Figure 1.3. Confocal image showing the morphologic features that characterize midget cell (A) and 
parasol cell (B) from glaucomatous eyes. Although the soma size o f the midget cell (A) is comparable 
to the soma size of the normal midget cell in Figure 1.2, its dendritic arbour is reduced and its axon is 
very thin compared with that o f other midget cells o f similar soma size. Arrowhead indicates 
intraretinal axon segment, while arrow indicates dendritic abnormalities. Scale bar, 10 pm (A) and 25 
pm (B) (Weber et al., 1998).
1.1.8. Models of experimental glaucoma
Our understanding of how the retina and optic nerve head respond in human glaucoma 
has been limited by the lack of non-invasive methods for assessing cellular responses 
in humans. Therefore, cellular function has to bo investigated using appropriate 
animal models. Most commonly used animal models of glaucoma are created by 
experimentally induced elevation of IOP, the only risk factor against which all 
glaucoma therapy is currently focussed. However, visual field progression occurs in 
some patients despite a clinically acceptable decline in IOP (Morrison et al., 2005). 
Although these models can be regarded as models of pressure-induced optic nerve 
damage rather than glaucoma models, it might be anticipated that knowledge of the 
mechanisms by which enhanced IOP causes optic nerve damage will be useful for 
understanding optic nerve damage in human glaucoma. This knowledge might then be 
applied to develop and examine specific therapies to preserve vision in glaucoma 
patients (Morrison et al., 2005).
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There are two types of chronically elevated IOP models, spontaneous and 
experimentally induced (Morrison et al., 2005). Naturally occurring models do not 
require experimental manipulations that might induce responses that could be wrongly 
recognised as responses to pressure (Morrison et al., 2005). Another benefit is that the 
onset of IOP occurs and builds up slowly. However, since the pressure elevation is 
usually bilateral in these models (Libby et al., 2005) they lack the built-in control of a 
normotensive contralateral eye. Moreover, it might be difficult to predict the time of 
pressure elevation, thus not allowing for the determination of early events in the 
damage process. In contrast to spontaneous models, experimental models provide the 
fellow eye as a control due to the unilateral elevation of IOP. Also, the timing of the 
IOP increase is usually straightforward to predict after the experimental manipulation, 
which enables determination of the sequence of events of retina and optic nerve 
damage as a result of increased IOP (Morrison et al., 2005).
There are three important issues that have to be considered with animal models of 
experimentally pressure-induced optic nerve damage. Firstly, developing techniques 
for measuring IOP should accurately reflect the level of pressure to which the optic 
nerve head and retina are exposed. Secondly, optic nerve damage is usually 
determined histologically and electrophysiologically and, in the case of non-human 
primates, by psychophysical methods. Finally, the best way to achieve a chronic 
increase in IOP is to obstruct aqueous humour outflow (Morrison et al., 2005).
1.1.8.1. Mouse model of glaucoma
Chronically elevated IOP in the mouse eye that contributes to the damage or loss of 
RGC and optic nerve axons can be induced either experimentally (Aihara et al., 2003; 
Grozdanic et al., 2003; Mabuchi et al., 2003; Ruiz-Ederra and Verkman, 2006) or can 
occur spontaneously in certain strains (Sheldon et al., 1995).
Various mouse models with genetic changes relevant to glaucoma have been studied, 
including models with dysgenesis of the anterior segment, those lacking specific 
receptors and those with targeted mutations of signalling or structural proteins 
(Lindsey and Weinreb, 2005).
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Although experimental rat models of elevated IOP are extremely valuable in 
understanding the mechanisms that occur in glaucoma, IOP is increased rapidly to 
detrimental levels and RGC usually die faster than in natural or inherited glaucoma 
(Libby et al., 2005).Therefore, inherited mouse glaucoma models have been 
developed with spontaneously occurring secondary glaucoma and sequential RGC 
damage. These include the DBA/2NNia, DBA/2J and AKXD-28/Ty inbred mouse 
strains (Anderson et al., 2008; Anderson et al., 2001; John et al., 1998; Sheldon et al., 
1995). One of these models, DBA/2J, is characterised by an increase in IOP starting at 
approximately 6 months of age and the presence of peripheral anterior synechiae, iris 
atrophy, and pigment dispersion. Changes in the iris and the anterior chamber angle 
cause aqueous outflow obstruction and induce secondary glaucoma in this model 
(John et al., 1998). However, there might be differences in the mechanism of neural 
damage compared to clinical glaucoma since the mouse lacks a lamina cribrosa (May 
and Lutjen-Drecoll, 2002).
IOP can be measured in mouse using various methods, including insertion of a glass- 
tipped micropipette into the anterior chamber that is connected to a pressure 
transducer (Aihara et al., 2002; John et al., 1997), the servo-null method (Avila et al., 
2001), Goldmann tonometer (Cohan and Bohr, 2001), rebound tonometer (Danias et 
al., 2003), TonoPen (Reitsamer et al., 2004) and modified Schiotz indentation 
tonometer (Gross et al., 2003). Due to the small size of the mouse eye, reliable 
measurements can be difficult to obtain. Additionally, eye displacement or transient 
pressure changes related to one method might not allow for obtaining valuable 
measurements using another method. Thus, validation of the results might be difficult 
to obtain. Another drawback of inherited glaucoma models is that they are more 
expensive and time-consuming to study than experimentally induced models (Libby et 
al., 2005).
1.1.8.2. Non-human primate model of IOP-induced optic nerve damage
The most commonly used models at present are non-human primates and rodents. 
Because of the close anatomic similarities between the structure of human and non­
human primate optic nerve, the best-established models of pressure-induced optic
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nerve damage have been developed in non-human primates. The primate optic nerve, 
as in the human, is composed of a nerve fiber layer as well as prelaminar, laminar, and 
retrolaminar regions (Anderson, 1969; Anderson, 1970).
The methods used for inducing elevated IOP in primates include laser 
photocoagulation of the trabecular meshwork (Gaasterland et al., 1978) and injection 
of various particles into the anterior chamber, including ghost red blood cells (Quigley 
and Addicks, 1980) as well as latex microspheres (Weber and Zelenak, 2001). In non­
human primates, IOP can be measured using a modified Goldmann tonometer 
(Kaufman and Davis, 1980), TonoPen tonometer (Peterson et al., 1996) or 
pneumatonometer (Toris et al., 2000). Most frequently, IOP measurements are 
performed with the use of a general anaesthetic, which was reported to be the least 
likely to artifactually lower IOP (Erickson-Lamy et al., 1984). Nevertheless, due to 
the cumulative harmful effects which anaesthetics might have on the primates and 
their physiology, topical anaesthesia has been recently utilised, enabling accurate 
measurement of the IOP in the awake animal (Toris et al., 2003). Compared with 
applying general anaesthetics, this approach allows for more straightforward detection 
of subtle changes in IOP and more reproducible measurements of IOP response 
(Morrison et al., 2005).
Optic nerve and retinal damage in the monkey are assessed histologically. Axon loss 
can also be assessed by analysing the nerve fiber layer in the retina using fundus 
photography (Quigley, 1986). Additionally, this method allows clinical evidence of 
optic nerve head cupping to be obtained. Cupping can be also identified with the use 
of laser scanning ophthalmoscopy (Burgoyne et al., 2002).
One of the drawbacks of using primates is associated with difficulties in inducing a 
moderate increase of IOP that mimics the IOP observed in human open angle 
glaucoma. The interpretation of the consequential optic nerve damage can be 
complicated by the obstructed retinal blood flow in the case of a high elevation of 
pressure. However, this can be overcome by administration of topical pressure- 
lowering agents (Pena et al., 2001). Another drawback of using the monkey is related 
to obtaining accurate measurements of IOP in awake animals which must be trained 
for this purpose (Toris et al., 2003). Problems caused by general anaesthetics have
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already been mentioned (Morrison et al., 2005). Additionally, monkeys are expensive 
to purchase and to maintain and can be potentially risky for the health of animal care 
workers. Owing to the cost of these animals, it might be difficult to provide the large 
numbers of monkeys necessary for experiments aimed at studying cellular functions 
in the optic nerve head and retina in relation to IOP (Morrison et al., 2005).
1.1.8.3. Rat model of IOP-induced optic nerve damage
Due to the several disadvantages of using non-human primate models, there is a need 
for a more cost-effective, easier to handle model of pressure-induced optic nerve 
damage. A suitable model should enable identification of the cellular mechanisms of 
optic nerve damage and the development of potential treatments for glaucoma 
(Morrison, 2005). Experimental rat models are relatively inexpensive to purchase and 
maintain, allowing for a large number of animals to be used per experiment and 
therefore for obtaining more valid results (Morrison et al., 1995). They are also easy 
to handle, enabling frequent measuring of IOP in the awake state. In addition, the 
biology of a rat’s central nervous system and optic nerve damage are well described, 
allowing for straightforward assessment of changes caused by the variations in IOP. 
Eventually, the data obtained from the work with a rat model can be further 
investigated in more focussed experiments in primate models, linking basic studies 
and human glaucoma (Morrison 1995).
There are several anatomic similarities and differences between the rat and primate 
optic nerve. In both species, axons in the optic nerve head are unmyelinated, though 
myelination in primates commences at the posterior sclera, while in rats roughly 
0.5mm posterior to the sclera (Morrison et al., 1995). The rat’s lamina cribrosa is less 
developed than in the primate, with single collagen bundles forming a lamina-cribrosa 
like structure (Albrecht May, 2008). Due to the thinner sclera in the rat compared with 
the primate, it is likely that the chronic elevation of IOP resulting from experimental 
aqueous humour outflow obstruction has more impact on the rat’s optic nerve than the 
primate nerve (Morrison et al., 1995). Finally, because of a similar close 
ultrastructural relationship between optic nerve head astrocytes and axons in rats and 
primates, rat models are considered to be very relevant for evaluating cellular 
mechanisms of axonal injury from increased IOP (Morrison et al., 2005).
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There are different methods for the induction of chronic experimental IOP increase in 
rats. Significant elevation of IOP, caused by enhanced resistance to aqueous humour 
outflow, can be induced by scarring of the eye angle. This can be performed by 
injection of hypertonic saline into aqueous humour outflow pathway (Morrison et al., 
1997) or by laser treatment of the eye angle (Woldemussie et al., 2001). Another 
technique, in contrast to the methods mentioned above, generates less optic nerve and 
RGC damage over time. This method that provides a different mechanism of pressure 
elevation is cautery of episcleral veins, (Shareef et al., 1995). A more recently 
introduced method is the injection of various substances such as latex or polystyrene 
microspheres (Sappington et al., 2010; Urcola et al., 2006) into the eye anterior 
chamber that leads to the obstruction of trabecular meshwork channel. This method 
tends to be less technically challenging from the other methods that induce chronic 
IOP.
IOP is most commonly measured in glaucomatous rats using the TonoPen tonometer 
due to its ready availability, its high reliability and no requirement for special 
modification. Moreover, circadian fluctuations in IOP can be assessed with the 
TonoPen in conscious animals (Moore et al., 1996). Other instruments include the 
pneumatonometer (Shareef et al., 1995), modifications of the Goldmann tonometer 
(Cohan and Bohr, 2001) and the rebound tonometer (Goldblum and Mittag, 2002). 
The Goldmann tonometer can be used in anaesthetized rats, while modification of this 
tonometer allowed for measuring IOP in conscious, unsedated rats (Cohan and Bohr,
2001).
Pressure-induced damage can be determined by counting axons using light or electron 
microscopy in optic nerve cross sections which are then compared to control sections 
(e.g. from the other eye) (Chauhan et al., 2002; Levkovitch-Verbin et al., 2002). 
Another method, a qualitative damage scale (Chauhan et al., 2006), allows for easy 
and rapid estimation of many optic nerves. By counting cells in the retinal ganglion 
cell layer of the retina (Schlamp et al., 2001), or by staining cells with dye exposed to 
the superior colliculus or the optic nerve (Sawada and Neufeld, 1999), damage can be 
assessed by estimating the loss of retinal ganglion cells (Schlamp et al., 2001). Due to 
the lower number of axons and RGCs in the rat eye compared to the primate, these 
methods are easier to carry out in rats (Cepuma et al., 2005). Apart from studying
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cellular and physiologic mechanisms of glaucomatous optic nerve damage, rat models 
can be also used to evaluate potential neuroprotective strategies (Morrison, 2005)
1.1.8.4. In vitro systems
In vivo experimentation, though necessary, might sometimes be affected by various 
uncontrollable factors. Therefore, in vitro systems are often used to perform highly 
controlled preliminary studies. The in vitro systems used in glaucoma research 
include retinal explant organ culture and primary RGC culture.
1.1.8.4.1. Retinal explant culture
Retinal explant cultures serve as a model of glaucoma since the explanation of the 
retina requires the severing of all axons within the optic nerve and the consequential 
degeneration of RGCs. This system is particularly useful for experiments that require 
the presence of the whole retinal tissue but cannot be conducted in vivo due to 
limitations involving tissue access, confounding systemic factors, or control over 
microenvironment. Nevertheless, this in vitro system is not as complex as animal 
models and thus in vitro experiments must be supported by in vivo studies (Johnson 
and Tomarev, 2010).
1.1.8.4.2. Retinal ganglion cell culture
Retinal ganglion cell culture is useful in studying the response of RGCs to specific 
conditions in isolation from the rest of the eye. RGCs may be obtained by the 
chemical or enzymatic treatment of freshly isolated rodent retina to produce a 
dissociated primary culture (Otori, 2008).
The RGC-5 cell line is an immortalised cell line derived from the rat that express 
Thyl, Bm3C, Trk-A, and various neurotrophic factors (Agarwal et al., 2007; 
Krishnamoorthy et al., 2001). However, this cell line differs in many aspects from true 
RGCs, therefore results obtained with the cell line must be interpreted with caution 
(Frassetto et al., 2006). RGC-5 cells are more similar to glial cells in culture than to 
primary RGCs and do not express the range of electrophysiological ion channels that
21
are attributed to RGCs. In addition, RGC-5 cells responded to the broad-spectrum 
protein kinase inhibitor staurosporine in a different way than RGCs (Frassetto et al., 
2006).
1.2. Neuroplasticity
In neuroscience, plasticity has been described as the ability of the nervous system to 
modify its organisation and eventually its function (Guterman, 2007; Kolb et al., 
2003) or, more distinctively, as the capacity to rearrange patterns and systems of 
connections (Guterman, 2007; Stiles, 2000). Donald Hebb (1949) assumed that 
synaptic efficacy could be selectively modified by experience, while Konorski (1948) 
linked neural plasticity to the ability of an organism to undergo habit, extinction and 
conditioning formation. There are two types of plasticity: synaptic and anatomical 
plasticity. Synaptic plasticity is defined as activity-dependent changes in the efficacy 
of synaptic transmission across synapses, while anatomical plasticity (also known as 
structural plasticity or remodelling) is defined as the change in anatomical 
arrangement of neural connections with the formation of new synapses (Galtrey et al.,
2007). Plasticity has an important function in the alteration of connections during 
development whereas, in the adult central nervous system (CNS), plasticity occurs at 
a lower level in response to experience, age or injury (Galtrey et al., 2007). Plasticity 
at the single synapse level has been shown by demonstrating the capability of synaptic 
transmission to change as a function of other simultaneous inputs received by the 
post-synaptic neuron (Kandel, 1970; Kandel and Schwartz, 1982). In addition to 
synaptic plasticity, neural plasticity might be linked to other mechanisms such as 
modulation of neuronal excitability or experience-dependent neurogenesis (Giese et 
al., 2001; Karten et al., 2005; Shors et al., 2001). Acknowledgment of the highly 
plastic nature of the CNS, and the fact that it changes constantly during life, is a fairly 
novel development. Until very recently, most neuroscientists considered that the 
nervous system modifies at particular sites only using very few mechanisms (Wolpaw 
and Carp, 2006). Although there is poor recovery after injury in adult mammalian 
CNS, partial functional recovery has been observed, suggesting the presence of at 
least some neuronal plasticity. However, it is still poorly understood what functional 
mechanisms and anatomical features are associated with CNS plasticity (Ahmed et al., 
2001a). Structural reorganisation of soma, axons or dendrites as well as atrophy or
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hypertrophy of somata in neurons has been observed after lesions (Eysel and 
Wolfhard, 1984; Steward and Vinsant, 1978). Lesion-induced dendritic plasticity has 
been detected in the fetal, adult and aged CNS (Buell and Coleman, 1979; Buell and 
Coleman, 1981). Apart from humans, plasticity has been detected in various 
mammals, including cats, rabbits, rats and mice (Peichl and Bolz, 1984; Rothblat and 
Schwartz, 1979; Valverde, 1967).
1.2.1. Neuroplasticity and diseases of the CNS
Imbalanced plasticity of neuronal networks in the brain involved in perceptual, 
cognitive, and motor behaviour might be associated with deficits in the integration of 
efferent and afferent processes in schizophrenia (Guterman, 2007). Injuries of the 
CNS, such as stroke, traumatic brain injury and spinal cord injury, can lead to 
devastating and permanent failure of function. At present, there are no approved 
medicines with the capacity to restore lost higher and sensimotor functions. Therefore, 
it is necessary to understand how to overcome mechanisms that inhibit regeneration as 
well as mechanisms that increase neuronal plasticity to design new therapeutics for 
the treatment of CNS injuries (Wieloch and Nikolich, 2006).
1.2.2. Regulators of neuroplasticity
Loss of function during stroke is caused by neuronal death in the infarcted tissue, as 
well as, cell dysfunction in the areas neighbouring the infarct. Three distinct, 
subsequent mechanisms are involved in functional recovery. This includes reversal of 
diaschisis and activation of cell repair, followed by functional cell plasticity involved 
in changing the characteristics of existing neuronal pathways, and finally 
neuroanatomical plasticity leading to the development of new connections. The first 
two phases are involved in normal learning, the powerful force throughout functional 
recovery (Wieloch and Nikolich, 2006). Spontaneous functional recovery after stroke 
can be increased by external interventions. Activators of the noradrenergic, 
dopaminergic and cholinergic systems stimulate functional plasticity (Floel et al., 
2005; Sawaki et al., 2002; Wieloch and Nikolich, 2006), while growth factors and 
attenuators of axonal growth inhibition enhance neuroanatomical plasticity (Sugiura et 
al., 2005; Wang et al., 2004). Physical therapy increases recovery during the chronic
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phase, and might be improved by adjuvant treatments (Wieloch and Nikolich, 2006; 
Will et al., 2004).
1.2.3. Neuroplasticity in the retina
During the prenatal period, when the mammalian visual nervous system self- 
organises, spontaneous activity is a main force driving this process (Shatz, 1996). 
This activity is inherent to the visual system and enhances a distribution of neurons 
and connections that normally does not occur in the adult visual system. However, 
retinal plasticity has been observed also in the adult visual nervous system. Retinal 
lesion leads to a reorganisation of the cortical receptive field distribution. In 
particular, cortical neurons selective to visual stimuli in the area of the visual field 
corresponding to the scotoma become selective to stimuli originating in other parts of 
the retina (Andrade et al., 2001).
Some studies imply an association between the lesion-induced increase in the soma 
size of RGCs and soma density in the visual system. Experiments conducted in the 
visual system of developing rats suggest that RGCs soma size is dependent on the 
available space in the retina and is also influenced by the target tissue. Reductions of 
RGC density in the retina have been observed after tectal lesions induced by vacuum 
aspiration or kainic acid injection and to the increase of soma size of the surviving 
RGCs (Bahr et al., 1992; Carpenter et al., 1986). Another study showed that RGCs 
were removed rapidly without affecting bipolar or amacrine cells following the 
transection of rat optic nerve at birth, implying that cutting the optic nerve affects only 
RGCs (Beazley et al., 1987). Similar changes have been detected in studies of other 
vertebrate species. Alterations in dendritic morphology, although smaller in older 
animals, were observed in RGCs lying adjacent to regions of degeneration after retinal 
lesions in postnatal cats (Eysel et al., 1985). Another example is the increased soma 
size of the remaining RGCs after a reduction in the RGC density at the area centralis 
after transection of the optic nerve in postnatal cats (Rapaport and Stone, 1983). Kirby 
and Chalupa (1986) showed crowding of RGCs in the remaining eye of the embryonic 
cat after enucleation. The authors concluded that the spaces left by dying cells enabled 
an increase in soma size and dendritic field of the remaining RGCs. Similarly, Ahmed 
et al. (2001a) showed an increase in soma size of RGCs and an expansion of their
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dendritic fields after an increase in IOP (Figure 1.4). One explanation for the increase 
in dendritic trees o f the surviving RGCs could be the presence of free synaptic 
endings of bipolar and amacrine cells which might stimulate hypertrophy of the 
remaining RGCs. Synaptic connections might then be formed by these cells onto these 
remaining cell dendrites (Ahmed et al., 2001a). In contrast to the studies showing an 
increase in dendritic field and soma, other investigators observed dendritic pruning 
and RGC soma shrinkage in rat and primate experimental glaucoma (Morgan et al., 
2006).
Figure 1.4. Dil-labelled RGCs in control (A) and experimental (B) eyes after 10 weeks post IOP 
elevation. Scale bar: 75 pm (Ahmed et al., 2001a).
Apart from RGCs, morphological plasticity has been observed in other cells of the 
adult mammalian retina. Significant reduction in the type A horizontal cell dendrites, 
which sprouted into the inner retina, has been observed in cat and rabbit after a sub- 
lethal doses of kainic acid (Peichl and Bolz, 1984). Another example is the elongated 
processes of rod and horizontal bipolar cells in adult cat retina following 
experimentally induced retinal detachment (Lewis et al., 1998).
1.2.4. Neurotrophins
Reduction of IOP leads to improved axonal function, and consequently to the 
increased retrograde transport of neurotrophins to the cell body (Herzog and von
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Bartheld, 1998). Neurotrophins, due to their autocrine, endocrine and paracrine 
properties, can regulate survival, differentiation and regeneration of neurons (Herzog 
and von Bartheld, 1998). Neurotrophins are a family of closely related proteins that 
were originally identified as promoters of neuronal survival, but have since been 
demonstrated to regulate neuronal survival, development and function in both the 
peripheral and central nervous system. Four neurotrophins are expressed in mammals, 
including NGF, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) 
and neurotrophin-4 (NT-4). Each activates at least one of the tropomyosin-related 
kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB, TrkC) and p75 
neurotrophin receptor (p75 NTR), a member of the tumour necrosis factor receptor 
superfamily (Figure 1.5.). Activation of Trk receptors results in activation of Ras, 
phosphatidyl inositol-3 (PI3)-kinase, phospholipase C-y 1 and signalling pathways 
regulated through these proteins. P75NTR activation leads to activation of the nuclear 
factor-xB (NF- kB), Jun kinase and other signalling pathways. During development, 
the number of surviving neurons is controlled by restraining quantities of 
neurotrophins. Moreover, the neurotrophins control axon growth, dendrite growth and 
pruning, cell fate decisions and the expression of proteins important for neuronal 
function. In the adult CNS, neurotrophins regulate synaptic function and plasticity in 
addition to sustained neuronal survival, morphology and differentiation. Thus, their 
constant presence is essential. Additionally, mutations in neurotrophins or their 
receptors have been associated with many human genetic diseases (Reichardt, 2006).
In the visual system, neurotrophins are involved in the development and maintenance 
of RGCs. BDNF has frequently appeared as a very important neurotrophic factor that 
affects development of vertebrate RGCs, including survival, morphological 
differentiation of axons and dendrites, synapse formation, and regeneration (Bahr, 
2000; Frost et al., 2001; Isenmann et al., 2003; von Bartheld, 1998). Although BDNF 
does not modulate programmed cell death of RGCs in vivo (Cellerino et al., 1998; 
Pollock et al., 2003; Rohrer et al., 2001), it has been shown to act as a potent survival 
factor for axotomised and injured RGCs (Di Polo et al., 1998; Mansour-Robaey et al.,
1994). In addition, BDNF can increase the extension and regeneration of retinal 
neurons in vitro (Goldberg et al., 2002; Lorn and Cohen-Cory, 1999; Takano et al.,
2002).
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Figure 1.5. Neurotrophin-receptor interactions. Each neurotrophin binds to p75NTR but 
not to the Trk receptors. After maturation of the proneurotrophins through proteolysis, each 
mature neurotrophin can bind and activate p75NTR, but shows more specific interactions 
with the three Trk receptors. NGF recognises TrkA, BDNF and NT4 activate TrkB, and 
NT3 binds TrkC (Reichardt 2006).
1.2.5. Perineuronal nets
I.2.5.I. Structure and composition
Perineuronal nets (PNNs) were originally described by Golgi and Cajal in the 1890s 
as a reticular system present on the surface of neuronal bodies and proximal dendrites 
(Rhodes and Fawcett, 2004). They develop postnatally and finally emerge as net-like 
features on the cell surface as a consequence of extracellular matrix (ECM) materials 
deposited around synaptic endings as well as in the space between neurons and 
astrocytic processes. Although PNNs are usually found around gabanergic 
intemeurons containing parvalbumin (Bruckner et al., 1994; Hartig et al., 1992; 
Murakami et al., 1995), pyramidal cells (Hausen et al., 1996) in the cortex, projection 
neurons and large motoneurons of the brain stem and spinal cord (Murakami et al.,
1995), it is not completely recognised which cell types produce the PNNs and for 
what reasons. It is suggested that astrocytes might be involved in PNN formation 
since glial cells in vitro were found to be capable of producing ECM similar to PNNs 
observed in vivo, even in the absence of neurons (Michael Maleski, 1997).
Extracellular matrix in the CNS is composed of hyaluronan; chondroitin sulphate 
proteoglycans (CSPGs), mainly the lectican family; link protein, a glycoprotein that 
binds hyaluronan and aggrecan; and tenascin, an adhesive molecule that interacts with 
CSPGs (Galtrey and Fawcett, 2007). In contrast to ECM in other tissues, the ECM in 
CNS contains a small quantity of fibrous proteins and a high quantities of 
glycosaminoglycans (GAGs) (Novak and Kaye, 2000). GAG chains may be 
covalently linked to a protein to form proteoglycans. GAGs are highly negatively 
charged repeating disaccharide units composed of two alternating monosaccharides, 
namely uronic acid and either N-acetylglucosamine or N-acetylgalactosamine. The 
core protein can have from 1 to over 100 GAG chains attached, with the length of 
GAG chains varying from 10 to 400 000 kDa (Rhodes and Fawcett, 2004). Based on 
their glycosaminoglycans chains, proteoglycans are classified into four main groups: 
chondroitin sulphate, dermatan sulphate, keratin sulphate and heparin sulphate 
(Inatani and Tanihara, 2002). There are several types of CSPGs, including large 
aggregating proteoglycans such as aggrecan (Paulsson et al., 1987) and versican 
(Krusius et al., 1987); the brain specific proteoglycans neurocan (Grumet et al., 1993)
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and brevican (Yamada et al., 1994); NG2 (Levine and Card, 1987; Stallcup and 
Beasley, 1987) and phosphacan/DSD-1 (Grumet et a l, 1993; Grumet et al., 1994).
CSPGs in the ECM play an important role in determining the functional responses of 
cells to their environment during development, cell migration, maturation 
differentiation and survival and tissue homeostasis (Oohira et al., 2004). Many of the 
functional properties of CSPGs are attributed to the attached CS-GAG chains. CS- 
GAGs bind various growth factors and growth inhibitory factors (Galtrey et al., 2007). 
CS-PGs are particularly strongly expressed in the embryonic brain (Oakley and 
Tosney, 1991; Snowetal., 1990).
I.2.5.2. Functional roles of PNNs in plasticity
There are several possibilities for the function of PNNs: synaptic stabilisation and 
limitation of synaptic plasticity (Hockfield et al., 1990), neuroprotection (Morawski et 
al., 2004) or support of ion homeostasis in the region of very active neurons (Hartig et 
al., 1999).
The assumption that PNNs have a role in the maintenance of tissue architecture and 
maturation of synapses on motomeurons originated from the observation of the late 
development of PNNs, and their association with only certain types of neurons (Celio 
and Blumcke, 1994; Kalb and Hockfield, 1990; Margolis and Margolis, 1993). The 
late postnatal appearance of PNNs in the visual cortex has been found to overlap with 
the end of a critical period (Sur et al., 1988; Zaremba et al., 1989), the developmental 
phase during which synapses are still susceptible to experience (Daw and Wyatt, 
1976). Although synaptic plasticity is significantly reduced at the end of the critical 
period, visually deprived rats preserved some plasticity of the visual cortex (Cynader 
et al., 1976). Since previous studies observed alterations in CSPGs expression in the 
visual cortex in visually deprived rats (Guimaraes et al., 1990; Hockfield et al., 1990; 
Zaremba et al., 1989), CSPGs and PNNs are involved in maintaining synaptic stability 
and preventing plasticity in the mature animal (Rhodes and Fawcett, 2004). The above 
studies have been supported by (Pizzorusso et al., 2002), who demonstrated 
restoration of synaptic plasticity after the treatment of mature rat visual cortex with 
bacterial enzyme chondroitinase ABC, which degraded CSPGs present in the PNNs.
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Synaptic plasticity is normally observed only in animals reared in the dark or during a 
critical period in development.
Chondroitinase has been applied to models of CNS injury in vivo. Bradbury et al. 
(2002) demonstrated degradation of chondroitin sulphate glycosaminoglycans (CS- 
GAG) around the lesion site and axonal regeneration after treatment of the lesioned 
adult rat dorsal column with chondroitinase. Additionally, his studies showed an 
associated increase in the expression of the growth associated protein (GAP)-43 in 
lesioned neurons, restoration of post-synaptic activity below the lesion and functional 
recovery. Further studies also support the positive effects of chondroitinase ABC 
(ChABC) on axonal regeneration after injury (Krekoski et al., 2001; Tropea et al., 
2003; Yick et al., 2003; Zuo et al., 2002).
Tropea et al. (2003) studied effects of the combined treatment with ChABC and 
BDNF on injured RGCs. Delivery of brain-derived BDNF was performed to enhance 
the intrinsic ability of RGCs to re-elongate their axons, while the treatment with 
chABC was conducted to reduce the neurite growth-inhibitory properties of the adult 
chondroitin sulphate proteoglycans. The results showed that the combined treatment 
had effects on axon growth and synapse formation by the sprouting axons, implying 
the potential of this approach in therapies for the repair of the damaged adult CNS 
(Tropea et al., 2003).
Taken together, the above studies strongly support the potential to restore neuronal 
growth and plasticity to the adult CNS (Rhodes and Fawcett, 2004).
1.3. Hypothesis
This project addresses the hypothesis that the changes in the dendritic tree of RGCs in 
the experimental glaucoma model can be reversed by the reduction of IOP followed 
by the enzymatic digestion of CSPGs to disrupt the perineuronal net. The action of the 
enzyme chABC might be enhanced by the action of neuroprotective agents such as 
BDNF.
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1.4. Project aims
The main aims of this project are:
> To identify changes in RGC morphology and quantify RGC loss after the 
induction of ocular hypertension in a rodent model of experimental glaucoma.
> To determine if RGC remodelling in glaucoma might be driven by combined IOP 
reduction and manipulation of retinal perineuronal nets/retinal neurotrophin levels. 
(Proteoglycan perineuronal net will be disrupted by intravitral injection of chABC 
and the levels of neurotrophins increased by intravitreal injection of BDNF).
> To investigate and compare the presence of CS-GAGs, the key components of the 
ECM in the CNS, and aggrecan core protein epitopes in young, old and 
glaucomatous rat retinas.
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Chapter 2: Materials and Methods
2.1. Ex vivo -  retinal explant culture
2.1.1. Experimental animals
Experiments were performed either on adult mice with mixed background, strains 
C57BL/6Crl and C3H/HeJ, or adult male Norwegian Brown rats (Rattus norvegicus). 
Mice, obtained from Ingenium Pharmaceuticals, Germany, were killed by cervical 
dislocation. Rats, obtained from Harlan, UK, were euthanised by over-exposure to 
C02, and death was confirmed by cervical dislocation. Eyes were enucleated 
immediately post-mortem.
2.1.2. Retinal dissection
To optimise the protocol for retinal dissection, different approaches were tested. 
Initially, dissection of the retina was performed under non-sterile conditions. To 
eliminate contamination problems, dissection was then performed using aseptic 
technique within a Microflow laminar flow hood. Surgical instruments were 
autoclaved at 120 °C for 20 minutes and immersed in 70% ethanol directly before 
dissection.
Initially, dissection was carried out on a petri-dish covered with Sylgard 184 silicone 
elastomer (Dow Coming, UK) and, in later experiments, directly on a petri-dish. The 
freshly enucleated eyes were immersed in medium. A number of media were tested to 
optimise the dissection protocol to ensure retinal viability. These can be seen in Table
2.1. A slit was cut in the sclera close to the cornea and the anterior chamber was 
dissected. The retina was then carefully isolated from the retinal pigment epithelium 
(RPE) remaining in the eyecup, and the vitreous still attached to the retina was 
carefully removed either on a culture plate (initially) or during dissection (later). The 
retina was flattened using a brush or by cutting slits in the retina. In later experiments, 
a brush was not used for dissection to minimise mechanical damage during the 
procedure. In preliminary experiments, the isolated retina was placed with vitreous 
side up on a culture dish covered with pieces of glass or on a black Millipore filter 
(AABP02500) to prevent folding. Since this approach did not prevent folding of the
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retina, in subsequent experiments, the tissue was placed with ganglion cell side up on 
0.4 pm Millicell culture plate inserts (Millipore). Excess media was aspirated.
Finally, the following protocol was optimised for retinal dissection. The whole 
procedure was carried out with as little disruption and manipulation as possible to 
avoid mechanical damage. Dissection was performed using aseptic technique within a 
Microflow laminar flow hood. Surgical instruments were immersed in 70% ethanol 
directly before dissection. The freshly enucleated eyes were immersed in a 
refrigerated HBSS (Gibco, UK) medium. A slit was cut in the sclera close to the 
cornea and the anterior chamber was dissected. The retina was then carefully isolated 
from the retinal pigment epithelium remaining in the eyecup, and the vitreous still 
attached to the retina was carefully removed. The retina was placed with ganglion cell 
side up on 0.4 pm Millicell culture plate inserts (Millipore) and excess media was 
aspirated.
Medium Serum Supplement Other
DMEM 
(Dulbecco's 
Modified Eagle 
Medium) (lab 
stock)
heat-inactivated 
FBS (lab stock)
2mM
L-glutamine
100 U/ml
penicillin/streptomycin
50% MEM 
(Minimum 
Essential Medium) 
(Gibco)
25% heat- 
inactivated horse 
serum (lab stock)
25% HBSS (Gibco)
6.5 mg/ml glucose 
100 U/ml
penicillin/ streptomycin
oxygenated Ames’ 
(Sigma)
- - -
Table 2.1. Media used during optimisation of retinal dissection protocol.
2.1.3. Culture conditions
The isolated retinas were cultured in 5% C02 at 37°C in various media as indicated in 
Table 2.2 for at least one hour prior to ballistic labelling. Media were changed daily or
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every other day. The culture conditions and media tested were those previously 
described by other investigators (Gutierrez et al., 2005; Koizumi et al., 2007; Sun et 
al., 2002; Wang et al., 2002; Xin et al., 2007). Eventually, the following protocol was 
established: the retina was cultured in 5% C02 at 37°C in Neurobasal-A (Gibco, UK) 
medium containing 0.8 mM L-glutamine, 2% B27 and 1% N2 supplements (Gibco, 
UK) and 100 U/ml penicillin/streptomycin before diolistic labelling. The medium was 
exchanged daily.
Medium Serum Supplement Other
DMEM heat-inactivated FBS 2mM L-glutamine 100 U/ml
penicillin/streptomycin
50% MEM 25% heat-inactivated 
horse serum
25% HBSS 
6.5 mg/ml glucose 
100 U/ml
penicillin/streptomycin
Oxygenated Ames’
— — —
Ames’ 1% heat-inactivated 
horse serum
1% N2 supplement 
(Gibco)
0.3 mg/ml 
L-glutamine
Neurobasal-A
(Gibco)
2% heat-inactivated 
horse serum
2mM L-glutamine 
2% B27 supplement 
(Gibco)
100 U/ml
penicillin/streptomycin
Neurobasal-A 2mM L-glutamine 
2% B27 supplement 
1% N2 supplement
100 U/ml
penicillin/streptomycin
Neurobasal-A 0.8mM L-glutamine 
2% B27 supplement 
1% N2 supplement
100 U/ml
penicillin/streptomycin
Table 2.2. Media used during retinal culture.
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2.1.4. Cell viability assays
Cell viability of retinal culture was assessed using propidium iodide (PI) (Sigma. UK) 
as a marker of necrosis and the vital dye calcein AM (Invitrogen, UK). Propidium 
iodide (3,8-Diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium 
diiodide), which binds to double-stranded DNA, labels the nuclei of non-viable cells 
but can not cross the membrane of viable cells (Smith et al., 2007). Calcein 
acetoxymethyl ester (AM) is retained in cells with intact membranes but cannot stain 
dead cells. In live cells, following acetoxymethyl ester hydrolysis by intracellular 
esterases, the nonfluorescent calcein AM is converted to a green-fluorescent calcein 
(Caspi et al., 2007; Decherchi et al., 1997).
For cell viability assays, retina was isolated as described in section 2.1.2 and the 
wholemount retinas were cultured in duplicates either in HBSS (control), 50% MEM 
(formulated as described in section 2.1.3.), Neurobasal-A containing 2% B27 
supplement, 1% N2 supplement, 0.8mM L-glutamine and 100 U/ml 
penicillin/streptomycin or Neurobasal-A containing 2% B27 supplement, 2% horse 
serum, 2mM L-glutamine and 100 U/ml penicillin/streptomycin. The retinas, after 1 
and 3 days of culture, were incubated with propidium iodide and calcein AM for 
approximately 40 minutes (section 3.2.1).
For comparison of the effects of biolistic transfection on tissue survival, retinas were 
cultured in HBSS (control), Neurobasal-A medium without serum (supplemented as 
above) or Neurobasal-A medium with serum (supplemented as above). The explants, 
after 2 days of culture, were incubated with calcein (5 pi was added to the surface of 
the tissue submerged in 1 ml medium) for approximately 40 minutes (section 3.2.2).
2.I.4.I. Image capture of labelled RGCs
The retinas were imaged using a Zeiss Axiovert200 inverted fluorescent microscope 
and LSM510 software.
The average fluorescence (RGB) intensity of propidium iodide and calcein signal 
were measured using ImageJ (Image Processing and Analysis in Java) plugin
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(Measure RGB) program and were shown as mean RGB values for the entire image. 
The intensities were obtained, based on a standard 256 intensity level scale. Based on 
the mean RGB values, standard deviations were obtained with the program. The 
camera settings were fixed to permit direct comparison between preparations.
2.I.4.2. Statistical analysis
Retinal explants were compared to determine if there was a significant difference 
between the explants maintained under different conditions of culture and 
transfection. The data were tested for normality using SPSS 16.0. The non-parametric 
data described in section 3.2.5 were then analysed using Mann-Whitney Test in SPSS 
16.0.
2.1.5. Gene gun processes
The Helios gene gun (BioRad, UK) enables rapid and direct gene transfer into cells 
(Figure 2.1.). It can be applied to study gene therapy, DNA vaccination and in vivo 
transformation of plants. An adjustable low-pressure helium pulse is used to deliver 
the DNA- or RNA-coated gold or tungsten microcarriers directly into the target cells 
or tissue (Figure 2.2.). The tubing preparation station and the tubing centre included in 
the system allow the preparation of up to 50 sample cartridges with coated 
microcarriers at once. The cartridges are loaded into the holder, which is then inserted 
into the device ready for labelling. In this study, the gene gun was used to deliver both 
plasmid DNA and fluorescent dyes (Dil) to the RGCs within isolated retina.
Figure 2.1. The Helios Gene gun (copied from www.bio-rad.com).
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Figure 2.2. Sample delivery. The helium pulse sweeps the microcarriers from the inside wall o f the 
sample cartridge (copied from www.bio-rad.com).
2.1.5.1. Biolistic labelling
After at least 1 hour incubation in 5% C02 at 37°C, the retina on the insert was put on 
a clean petri-dish, and RGCs were labelled by the biolistic delivery of gold particles 
(1.6 pm diameter; BioRad) coated with either expression plasmid (Clontech, UK) for 
yellow fluorescent protein (EYFP), red fluorescent protein (ERFP) or green 
fluorescent protein (EGFP) with a kB  reporter plasmid and ERFP into the 
wholemount retina using the hand-held gene gun. The coated gold particles (BioRad, 
UK) were propelled into the cultured tissue at a helium pressure that varied from 100 
to 150 psi. In order to protect the tissue from the shock wave, a 70 pm nylon mesh 
screen (lab stock) or a 3 pm filter in later experiments, was placed between the gun 
and the culture. The preparation was quickly transferred to the insert in the culture 
medium and excess medium was aspirated such that the remaining medium just 
covered the retinal surface.
2.1.5.2. Diolistic labelling
In contrast to the GFP labelling techniques based on viral transfection requiring 
several hours for fluorescent protein to be expressed in transfected cells, the diolistic 
technique enables rapid labelling of cells in various neuronal tissues (Gan et al., 
2000). In order to observe labelled RGCs in wholemount preparations of retina,
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RGCs were labelled by the ballistic delivery of 1.7 pm tungsten microparticles coated 
with lipophilic dye - Dil beads (Molecular Probes, UK) (l,r-diocta-decyl-3,3,3’,3’- 
tetramethylindocarbocyanine perchlorate) using the hand-held gene gun (Helios 
Gene-gun, BioRad). In order to prevent clusters of dye-coated particles from landing 
on the preparation, cell culture inserts (Becton Dickinson Labware) with 3 pm pore 
size were interposed between the gene gun and the target tissue. The tungsten 
particles were propelled into the tissue at a pressure of 100-150 psi. After shooting, 
the retinal preparations were fixed with 4% paraformaldehyde in 0.1 M phosphate 
buffer (pH 7.4).
2.I.5.3. Image capture of labelled RGCs
Approximately 0.5 hour after diolistic or 24-48 hours after biolistic labelling, the 
wholemount retinas were imaged using a Zeiss Axioplan laser scanning confocal 
microscope and LSM510 software.
2.1.6. Effects of BDNF and caspase inhibitors on neuronal survival and axonal 
growth cones formation
Retinas were isolated from Brown Norwegian male rats 8-12 weeks of age and 
cultured on 0.4 pm Millicell culture plate inserts in Neurobasal-A medium containing 
2% B27 supplement, 1% N2 supplement, 0.8 mM L-glutamine and 100 U/ml 
penicillin/streptomycin at 37°C in 5% C02. A Helios gene gun system was used for 
particle-mediated transfer of an YFP-expressing plasmid to RGCs as described in 
section 2.1.5.1. Retinal explants were treated with 250nM broad-spectrum, 
irreversible caspase inhibitor (Boc-D-FMK) or with 100 ng/ml recombinant human 
brain-derived neurotrophic factor (rhBDNF). The morphology of RGCs in the treated 
and the control explants was observed by confocal microscopy (Zeiss Axioplan laser 
scanning confocal microscope and LSM510 software).
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2.2. In vivo - experimental glaucoma models
2.2.1. Introduction to animal techniques
All experimental procedures complied with Home Office (UK) regulations concerning 
the Animals (Scientific procedures) Act 1986 and ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research. Experiments were performed according 
to personal license number (PIL) 30/7912, and under project license number (PPL) 
30/2470.
The animal models used were based on the episcleral drainage vessel sclerosis rodent 
model of glaucoma (Jia et al., 2000; Morrison et al., 1997; Morrison et al., 1998) 
(section 2.2.3) and injection of ferro-magnetic microspheres into the anterior chamber 
(section 2.2.4). Six to 8 month old male ex-breeder Brown Norway rats (Rattus 
Norwegicus) were housed at 21°C on 24 hour 40-60 lux and provided with standard 
laboratory diet and water ad libitum. Animals were handled for at least 1 week before 
commencing the experimental procedure. Their weights were recorded as an index of 
health.
2.2.2. Calibration of the Tonolab rebound tonometer in cannulated rat eye
The Tonolab rebound tonometer (Tiolat, Oy, Finland) (Figure 2.3) used in the study 
has been developed for measuring rodent IOP, especially in glaucoma research (Wang 
et al., 2005). This device projects a very light probe towards the cornea and calculates 
IOP based on the probe’s rebound kinetics. An IOP value corresponding to a weighted 
average of 6 readings, rounded to the nearest integer, is displayed at each point when 
tonometry measurements are taken. These weighted average IOP values are referred 
to below as single readings.
Figure 2.3. Tonolab rebound tonometer (copied from http://www.tiolat.fi/images.htm).
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Calibration experiments were performed using enucleated eyes from Norwegian 
Brown rats. Directly after enucleation, eyes were mounted on a stand and a 30-gauge 
needle was inserted through the cornea into the anterior chamber. The needle was 
attached via polyethylene tubing to a 3-way connector, which was attached to a 
burette containing Balanced Salt Solution (Aqsia, Bausch & Lomb, U.K.), a pressure 
transducer with a full scale reading 0 to 2.5 psi (Omega PX800-002GV, Omega Corp., 
USA), and a custom-manufactured screw-gauge syringe. The pressure in the system 
could be varied with the screw-gauge syringe or by altering the level of fluid in the 
burette. With the cannulated eye and screw-gauge syringe isolated from the system, 
the pressure transducer was calibrated by recording its output voltage as a function of 
fluid height in the burette (since lmmH20 = 0.0735 mmHg, pressure in mmBSS was 
converted to mmHg using a conversion factor of 0.0735, under the assumption that 
mmBSS = mmH20). Then the burette was isolated and the pressure in the eye was 
varied using the screw-gauge. IOP was increased with the screw-gauge syringe from 
10 mmHg up to 60 mmHg and then back to 10 mmHg, in steps of approximately 5 
mmHg. The IOP was measured at each step using the rebound tonometer and 
recorded alongside the IOP measured by the pressure inducer.
To test the effect of small changes in the position of the tonometer relative to the eye, 
calibration was obtained with the tonometer positioned at varying distances from the 
cornea, i.e. 1mm and 3mm (Chapter 3). The calibration of tonometer was performed 
in collaboration with Dr Ankush Prashar.
2.2.3. Hypertonic saline model
2.2.3.1. Induction of glaucoma
2.2.3.1.1. Microneedle assembly
Disposable microneedles were made from 10 pi borosilicate glass pipettes (Sigma- 
Aldrich, UK) pulled using a pipette puller (David Kopf Instruments, USA). The rough 
microneedle tips were bevelled to avoid excessive tissue damage during injection and 
to allow for an easy injection into the vessel. The needle was lowered onto a flat 
rotating (14000 rpm) surface attached to an industrial rotator and covered with 
diamond lapping film (World Precision Instruments, UK). Microneedle diameter was
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measured using a DMRA2 microscope (Leica, UK) and Leica QWin image analysis 
software. Microneedles with an outer diameter of 10-40 pm were used, depending on 
the size of episcleral veins.
The narrow end of the microneedle was cut to approximately 3 mm segment. The 
segment was then inserted into the end of polyethylene tubing (Sandown Scientific, 
UK) with an outer diameter of 0.038 inches or 0.048 inches, and the 23G needle with 
the tip broken off was inserted into the other end of the tubing. Finally all the 
junctions were sealed with Superglue, UHU, or Araldite over-laid with high viscosity 
Superglue, followed by the additional sealing with heat-shrink tubing. A small plastic 
tab was positioned along the tubing and held with high viscosity Superglue to mark 
the bevel of the microneedle. After assembly, microneedles were stored in a plastic 
box or in a Petri-dish and then sterilised before use by applying 100% ethanol to the 
bevelled tip, followed by air-drying.
2.2.3.1.2. Anaesthesia
Before injection, rats were anaesthetised via inhalation of 4% isoflurane (Baxter) with 
oxygen in a chamber. For the surgical procedure, they were transferred to a respirator 
connected to a supply of oxygenated isoflurane. Rats were monitored throughout the 
surgery to assess the level of anaesthesia, and the supply of isoflurane was adjusted 
appropriately. The operated eye was hydrated during surgery with 0.9% sterile saline 
drops.
2.2.3.1.3. Surgical procedure
The conjunctiva was incised under a surgical light microscope (Zeiss, USA). A small 
plastic ring (width <2.5 mm, with diameter matching the rat eye just posterior to the 
limbus) was inserted using forceps so that it lied just posterior to the episcleral plexus 
of veins, but anterior to the equator of the eye. The plastic ring was retained under its 
own elasticity so that it exerted gentle compression of the veins with minimal 
distortion of the globe. The ring was incomplete so that one sector (approximately 30- 
60 degrees) was open to identify and cannulate a single episcleral vein. The ring was
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removed following injection of hypertonic saline (1.75M) into episcleral venous 
system of the left eye under general anaesthesia. A topical antibiotic chloramphenicol 
(Chauvin Pharmaceuticals Ltd, UK) was given post injection to reduce the risk of 
infection.
2.2.3.2. IOP measurements
In order to minimise diurnal fluctuations in IOP, rats were housed in a constant low- 
light environment (40-60 lux). IOPs were measured at least 3 times before injection 
and daily to every 7 days, normally every 3 days after injection using a rebound 
tonometer (Tiolat, Oy, Finland) calibrated for use with a rat eye (Wang et al., 2005). 
All measurements were made in awake animals in which the cornea was anaesthetised 
using topical 0.4% oxybuprocaine hydrochloride eye drops (Chauvin, UK). IOP 
measurements were taken from the experimental (left) and contralateral (right) eye. 
The IOP was taken as the mean and standard deviation (SD) of 6 readings.
2.2.3.3. Euthanasia
Animals were killed at variable intervals from 33 to 136 days following the induction 
of ocular hypertension (n=27). One rat, uninjected, was killed due to severe injury that 
did not respond to the treatment. Another rat died due to an overdose of isoflurane 
during the surgery.
All other rats received a lethal dose (approximately 1ml) of sodium pentobarbital 
(Euthatal) (n=28). In most cases, this was followed by transcardial perfusion (n=19). 
A rat was placed on the operating table with its back down and the pinch-response 
method was used to determine if the reflexes were absent. Once an animal was 
unresponsive to this stimulus, an incision with large scissors was made through the 
abdomen for the length of the diaphragm and the connective tissue at the bottom of 
diaphragm was cut through to allow access to the rib cage. Two horizontal cuts were 
made through the rib cage and the thoracic cavity was opened up. It was clamped 
spread open to expose the heart and provide drainage for blood and fluids. While 
holding the beating heart steady with forceps, a needle was inserted directly into the 
left ventricle and extended straight up about 5 mm. The needle, connected to a Cole
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Parmer (USA) perfusion pump, was held in position by clamping in place near the 
point of entry. A cut in the right atrium was made and blood was flushed out using
0.9% saline. When blood had been cleared from the body, saline was changed to 4% 
paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4). Perfusion was stopped 
shortly after reflex movements ceased and the needle was removed from the heart. 
Approximately 200ml of PFA was used for each rat. The eyes were removed and 
stored in 4% PFA at 4°C.
2.2.4. Magnetic bead model
2.2.4.I. Induction of glaucoma
Sixty one male breeder Brown Norway rats were housed in a constant low-light 
environment (40-60 lux) to minimise diurnal fluctuations in IOP, with food and water 
provided ad libitum. IOPs were measured 3 times before injection and every 2-3 days 
after injection using a TonoLab rebound tonometer (Tiolat, Oy, Finland) calibrated for 
use with the rat eye (Wang et al., 2005). All measurements were made in awake 
animals in which the cornea was anaesthetised using topical 0.4% oxybuprocaine 
hydrochloride eye drops (Chauvin, UK). The IOP was taken as the mean and standard 
deviation (SD) of 5 readings.
In each animal, the IOP was elevated in the left eye by injecting a sterile BSS, Alcon 
Corp.) containing 30 mg/ml ferro-magnetic microspheres (CHI Scientific, Inc., USA, 
bead diameter 5 microns) into the anterior chamber. All injections were made under 
Isoflurane anaesthesia (as described in section 2.3.1.2), with topical chloramphenicol 
(0.5%) administered pre and post injection (Cusi, UK). Microspheres were sterilised 
by y-irradiation with a Gammacell 1000 Elite (Nordon International Inc. 22 TBq 
Caesium Source). Approximately 10 to 20 pi was injected into the anterior chamber 
o f  the left eye, delivering approximately 0.3 to 0.6 mg of beads. The right eye acted as 
an unoperated control. Injections were made using a sterile 32 (Hamilton) or 33-gauge 
(WPI Corporation) needle parallel to the iris under general anaesthesia. The 3 3-gauge 
needles were bevelled on 3 sides to facilitate injection through the cornea. A tunnelled 
injection was made with the needle running parallel to the anterior surface of the iris 
to minimise the risk of iris trauma. Since the beads tended to settle under the
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influence of gravity (Figure 2.4 A & B), the syringe and needle were agitated using a 
vortex stirrer for approximately 10 seconds prior to injection to resuspend the beads in 
BSS. The minimum period between subsequent injections was 1 week in accordance 
with Home Office license requirements (UK).
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Figure 2.4. Surgical set-up used during the microinjection procedure. Rats were 
anaesthetised in a chamber before surgery. Anaesthesia was maintained via an inhalation 
mask (A). Photographs of magnetic beads before (left eppendorf) and after agitating 
(right eppendorf). Since the beads tended to settle under the influence of gravity, they 
were agitated using a vortex stirrer for approximately 10 seconds prior to injection (B).
Once the injection of beads was completed, the needle was kept in position and the 
beads then drawn away from the injection site using a small hand held magnet (0.45 
Tesla, 2.5 cm long) which prevented the egress of beads from the injection track. The 
magnet was then used to distribute the microspheres around the iridocorneal angle to 
reduce the outflow of aqueous humour via the trabecular meshwork (Figure 4.4). Four 
rats were injected with 10 pi or 20 pi of magnetic microspheres without directing 
them to the iridocorneal angle using a magnet. One rat received a vehicle injection of 
10 pi BSS into the anterior chamber. Immediate increases in IOP could be minimised 
by leakage of aqueous around the injection cannula once the beads had been drawn 
away from the injections site. Injections of microspheres were performed up to three 
times in the left eye, depending on the required level and duration of the IOP 
elevation. Rats were killed by an overdose of CO2 and the retinas were dissected out 
for a short-term culture in Neurobasal-A medium (Invitrogen, UK) (section 2.1.3) for 
subsequent studies. The cells in RGC layer were then immediately labelled by gene 
gunning with fluorescent dye Dil (section 2.5.1.2).
An elevated IOP was defined as 5 mmHg or greater elevation compared with the 
contralateral control eye. A sustained IOP was defined as 5 mmHg or greater 
elevation compared with the contralateral control eye on at least 7 consecutive days.
Anterior segment images of the beads distribution were taken as required with a 
Nikon Coolpix 4500 camera attached to a Haag Streit slitlamp.
2.2.4.2. Chondroitinase ABC and BDNF injections into a glaucomatous rat eye
The injections were performed after a 3-4 weeks period of IOP elevation that was 
followed by a 1 week period of decreased IOP. All injections were made under 
isoflurane anaesthesia, with topical chloramphenicol (0.5%) administered pre and post 
injection (Cusi, UK). Before anaesthesia, the experimental eye was treated with 
phenylephrine hydrochloride or 1% tropicamide (Chauvin Pharmaceuticals, UK) to 
dilate the pupil. Either 3pi of lOmU/eye chondroitinase ABC (from Proteus vulgaris; 
protease free; Seikagaku, Tokyo, Japan), 1 pi of lpg/ml recombinant human BDNF 
(R&D systems, UK) or both agents (during the same procedure) were injected into the 
vitreous of a glaucomatous, left rat eye. The right eye acted as an unoperated control.
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Alternatively, 3 pi of lOmU/eye chondroitinase ABC was injected into the normal rat 
eye. A thin sheet of transparent polypropylene was placed on the eye to allow the 
observation of the optic disc during the injections. A drop of sodium hyaluronate- 
Healonid (Pharmacia) was placed on the eye to prevent movement of the 
polypropylene . The needle tip was directed to the vitreous, above the optic disc. After 
injection, the needle was kept inside for a few seconds to enable the solution to settle 
in the vitreous and then slowly withdrawn. The animals were kept for two weeks after 
injection before being killed.
2.2.4.3. FD-OCT in vivo imaging
A frequency domain optical coherence tomography (FD-OCT) (Choma et al., 2003; 
de Boer et al., 2003; Fercher et al., 1995; Gerd and Michael Walter, 1998; Leitgeb et 
al., 2003; Nassif et al., 2004), also referred to as spectral or Fourier domain OCT 
system, was used to image rat retinas in vivo. The system enables high-speed, high 
sensitivity and depth-resolved measurements of the retina due to analysis of the 
interference pattern in the optical frequency spectrum. FD-OCT is based on all- 
reflective high-speed In-GaAs spectrometer, operating in the 1050 nm wavelength 
region with 70 nm bandwidth (~7 pm effective axial resolution) (Povazay et al., 
2007a) (Figure 2.5).
Animal preparation
Rats were first anaesthetised with 0.3 ml ketamine hydrochloride (Pfizer) injected 
intraperitoneally (IP) and eyes were then dilated with tropicamide (1%) (Bausch and 
Lomb) applied topically as drops. Approximately 7 minutes after ketamine injection, a 
rat was transferred to a stand where anaesthesia was maintained with isoflurane (1%) 
with oxygen inhaled via a mask and placed in a custom-made holder to minimize 
body and eye motion (Figure 2.6). The design of the holder was gradually developed 
during the experiments. The goniometric stage on which rats were placed was rotated 
to allow the optic disc to be clearly viewed with an ophthalmoscope. The optic disc 
was placed at the centre of field view by the sample arm optics to match the 
orientation of the OCT instrumentation. Narrow field scans were collected to focus on 
details of the optic disc whereas wider field scans were collected to the extent that the 
optics of the collection system would allow.
48
1050nm 
light source
grating^
reference
arm
InGaAs
camera spectrometer
patient
module
acquisition
computer
Figure 2.5. A photograph o f a custom-built OCT system (A) and schematics o f the 1050-nm encoded 
frequency domain OCT system (B). The broadband source is interfaced to a fiber-optic inferometer where 
the first arm is sent to an adjustable reference mirror in a free-space portion including dispersion 
compensation and an attenuator. The patient module consists o f collimation and focusing optics and a 2-D 
scanner. On its way back, the light from the sample arm is recombined with the reference light, producing a 
spectral interference pattern that is sent to an all-reflective imaging spectrometer with a reflective planar 
grating. Processing of the signal from the InGaAs camera is performed with a standard industrial personal 
computer, while an independent digital signal processor (DSP) serves the position galvanometers and 
synchronizes the acquisition (copied and cited from Povazay et al., 2007).
Figure 2.6. Photographs of a custom-built set-up for OCT imaging in vivo. A goniometric 
stage with a holder (A). An experimental rat placed in a holder to minimize body and eye 
motion (B). Imaging of the rat that has been rotated to a position to align the focusing 
beam with the optic disc. The rat had a mask for isoflurane inhalation (C). An OCT image 
of a retina with an optic nerve head displayed on the monitor (D).
Initially, during the entire procedure, BSS was applied to both eyes to prevent them 
from drying out. Later, zero-power, glass contact lenses were filled with ophthalmic 
saline and placed on the imaged eyes to prevent loss of corneal surface quality since 
the quality of the images was improved with lenses as compared to the images 
obtained from hydrated eyes. Rat eyes were imaged once before inducing 
experimental glaucoma by bead injection and then once (n=4 rats) 7-10 days after 
injection or twice: (n=5 rats) 7-10 days and 17-32 days after injection (Figure 4.9A).
Image acquisition system
A spectrometer based OCT engine utilizing a 70nm bandwidth (FWHM) light source 
centred at 1050 nm, was mated to a custom built ophthalmic sample arm. The beam 
at the exit pupil of the sample arm was approximately collimated (the sample arm 
allows +/- 8 Diopters of adjustment via Bidal system) at 0.5 mm l/eA2 diameter. The 
non-contact system allowed a working distance of 2 cm. A typical volume acquisition 
used was 500 x 500 scans, 15 degrees full scan centred at optic nerve head (ONH).
Postprocessing procedure - quantitative image analysis
The OCT data was processed for visualization using ImageJ. The steps involved: 
registration, filtering and reslicing. Manual segmentation was performed using 
custom-built Java code. Segmentation data was analysed and graphed using custom 
MATLAB code.
The protocol for data processing in ImageJ:
1. Import stack into ImageJ
2. Manually delete maybe the first, second and final slice due to image artefacts.
3. makeRectangle(l, 46, 511, 551); <— These dimensions apply to 512x512 images, 
and were different in 1024x1024 images
4. run("Crop");
5. run("8-bif'); <— by making the image '8-bit', any changes in contrast and 
brightness can be applied to the image and saved.
6. run("Brightness/Contrast..."); Manually adjust brightness/contrast
7. run("Remove Outliers...", "radius=0.5 threshold=0 which=Dark stack");
8. run("Remove Outliers...", "radius=0.5 threshold=0 which=Bright stack");
9. run("Brightness/Contrast..."); Manually adjust brightness/contrast again
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10. Select the middle slice as a reference point
11. run("StackReg ", "transformation=Translation"); <—StackReg
12. run("Reslice [/]...", "slice=1.000 start=Top avoid");
13. run("A trous filter stack", "kl=5 k2=2.2 k3=2.2 k4=0 k5=0 non std=1.50"); <—
14. run("Reslice [/]...", "slice=1.000 start=Top avoid");
15. run("Brightness/Contrast..."); Manually adjust brightness and contrast one final 
time.
16 Save as ..._newfilt.tif 
Postprocessing procedure - segmentation
Segmentation of the different layers was performed by distinguishing the texture of 
different layers and their interfaces. The retinal fibre layer (RNFL) thickness was 
segmented at the scleral rim (the inner limiting membrane, ILM to the retinal pigment 
epithelium, RPE). The ILM was identified, when starting from the vitreous, by 
finding the first signal above a threshold and the strongest signals in every depth scan. 
The RPE was identified the same way when starting from the opposite side of the 
tomogram (scleral side). The retinal nerve fiber layer surface was easily identified in 
all images..
Quantification of RNFL thickness
RNFL thickness was quantified from the OCT images of control and experimental 
eyes at different imaging times (Figure 4.9B). The mean was taken across the 
population of retinas. For the thickness comparison, the values for injected and 
control eyes were grouped according to the time of imaging (before injection, 7-10 
days or 17-32 days post injection), and the mean values from each group were 
compared to the mean values from other groups.
Statistics
Differences in RNFL thickness were analysed by Independent Sample T-test in SPSS 
16 for comparisons between different time points of imaging within the same group of 
eyes (control or experimental) or the same time points within different group of eyes. 
Data were expressed as the mean ± SEM (Figure 4.10).
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OCT data processing and postprocessing procedure was performed Dr Alex 
Tumlinson, Ketan Kapoor and Vedran Kajic. Vedran Kajic performed a manual 
segmentation. Ex vivo FD-OCT imaging was performed by Alicia Charlton, Dr Boris 
Povazay and supervised by Prof Wolfgang Drexler. I performed OCT imaging in vivo 
and data analysis of RNFL thickness.
2.3. Ex vivo evaluation of glaucomatous changes in experimental 
glaucoma models
2.3.1. Ex vivo FD-OCT imaging
Rats used for ex vivo OCT imaging were injected with hypertonic saline and perfused 
using 4% paraformaldehyde in 0.1 M phosphate buffer (section 2.3.1.5). The 
dissected posterior eye-cups containing retina were stored in fixative (4% 
paraformaldehyde) at 4°C until required for imaging. The samples were imaged by 
two optical coherence tomography systems, a 1300 nm Thorlabs Swept Source OCT 
(SS-OCT) and an 800 nm Three Dimensional Ultrahigh Resolution OCT (3D UHR- 
OCT). The left glaucomatous eyes were imaged using both OCT machines while the 
right control eyes only using the 800 nm UHR-OCT. Imaging parameters were 
determined according to the anatomical structures that were required to be visualised.
The OCT images from the rat CR308 were compared to the histological images of 
retinal sections from the same rat (Figure 4.13). Wax sections were prepared as 
described in section 2.4.2.2 and stained with Hoechst solution, as described in section
2.3.2.
2.3.2. Hoechst labelling
Hoechst solution, (bisbenzimide, Sigma-Aldrich), which labels cell nuclei by binding 
to DNA, was prepared by diluting a stock solution of 1 mg/ml bisbenzimide in PBS (1 
pi of 1 mg/ml bisbenzimide in 1ml PBS). Frozen sections were stained with Hoechst 
solution for 10 minutes, washed 3 times in PBS for 5 minutes each, and then mounted 
in Hydromount aqueous non-fluorescing mounting medium (National Diagnostics
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BDH, UK). The slides were then covered with aluminium foil and left to dry 
overnight. Hoechst stained sections were observed using a Leica AF6000 fluorescent 
microscope and imaged using Leica CTR6000 software.
2.3.3. Diolistics and analysis of RGC morphology (magnetic bead model)
2.3.3.1. Retinal dissection
Retinal dissection was performed as described in section 2.1.2 for the optimised 
protocol, except that antibiotics were not used for the short-term culture.
2.3.3.2. Preparation of dye-coated particles and diolistic labelling
Thirty milligrams of tungsten particles (-1.7 pm in diameter, Bio-Rad 165-2269) 
were spread on a clean glass slide. Three milligrams of l,r-dioctadecyl-3,3,3’,3’- 
tetramethylindocarbocyanine perchlorate (Dil, N-22880, Molecular Probes, UK) was 
dissolved in 100 pi of dichloromethane (methylene chloride, Sigma Diagnostics, UK) 
and applied over the tungsten particles on the glass slide. Dichloromethane quickly 
evaporated, and the tungsten particles were coated with Dil (Sun et al., 2002). After 
drying for 10-15 minutes, the dye-coated tungsten particles were scraped off with a 
clean razorblade onto a weighing boat. One end of the tubing (Bio-Rad) was sealed 
with parafilm and a 1-5 ml pipette tip was placed into the other end of the tubing. The 
powder was poured into the pipette tip and thus into the tubing. The open end of the 
tubing was then sealed, and the tube was shaken to get the powder to stick evenly 
across the whole tubing. Immediately before shooting, the “bullets” were cut into the 
appropriate lengths using the tube cutter (Bio-Rad) for use in the gene gun. A hand­
held gene gun (Helios Gene-gun, Bio-Rad) was used to propel the dye-coated 
particles into the wholemount retina. In order to prevent clusters of dye-coated 
particles from landing on the preparation, cell culture inserts (Becton Dickinson 
Labware, UK) with 3 pm pore size were interposed between the gene gun and the 
target tissue. The dye-coated particles were propelled into the tissue at a pressure of 
70-150 psi. The retinal preparations were fixed with 4% paraformaldehyde in 0.1 M 
phosphate buffer (pH 7.4) for at least 40 minutes before the subsequent Hoechst 
staining (section 2.1.6.3).
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Images of the Dil-labelled RGC stacks from the slides with wholemount retinas were 
obtained using a Zeiss LSM510 laser scanning confocal microscope and LSM510 
software.
2.3.3.3. Analysis of morphological parameters
The imaged Dil-labelled dendritic trees of RGCs were subjected to quantitative 
morphological analysis. The Sholl analysis was performed using Fast Sholl Matlab- 
based program (Gutierrez and Davies, 2007). In addition, the program made it 
possible to estimate the total dendritic length and the number of branching points. For 
dendritic field size, a polygon was drawn by linking the tips of dendrites, and the area 
calculated with ImageJ. Statistical analysis was performed in commercial 
softwareSPSS (SPSS, ver. 16.0 for Windows) using Mann-Whitney Test or 
Independent Student T-Test, with a significance level of p<0.05.
2.3.3.4. Neuron nuclei imaging and counting
For the quantification of retinal ganglion cell loss, retinas were prepared as 
wholemounts (retinal ganglion cell side up) and stained with a Hoechst 33342 (Sigma, 
UK) solution of 1 mg/ml bisbenzimide in PBS for 20 minutes, washed 3 times in PBS 
for 5 minutes each and mounted in Prolong Gold antifade medium (Invitrogen, UK). 
The number of cells in the retinal ganglion cell layer was counted to provide an index 
of cell damage. Although amacrine cells would have been included in the analysis 
(Cowey and Perry, 1979; Munemasa et al., 2008; Perry, 1981), this has been validated 
in the mouse glaucoma model as a useful surrogate measure of retinal ganglion cell 
damage that avoids the variability associated with RGC labelling (Jakobs et al., 2005). 
Images of the RGCL (retinal ganglion cell layer) were obtained using a fluorescent 
microscope (Leica 6000B) linked to (Microbrightfield) and Stereo Investigator 
(Microbrightfield) software. Retinal specimens were placed on a motorized stage and 
the cells in the RGCL were imaged with a 20x objective in a total of 12 fields (each 
with an area of 217141.8 pm2) arranged in a grid centred on the optic nerve. The 
number of labelled cells in each image, after cropping the image to 113094.7 pm2, 
was counted manually using the Cell Counter plug-in for ImageJ (NIH Image, NIH,
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USA). Approximately 2.4% of the retina was evaluated for cell count. Standard 
morphologic criteria were applied for discriminating non-neuronal cells (endothelial 
and glial cells) from neuronal cells.
Statistical analysis was performed using commercial software SPSS ver. 16.0 for 
Windows). Normally distributed data were compared using One-way Anova. IOP 
measurements for single animals were expressed as mean ± standard deviation (SD). 
Group values were expressed as means and standard errors of the mean (SEM).
2.3.4. Croyosections of the anterior chamber
The eye-cups were transferred into 30% sucrose in 4% PFA for 24-48 hours before 
sectioning. Cryosections (10 pm thick, cut on a sliding microtome) of the anterior 
chambers prepared on gelatine-coated slides were stained with Harri’s Haematoxylin 
which model and Eosin (H&E) (as described in section 2.1.6.2) and mounted under 
DPX (Raymond A Lamb) for DIC imaging. Section images were taken using a Leica 
DMRA2 brightfield microscope and Leica QWin v3 software.
2.4. Biochemical and immunohistochemical analyses of GAGs in a rat 
retina
Biochemical and immunohistochemical analyses of glycosaminoglycans (GAGs) in a 
rat retina were performed to identify differences in size and distribution of GAGs in 
young, old and glaucomatous retinas.
2.4.1. Biochemical analysis
2.4.1.1. Animals
Retinas used for biochemical analysis were obtained from 3 weeks old, old normal 
(including one chABC-injected eye) and old glaucomatous rat eyes (old eyes were 
over 6 months old). The adult normal eyes were contralateral to the glaucomatous 
eyes injected with magnetic beads.
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2.4.1.2. Guanidine extraction
After the rats were killed using C02, retinas were dissected and placed directly into 
the extraction buffer consisting of: 4 M guanidinium chloride, 0.05 M sodium acetate 
containing 0.01 M Na2EDTA, 0.1 M 6-amino hexanoid (caproic) acid. Directly 
before use, inhibitors were added to the extraction buffer: 5 mM benzamidine-HCl 
and 0.5 mM phenylmethylsulphonylfluoride (PMSF). The extraction was carried out 
at 4°C for 48h with continuous rolling. After extraction, the samples were centrifuged 
and supernatant was retained and dialysed exhaustively against Milli-Q grade water 
using Spectro/Por Dialysis Membrane 25mm/16mm (Spectrum Laboratories, Inc.).
2.4.1.3. Protein assay
Protein assay was performed using Quant-iT Protein Assay Kits (Invitrogen, UK) 
according to manufacturer instructions.
2.4.1.4. SDS-PAGE
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to separate proteins according to size. Proteinase-free chondroitinase ABC (Sigma) 
(0.01 unit/10 pg of GAG) was added to each sample to digest CSPGs and generate 
chondroitin sulphate stub epitopes. Digestion was carried out overnight at 37°C. 
Samples were diluted with an equal volume of 2X sample buffer, 1M Tris Acetate, pH 
8 (0.125 M Tris HC1, 4% SDS, 20% glycerol and 0.01% bromophenol blue pH 6.8) 
with 5% p-mercaptoethanol (Sigma). Samples were then boiled for 5 minutes to allow 
denaturation of the proteins prior to being loaded onto 4-12% Tris-glycine gels 
(Invitrogen) together with a marker (Bio-Rad, All Blue). Eighty pg GAG was loaded 
per lane. Samples were then subjected to electrophoresis in SDS-PAGE running 
buffer (192mM Glycine, 0.1% SDS and 25mM Trizma pH 8.3) at 120-150V.
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2.4.1.5. Western blotting
Following SDS-PAGE, proteins/proteoglycans were transferred onto nitrocellulose 
paper (Scheiler and Schuell Protran BA 83) in SDS-transfer buffer (25 mM Trizma, 
192 mM Glycine, 20% Methanol, pH 8.1-8.4) at 100V for 1 hour using the Bio-Rad 
electrophoretic transfer system. That was followed by blocking the nitrocellulose 
membrane with 5% bovine Serum Albumine (BSA) (Sigma) in PBS on a rocking 
plate for 1 hour. After washes in PBS, the membrane was incubated overnight at room 
temperature with primary antibodies diluted in 1% BSA in PBS as follows: mAbs 
2B6 (1: 100), 3B3 (1:10), 6B4 (1:100), 1B5 (1:100). PBS was then used to remove 
unbound primary antibodies, following addition of the secondary alkaline phosphatase 
(AP) conjugated mouse antibody (Promega) at 1:7500 dilution in 1% BSA in PBS for 
1 hour at room temperature. Unbound secondary antibodies were then rinsed off with 
three 10 minutes washes in PBS. Finally, bands were visualised using the substrate of 
10 ml AP buffer (100 mM NaCl, 5mM MgC12 and 100 mM Tris base pH 9.55) with 
66 pi Nitro Blue Tetrazolium (NBT) (Promega) and 33 pi 5-bromo-4-chloroindol-3-yl 
phosphate (BCIP) (Promega) at room temperature until colour had developed. The 
reaction was stopped by washing the membrane with water.
2.4.2. Immunohistochemistry
2.4.2.1. Animals
Immunohistochemical analysis was conducted on retinal sections obtained from 8 
weeks old, old normal and old glaucomatous rat eyes (old eyes were over 6 months 
old). The old normal eyes were contralateral to the glaucomatous eyes injected with 
hypertonic saline.
2.4.2.2. Preparation of wax sections
Rat eyes were enucleated and the anterior chamber was cut away from the rat eye. 
The eyes were dehydrated through a series of increasing alcohol concentrations (v/v 
distilled water) as follows: 50% alcohol for 30 minutes, 70% alcohol for 1 hour, 90% 
alcohol for 1 hour, 100% alcohol for 1 hour and 100% alcohol for 30 minutes. 
Dehydrated tissue was then immersed in 50% v/v mixture absolute alcohol/xylene for
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10 minutes and twice 100% xylene for 10 minutes. Then, most of the xylene was 
poured off and the eyes were warmed by placing in a wax oven for 10 minutes. 
Tissues were blotted on filter paper and placed into molten wax in clean pots in the 
oven for 30 minutes to remove xylene, then transferred to fresh molten wax and left 
overnight to ensure wax had impregnated the tissue. Finally, tissues were embedded 
in wax as described above and then refrigerated overnight. The wax blocks were 
removed from the mould, trimmed and then 7 pm serial sections were cut on a 
microtome (Microm HM330). Selected sections were placed into a cold water bath, 
then into a hot water bath (40°C), and finally transferred onto microscope slides with 
an adhesive coating (Histobond Lamb, UK). The slides were dried on a hot plate at 
36°C and then incubated at 56°C in an oven overnight to allow the sections to adhere 
to the slides.
2.4.2.3. Chondroitinase ABC digestion and immunostaining using DAB method
Wax sections were dewaxed by immersion in two changes of fresh xylene for 10 
minutes each and rehydrated through a series of decreasing alcohol concentrations 
(v/v distilled water) twice for 5 minutes in 100% alcohol, 3 minutes in 90% alcohol 
and 3 minutes in 70% alcohol, followed by washing in cold running water for 5 
minutes. The space around the sections was marked with a hydrophobic marker. 
Chondroitinase ABC (0.4U chABC/lml buffer) (Sigma, UK) was pipetted onto the 
sections to digest GAGs. The slides were left at 37°C for 2 hours. After 2 hours, the 
slides were washed in PBS for 5 minutes and then blocked with 0.25% fish skin 
gelatine, 5% goat serum, 0.1% Triton X-100 in PBS for 1 hour at room temp. The 
block was removed and primary antibodies were added at 1:100 dilutions in PBS 
(2B6, 3B3, 1B5,) or at 1:10 dilution in PBS (6B4). Monoclonal antibodies 2B6, 3B3, 
1B5 and 6B4 are specific to chondroitinase-generated chondroitin-4-sulphate (C4S), 
chondroitin-6-sulphate (C6S), chondroitin-0-sulphate (COS) disaccharide epitopes and 
aggrecan core protein IgD domain, respectively. Following an overnight incubation at 
4°C, the slides were washed 3 times for 5 minutes in PBS. Goat anti-mouse 
biotinylated secondary antibody diluted 1:100 in PBS was added to the slides and left 
at room temp for 1 h. After washing slides 3 times for 5 minutes in PBS, Vectastatin 
ABC reagent (antibiotin) (Vector, UK) was applied to slides for 30 minutes to detect 
immunolabelling. The slides were washed in PBS for 5 minutes, then DAB reagent
59
(peroxidise substrate solution) (Vector, UK) was used to visualise immunolabelling 
according to manufacturer’s instructions except that nickel-brown solution was not 
added to give a brown colour. Development of colour reaction was carried out for a 
maximum of 10 minutes. The slides were washed in water, dehydrated through a 
series of alcohols, cleared in xylene and mounted in DPX.
In addition, immunohistochemistry was conducted on a single chABC-injected, non- 
glaucomatous retina to confirm the presence of the enzyme in a rat retina following an 
intravitreal injection. The protocol used was as described above except that the 
primary antibody dilutions (3B3, 1B5, 2B6) were pooled together.
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Chapter 3: Retinal explant culture
3.1. Introduction
Establishment of a retinal explant culture technique
Retinal explant cultures serve as a model of glaucoma because the explanation of the 
retina requires the severing of all axons within the optic nerve and the consequential 
degeneration of RGCs. This system is particularly useful for experiments that cannot 
be performed in vivo due to limitations involving tissue access, confounding systemic 
factors, or control over microenvironment. Although tissue culture systems cannot 
reproduce the complexity of the natural environment completely, they provide a 
system that is more controllable and stable than in vivo systems. The control over this 
in vitro system can be further enhanced by using defined, serum-free media 
formulations (Johnson and Tomarev, 2010).
One way of transfecting retinal explants is to deliver genes by particle bombardment, 
also known as “gene gun” delivery or “biolistics”. This technique, first developed by 
Sanford, Klein and colleages as a method of gene transfer to plant cells, is a physical 
method of cell transfection in which high density particles coated with genes are 
accelerated to a high velocity by a gun apparatus to penetrate cell membranes (Klein 
et al., 1992; Sanford et al., 1987). A main advantage of this method, as compared to 
other transfection techniques, is that it is not dependent on target cell characteristics 
such as electrical potential, specific ligand receptors and /or the structural components 
on the cell surface (Uchida et al., 2009). This method has been useful in efficient 
transformation of various organisms and targets including mammalian cells (Zelenin 
et al., 1989), bacteria (Smith et al., 1992), fungi (Armaleo et al., 1990) and 
intracellular organelles (Johnston et al., 1988). In contrast to viral techniques, the 
biolistic transfection requires less advanced molecular biology facilities and is devoid 
of the side effects related to the use of recombinant viruses. In addition, the location 
of transfection can be determined by the specific areas of the tissue that are 
bombarded by gold particles. However, the biolistic transfection technique might 
contribute to the difficulties encountered in keeping the cultures alive due to 
mechanical stress resulting from the procedure. Therefore, the pressure wave should 
be minimised in order to avoid mechanical damage of the culture while maintaining 
enough particle acceleration for the desired degree of penetration (Lo et al., 1994).
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Experimental design
The purpose of the present study was to optimise culture conditions for an adult rat 
retina, to allow retinal explants to be maintained over a period of time sufficient to 
express fluorescent proteins in retinal culture, which is a key factor determining good 
labelling (section 2.1 & 2.1.2). A subsequent aim was to optimise parameters for gene 
gun delivery technique into retinal ganglion cells (section 2.1.5). The expression of 
genes delivered to retinal ganglion cells by particle-mediated transfer enabled an 
investigation of the morphology of retinal ganglion cells and the effects of expressed 
proteins on morphological changes of the cells in the axotomised retina (section 
2.1.5.1). Another method of cell labelling used in this study was the diolistic method, 
which enabled random RGC labelling with gene gun propelled lipophilic fluorescent 
dye, Dil, coated particles (section 2.1.5.2). As with the biolistic technique, the 
diolistic method enables the visualization of the dendritic field, the cell body, and the 
intraretinal axon of each labeled neuron (Qin et al., 2006). Both techniques, biolistic 
and diolistic, require viable tissue to label RGCs. However, the “shooting” with the 
diolistic technique can be done almost immediately after retinal explanation whereas 
biolistics requires at least 24 hours of culture before the labelled cells can be 
observed. In general, better labelling is obtained with the biolistic technique due to the 
expression of fluorescent proteins.
The initial step for optimisation of culture conditions was to assess the effects of 
various media formulations on the viability of retina in culture (sections 3.2.1 & 
2.1.4). The viability of the retinal preparations incubated in two different media 
formulations was compared using propidium iodide and a vital dye calcein. Propidium 
iodide is a red marker of necrosis that labels the nuclei of non-viable cells but cannot 
cross the membrane of viable cells (Smith et al., 2007). Calcein is retained in cells 
with intact membranes, where the nonfluorescent calcein is converted to a green- 
fluorescent calcein (Caspi et al., 2007; Decherchi et al., 1997).
Since the initial results showing transfected RGCs were difficult to reproduce (section 
3.2.2), it was likely that the process of transfection might affect the survival of retinas. 
To understand the effects of biolistic transfection on the culture survival, the retinas 
were shot with gold particles (1.6 pm diameter, 0.2 pg plasmid / cartridge, 20 mg gold 
for 20 cartridges) at 150 psi using a filter with 70 pm pore size to protect the tissue
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from the shock wave and the viability of the non-shot retinal explants was compared 
to the viability of the explants propelled with plasmid DNA-coated gold particles 2 
days post shooting, using the vital dye, calcein (sections 3.2.3 & 2.1.4).
Once the culture conditions and biolistic transfection were optimised, it was possible 
to study the effects of various factors on neuronal survival and the number of axonal 
growth cones, as described in sections 3.2.5 & 2.1.6. Statistical analyses were 
performed using Mann-Whitney Test in SPSS 16.0.
3.2. Results
3.2.1. Assessment of retinal explant viability with calcein AM and propidium 
iodide
Retinal wholemount preparations were cultured for 1 day in duplicate in 50% 
Dulbecco's Minimal Essential Medium (as described in the section 2.1.3, according to 
Gutierrez et al., 2005) or Neurobasal-A containing 2% B27 supplement, 1% N2 
supplement, 0.8mM L-glutamine and lOOU/ml penicillin/streptomycin (according to 
Wang et al., 2002) or in Hank’s Balanced Salt Solution (HBSS) for control. The 
retinas were stained with propidium idodide and calcein AM to asses the viability of 
tissue. The results were based on a single experiment (Figure 3.1).
The mean values of calcein and propidium iodide labelling intensity in explants were 
compared to determine differences in the viability of tissue cultured in different 
media. The method of measuring intensity (RGB±SD) is described in Methods 
Chapter 2, section 2.1.4.1. The intensities of red propidium iodide staining were 
56.50±12.19, 34.19±3.86 and 27.94±5.24 in retinas incubated in HBSS, Dulbecco's 
Minimal Essential Medium and Neurobasal-A medium, respectively (Figures 3.1 A, C, 
E & 3.2A). The fluorescent intensities of calcein staining were 24.27±3.2, 31.51±3.53 
and 38.45±17.70 in retinas incubated in HBSS, Dulbecco's Minimal Essential 
Medium and Neurobasal-A medium, respectively (Figures 3.IB, D, F & 3.2B).
64
After 3 days in culture, intensive staining with calcein AM (67.43±10.33) and low 
counterstaining with propidium iodide (28.55±1.95) were observed in retinal explants, 
indicating the good viability of the specimens (Figure 3.3).
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PROPIDIUM IODIDE CALCEIN
Figure 3.1. Fluorescent images of wholemount retinal explants stained with propidium 
iodide (A, C, E) and calcein (B, D, F) cultured in HBSS (control) (A, B), MEM (C, D) and 
Neurobasal-A (E, F) for 1 day. Scale bars: 50 pm.
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Figure 3.2. Mean values o f propidium iodide (PI) (A) and calcein AM (B) fluorescence 
intensity from retinal explants, based on a single experiment. Diagonal bars indicate 
fluorescence intensity in explants cultured in HBSS, grey in MEM and black in 
Neurobasal-A medium. Error bars indicate standard deviation (SD).
Figure 3.3. Positive staining of retinal explants with calcein AM (A) and counterstaining 
with propidium iodide (B) shows good survival after 3 days in culture. Scale bars: 500 pm.
3.2.2. Evaluation of the biolistic transfection technique
Since assays (section 3.2.1) demonstrated the viability of explants after 3 days in 
culture (Figure 3.3), the applicability of the particle-mediated gene delivery to the 
tissue was assessed. In the present study, the success of plasmid delivery was 
examined by the observation of fluorescent protein expression after biolistic transfer 
of plasmid DNA-coated gold particles.
Since mice were more needily available for the experiments than rats, the initial 
experiments with biolistic transfection were performed using mouse retinal explants. 
Mice retinas were isolated (as described in section 2.1.2) and mounted ganglion cell 
side up on a black Millipore filter paper or on 0.4 pm Millicell culture plate insert 
(Millipore) and incubated in Neurobasal-A (as described in section 2.1.3). After 
approximately 1-2 hours of incubation at 37°C, the retinas were transfected by the 
biolistic delivery of gold particles coated with a pYFP only (Figure 3.4) or pYFP and 
pRFP (Figure 3.5). The microcarriers were propelled into the retina at a delivery 
pressure of 150 psi. Fluorescent protein expression was observed in 1 out of 2 retinas 
at 2 days post transfection (Figure 3.4) or in 1 out of 4 retinas at 1 day post 
transfection (Figure 3.5). In Figure 3.4, dendritic fields with somas were clearly 
visible in 4 cells (3 labelled red, 1 yellow and 1 green), while in 3 cells (2 labelled 
yellow and 1 green) only somas were visible. Axons were not visible in any of these 
cells. A neuron with a cell body, a medium-sized dendritic field and an axon was 
observed in Figure 3.5 B. Although the preliminary results showed the presence of 
some transfected RGCs, it was difficult to reproduce these results, suggesting that 
further optimisation of the technique was required.
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♦Figure 3.4. Expression of YFP and RFP in mouse RGCs, 2 days post transfection. 
Confocal image of RGCs transfected with expression plasmids for YFP (labelled green) 
and RFP (labelled red). Some cells were labelled with pYFP and pRFP (labelled orange). 
Scale bar: 100 pm.
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Figure 3.5. Expression of YFP in mouse RGCs, 1 day post transfection. Confocal images 
of RGCs transfected with expression plasmids for YFP (labelled yellow). The arrow 
indicates an axon. Scale bars: 100 pm.
3.2.3. Assessment of the effect of ballistic transfection on tissue survival
Since the initial results showing transfected RGCs were difficult to reproduce (section
3.2.2), it was likely that the process of transfection might affect the survival of the 
retinas. The fluorescent intensity of calcein staining varied between the samples shot 
with DNA-coated gold particles using a gene gun and the non-shot samples, the 
fluorescent intensity of calcein being higher in the non-shot preparations, and 
displaying an intense green fluorescence (Neurobasal-A with serum, 47.06±4.60; 
Neurobasal-A, 35.91±7.52) (Figures 3.6 B, D & 3.7), in contrast to lower fluorescence 
intensity in the shot explants (Neurobasal-A with serum, 21.81±2.37; Neurobasal-A, 
16.58±3.02) (Figures 3.6 C, E & 3.7). The explants incubated in HBSS (17.29±1.04) 
were found to be unattached to the inserts, indicating that tissue had died. These 
observations suggested that the viability of the culture was disrupted by the biolistic 
particle-mediated gene transfer, which was probably due to the mechanical shock 
associated with the procedure. The results were based on a single experiment.
3.2.4. Assessment of the morphology of labelled RGCs using the diolistic 
technique
In addition to ballistic labelling, the morphology of RGCs can be assessed in tissue 
labelled with a lipophilic dye -  Dil. Although this strategy can not be used in 
combination with gene delivery, it can be applied to test the effects of various growth 
factors and other reagents added to the culture medium on the RGCs morphology and 
remodelling. In order to observe the morphology of labelled RGCs in fixed retinal 
explants, retina was labelled by the ballistic delivery of tungsten particles coated with 
Dil followed by fixation in 4% paraformaldehyde. The Dil staining of retinal culture 
demonstrated that the morphology of cells had been preserved during the diolistic 
labelling procedure. Cell soma, dendritic field and axon were all visible after labelling 
(Figures 3.8 A & B). The final protocol for diolistic labelling that was used in the later 
experiments (chapter 5) is described in section 2.3.3.2.
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Figure 3.6. Fluorescent images of wholemount retinal explants stained with calcein AM, 
cultured in HBSS (A), Neurobasal-A with B27 and N2 supplements (B, C) and Neurobasal- 
A with B27 and horse serum (D, E) for 2 days. Intense green fluorescence was detected in 
the non-transfected samples (B, D), in contrast to the virtually absent fluorescence in the 
transfected samples (C, E). The gold particles were propelled into explants at a pressure 
200 psi. The images were taken from the centre o f the wholemount preparations. Scale 
bars: 200pm.
Figure 14. Fluorescent images o f wholemount retinal explants stained with calcein AM, cultured 
in HBSS (A), Neurobasal-A with B27 and N2 supplements (B, C) and Neurobasal-A with B27 and 
horse serum (D, E) for 2 days. Intense green fluorescence was detected in the non-shot samples 
(B, D), in contrast to the virtually absent fluorescence in the samples that were shot with DNA- 
coated gold particles (C, E). The images were taken from the centre of the wholemount 
preparations. Scale bars: 200pm.
Figure 3.6
72
70
&
</> 60 i
1
C  50
0> o  c<D O </>
£  30
o□
a>o
<TS
O
40
20
0 HBSS N+serum N+serum
Figure 3.7. Mean values o f calcein AM fluorescence intensity in retinal explants, based on 
a single experiment. Diagonal bars indicate fluorescence intensity in explants cultured in 
HBSS, grey bars indicate fluorescence intensity in explants that were not shot with DNA- 
coated gold particles, incubated in Neurobasal-A medium with serum (N+serum) or 
Neurobasal-A medium (N) and black bars indicate fluorescence intensity in explants that 
were shot with DNA-coated gold particles, incubated in Neurobasal-A medium with serum 
(N+serum) or Neurobasal-A medium (N). The Error bars indicate standard deviation (SD).
BFigure 3.8. Confocal images o f RGCs from fixed retinal explants labelled with Dil-coated 
tungsten particles. Retinal explants were cultured in Neurobasal-A medium (with B27 
supplement, horse serum, L-glutamine and penicillin/streptomycin) for approximately 15 
minutes before labelling. The somas, dendritic fields and axons are visible. Scale bars: 100 
pm.
3.2.5. Effects of caspase inhibitors and BDNF on neuronal survival and the 
number of axonal growth cones after axotomy
Retinal explants have been used to study the effects of inhibiting the apoptotic 
pathway on retinal ganglion cell death (Kermer et al., 2000). In the present study, 
biolistic transfection of retinal explant cultures as a model to study RGC survival and 
axonal growth cones formation in living retinal ganglion cells was used. The effects 
of caspase inhibitors and BDNF on neuronal survival and the number of axonal 
growth cones after axotomy were tested. Retinas were isolated from Brown 
Norwegian male rats at 8-12 weeks of age.
3.2.5.1. Effects of caspase inhibitor on the survival of transfected RGCs
Thirty one explants per group were cultured in the medium supplemented with either 
a broad-spectrum caspase inhibitor or control medium. A significant increase 
(P<0.05) in the number of RGCs was observed in retinas cultured with caspase 
inhibitor compared to control explants after 2 days in culture (Figure 3.9). Figure 3.10 
shows an example of RGC cultured in caspase inhibitor-supplemented medium.
3.2.5.2. Effects of caspase inhibitor on the number of axons in the proximity of 
the optic disc
Growth cones on axons were observed in RGCs cultured in caspase-inhibitor 
supplemented with medium after 2 days in culture (Figure 3.11). The production of a 
new growth cone, a structure essential for axonal extension, is required for regrowth 
after axotomy (Bray et al., 1978).
The number of axons per number of transfected RGCs within 500 pm of the optic disc 
was estimated in 31 control and 31 caspase inhibitor-treated explants. RGCs in 
caspase inhibitor-treated explants displayed a significant increase (P<0.05) in the 
number of axons within 500 pm of the optic disc compared to control explants after 2 
days in culture (Figure 3.12).
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Figure 3.9. Average numbers o f surviving RGCs per explant in control and caspase 
inhibitor-treated explants. A two-fold increase in the number of RGCs was observed in 
retinas cultured with caspase inhibitor than in control explants after 2 days in culture. 
Analyses are based on 31 explants per group. Error bars represent standard error (SEM).
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Figure 3.10. RGC transfected with YFP-expressing plasmid, cultured in caspase inhibitor- 
supplemented medium. Scale: 100 pm.
Figure 3.11. Growth cones on axons in RGCs cultured in caspase inhibitor-supplemented 
medium after 2 days in culture. Scale, 20 pm.
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Figure 3.12. Number o f axons within the distance o f 500 pm from the optic disc in control 
and caspase inhibitor-treated explants. RGCs in caspase inhibitor-treated explants 
displayed a significant increase in the number o f axons within 500 pm of an optic disc 
compared to control explants after 2 days in culture. Analyses are based on 31 explants per 
group. Error bars indicate standard error (SEM). * p<0.05.
The confocal images show axons within the distance of 500 pm from the optic disc 
in control and caspase inhibitor-treated explants after 2 days in culture. The retinas 
were transfected with YFP-expressing plasmid (Figure 3.13).
Due to the observation of an increased number of axons near the optic disc, the 
distance from the axon tip to the optic disc was measured after 2 and 3 days in culture. 
The distance to the optic disc was reduced by approximately 40pm after 3 days 
compared to 2 days in culture (Figure 3.14 A & B).
Axonal sprouting was observed after 2 days (Figure 3.14 C) but not after 3 days in 
culture (Figure 3.14 D).
3.2.5.3. The number of axonal growth cones and the number of axons in the 
proximity of the optic disc in BDNF-treated explants
Retinal explants were cultured in the medium with or without BDNF. The number of 
all axons and the number of axons with growth cones was estimated per number of 
transfected RGCs. A significant increase (P<0.05) in the number of growth cones was 
observed in explants cultured with BDNF compared to controls after 2 days in culture 
(Figure 3.15). Figure 3.16 illustrates the growth cones on axons in RGCs cultured in 
control and BDNF-supplemented medium.
The number of axons per number of transfected RGCs within 500 pm of the optic disc 
was estimated in thirteen control and thirteen BDNF-treated explants. There was no 
difference (P>0.05) between BDNF-treated explants and control explants after two 
days in culture (Figure 3.17).
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Figure 3.13. Confocal images of the optic discs from retinas transfected with YFP- 
expressing plasmid. Axons can be seen in the proximity o f the optic discs in control and 
caspase inhibitor-treated explant after two days in culture. Scale: 100 pm.
Figure 3.14. Axon in the proximity of the optic disc after 2 days (A) and the same axon 
after 3 days (B) in culture. The measured distance to the optic disc was reduced by 
approximately 40pm after 3 days compared to 2 days in culture. Axonal sprouting was 
observed after 2 days (C) but not after 3 days in culture (D). Scale: 20 pm.
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Figure 3.15. Ratio of axons with growth cones to all analysed axons (18 for controls and 10 
for BDNF-treated axons). A significant increase in the number of growth cones was 
observed in explants cultured with BDNF compared to controls after 2 days in culture. Error 
bars indicate standard error. * p<0.05.
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Figure 3.16. Growth cones on axons in RGCs from explants cultured in control and BDNF- 
supplemented medium after 2 days in culture. Scale, 20 pm.
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Figure 3.17. Number of axons within the distance of 500 pm from the optic discs in control 
(not exposed to caspase inhibitor) and BDNF-treated explants. Analyses are based on 13 
explants per group. Error bars indicate standard error.
3.3. Discussion
3.3.1. Establishment of retinal explant culture
To establish viable retinal explant culture, culture conditions and biolistic transfection 
were optimised. The first step was optimisation of the dissection procedure, as 
described in section 2.1.2. In the second step, the effects of two different media 
formulations on the retinal tissue viability were assessed using propidium iodide and a 
vital dye, calcein (section 3.2.1). The explants cultured in Neurobasal-A had better 
viability than those incubated in Dulbecco's Minimal Essential Medium and control 
HBSS. Since the results showing the presence of some transfected RGCs were 
difficult to reproduce (section 3.2.2), the next step involved optimisation of the 
biolistic technique, including evaluation of the effects of biolistics on the viability of 
the explants. Viability assays using calcein demonstrated that retinal viability was 
reduced in the explants exposed to the biolistic procedure as compared to the non­
exposed explants (section 3.2.3).
During the course of these experiments, it was established that the helium pressure for 
the gene gun and the pore size of the filter used to protect from the shock wave were 
critical to the survival and successful transfection (not all data have been shown). 
Overall, the viability of tissue (estimated by calcein and propidium iodide staining) 
was better when lower helium pressure (100 psi) with a 70 pm filter was used. In 
addition to using lower pressure, a filter with 3 pm pore size was introduced to protect 
tissues from the shock wave.
Another critical factor to successful transfection was the rats’ age. In the literature, 
young adult rodents were commonly used (Koizumi et al., 2007; Kretz et al., 2004, 
Homma et al., 2007) for retinal explant culture. In general, the survival and 
transfection rate seemed higher in younger animals (data not shown), and therefore 8- 
12 weeks old rats were used in experiment involving caspase inhibitors and BDNF.
The adult mammalian retina is an important model for studying CNS function and 
diseases due to its easily accessible anatomical position, physiological properties and
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highly organised structure. Organotypic retinal cultures, in contrast to dissociated 
cultures, can preserve cell-cell contacts and interactions between various cell 
populations (Xin et al., 2007). Two different approaches for culturing retinal tissue 
have been reported: explant and slice culture (Feigenspan et al., 1993; Gahwiler, 
1981; Ogilvie et al., 1999). Feigenspan et al. (1993) used vertical slices of retina 
cultures on cover slips in a roller-tube system while Duenker et al. (2005) described a 
floating culture of whole-mount retina in a Petri dish (Duenker et al., 2005).
Retinal explant cultures of whole or partial retina were developed to maintain the 
tissue architecture characteristic of the retina in situ (Xin et al., 2007). Retinal 
explants, as other explanted tissues, preserve several histological and biochemical 
qualities of cells, allowing for long-term culture (Seigel, 1999). The explants retain 
the highest level of tissue preservation of all retinal cell culture systems and therefore 
have been used in in vitro studies requiring intact cell-cell associations (Xin et al., 
2007).
Retinas are difficult to culture, primarily due to the high metabolism of the 
photoreceptors (Ames et al., 1992). Therefore, most studies have been performed 
using very young or neonatal retinas with low metabolic demands, since their 
photoreceptors are not yet functional.
In the literature, there are wide variations in the technical aspects of retinal explant 
culture, suggesting that there is no general agreement on the best procedure. Sun et al. 
(2002) cultured a wholemount retina from adult rats on a black Millipore filter in 
oxygenated Ames medium. A slightly different formulation of Ames’ medium (with 
N2 supplement and horse serum) was used to culture adult rabbit retinas on Millipore 
Millicell culture inserts for up to six days (Koizumi et al., 2007). Two different types 
of culture chambers were used in their study (i.e. individual small dishes placed on a 
rocking plate and a large reservoir tank where the culture inserts were kept afloat on 
custom made stands), and the medium was agitated using a magnetic stirrer (Figure 
3.19). The method described by Xin and colleagues (2007) applied HBSS for 
dissection of mouse retinal wholemounts, which were then cultured on poly-D- 
lysine/laminin coated glass coverslips in Neurobasal-A medium containing horse 
serum and B27 supplement. Wang et al. (2002) used DMEM plus N2 for retinal
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explant culture and Neurobasal-A medium containing B27 and N2 supplements when 
prolonged culturing was necessary. DMEM with FCS and Fungizone were also used 
for mouse retinal culture for 4 weeks (Ogilvie et al., 1999).
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Figure 3.18. Incubation o f rabbit retina. Photograph (A) and schematic diagram (B) of the hybrid 
interphase/perfusion chamber (copied from Koizumi et al., 2007).
Since the method for adult rat retinal explant culture had not been previously used in 
our laboratory, it was necessary to develop the technique for culturing retina over a 
period of time sufficient to study protein expression. To optimise this culture 
technique for adult rodent retina, various culture protocols, described previously by 
other investigators, were tested. In preliminary experiments, the effects of two 
different media formulations on the culture viability were compared. One of the tested 
media, 50% Dulbecco’s Minimal Essential Medium, has been used to culture cortical 
slices from mouse cerebrum (Gutierrez et al., 2005).
Neurobasal-A is a serum-free medium that incorporates modification such as serum- 
free medium supplement B27, additional tropic factors and lower osmolarity to 
DMEM. The medium was formulated for the long-term viability of CNS neurons. It 
has resulted in excellent long-term viability of rat embryonic hippocampal neurons 
after 4 weeks in culture (Brewer et al., 1993). Adult hippocampal neurons were 
cultured for over 3 weeks in B27/Neurobasal culture medium during which they 
regenerated axons and dendrites (Brewer 1997). In addition, Neurobasal-A 
supplemented with B27 and horse serum allowed for maintenance of postnatal mouse 
retina for up to 14 days in culture (Xin et al., 2007). In our study, Neurobasal-A 
formulated, as described by Wang et al. (2002), was used. Using propidium iodide 
and calcein, the viability o f explants incubated in Neurobasal-A and Dulbecco's 
Minimal Essential Medium media was estimated. In addition, a viability of explants 
cultured in Neurobasal-A for another 2 days was estimated (section 3.2.1).
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The significant advantage of an organotypic retinal culture, when used with the 
biolistic technique, is that it enables expression of various genes without designing 
viral vectors or generating transgenic animals (Koizumi et al., 2007). Biolistic 
transfection is an efficient, rapid and flexible method of gene delivery to the retina. It 
allows for transfection of a combination of genes, since different plasmids can be 
coated simultaneously on the gold microcarriers (Koizumi et al., 2007). However, 
mechanical shock associated with this procedure may limit the survival of the culture 
(Lo et al., 1994). In two independent experiments, a few transfected cells at 1 and 2 
day post-transfection were observed. Since these results were not reproducible, our 
next approach was to assess the effects of the particle-mediated gene transfer on the 
viability of the culture using the vital dye calcein. Retinal viability was found to be 
disrupted by ballistic transfection as compared to the viable explants not exposed to 
the procedure, probably due to the shock wave produced by the helium pressure, 
which was set at 150 psi. Another factor that might influence the survival of explants 
during the transfection procedure is the type of screen placed between the gun and the 
culture to protect the cells from the shock wave. A 70 pm nylon mesh screen, as 
described by Gutierrez et al. (2005), was used. Uchida et al. (2009) found that an 
optimal helium pressure was 75 to 100 psi for effective gene gun transfection, 
however damage increased considerably at helium pressure over 150 psi. The results 
indicated that physical cell damage was mainly the effect of collision of the gold 
particles with the cells during particle bombardment (Uchida et al., 2009). 
Considering our findings, the next strategy involved manipulation of the delivery 
pressure and using a screen with a lower pore size. The final protocol for biolistic 
transfection, used for experiments involving caspase inhibitors and BDNF, was 100 
psi with a 3 pm screen (section 3.2.5).
The morphology of RGCs was assessed in fixed tissue labelled with Dil (section 
3.2.4). The diolistic technique allows for fast labelling of numerous cells with a wide 
variety of colours (Gan et al., 2000). Dil labelling of RGCs from normal rat retina 
showed a well preserved neuronal structure.
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3.3.2. Effects of caspase inhibitors and BDNF on neuronal survival and the 
number of axonal growth cones
In our study, a broad-spectrum caspase inhibitor increased the survival of RGCs and 
the number of axons in the proximity of the optic disc after axotomy (sections 3.2.5.1 
& 3.2.5.2.). However, it was not established whether the increase in the number of 
axons was due to the rescue of dying axons or due to axonal regrowth. Exogenous 
BDNF enhanced the number of growth cones on the axons of RGCs, but BDNF 
administration, in the absence of caspase inhibition, did not have an effect on the 
number of axons in the proximity of the optic disc (section 3.2.5.3). However, due to 
the lack of controls, ie freshly isolated retina, this could not be confirmed.
Our observations showing that a caspase inhibitor increased the survival of RGCs in 
culture are consistent with previous studies. In addition, a number of studies 
suggested the effects of caspase inhibitors on axonal regrowth. A decreased amount of 
RGC death was observed in retinal explant cultured with a caspase-3 inhibitor 
(Manabe et al., 2002). Caspase inhibitors-1, -3, -8 and -9 and neurotrophic factors 
such as BDNF and CNTF were reported to have an effect on RGCs survival and 
neurite regrowth in explant culture (Oshitari and Adachi-Usami et al., 2003). The 
most effective in RGC rescue and neurite regrowth was the combination of CNTF and 
caspase-9 inhibitor (Oshitari and Adachi-Usami et al., 2003). These results suggested 
that neurite regrowth can be supported by caspase inhibitors by preventing RGCs 
apoptosis and allowing the rescued RGCs to regenerate neurites (Oshitari and Adachi- 
Usami et al., 2003). Another study found that BDNF and NT-4 (but not NT-3 or 
CNTF) significantly increased the outgrowth of early embryonic and adult 
regenerating retinal ganglion cell axons, however the effect was more subtle in adult 
explants (Avwenagha et al., 2003).
Other growth factors such as insulin-like growth factor (IGF-I) considerably enhanced 
survival and neurite outgrowth from adult rat RGCs in retinal explants via a 
wortmannin-dependent mechanism. The downregulation of IGF-I resulted in the final 
upregulation of caspase-3 leading to RGC apoptosis after optic nerve injury (Homma 
et al., 2007).
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Apart from retinal explants, the effects of caspase inhibitors and neurotrophic factors 
on RGCs survival and regrowth were estimated in other in vitro systems as well as in 
vivo. BDNF was found to affect survival of cultured RGCs isolated from the perinatal 
rat retina (Johnson et al., 1986). Caspase inhibitors, when administered intraocularly 
at the time of the optic nerve transection, protected about 30-35% RGCs from death 
(Chaudhary et al., 1999).
3.4. Summary
The in vitro model of an organotypic retinal culture is relevant to glaucoma, since the 
process of explanation requires RGCs axotomy, resulting in severe axonal damage. 
The advantage of this model is that the conditions can be controlled more precisely 
than in in vivo glaucoma models. The ability to control the in vitro environment offers 
an opportunity to test the effects of long-term application of substances on retina as 
well as to study hypotheses that can not be tested in vivo (Johnson and Tomarev, 
2010).
When used with biolistic transfection, this model allows for expression of proteins in 
the retina and the subsequent observation of changes in RGCs morphology during the 
experimental period. We found that the most critical parameters for the successful 
transfection were the helium pressure, the pore size of a filter between the tissue and a 
gene gun, and the age of animals.
The optimisation of an adult rat retinal explant culture technique together with 
biolistic transfection enabled the assessment of the effects of caspase inhibitors and 
BDNF on neuronal survival and axonal growth cones formation. A broad-spectrum 
caspase inhibitor enhanced the survival of adult RGCs and the number of axons in the 
proximity of the optic disc, while exogenous BDNF enhanced the number of growth 
cones on the RGC axons.
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Chapter 4: Experimental glaucoma: profiling 
intraocular pressure, cell loss and optic nerve 
head damage in experimental glaucoma
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4.1. Introduction
4.1.1. IOP profiles and cell loss
Considerable advances have been made in our understanding of the pathophysiology 
of glaucoma, helped in part by the availability of cost effective models of disease 
based on rodents, such as the rat and mouse (John, 2005; Morrison et al., 2008). 
While spontaneous genetic models of glaucoma exist (John et al., 1999), the use of 
models in which the precise onset of glaucoma can be determined is important for 
grading diseases and for the evaluation of novel therapies.
A variety of methods have been developed for the elevation of intraocular pressure 
(IOP), each with advantages and disadvantages. For example, cautery of episcleral 
vessels (Laquis et al., 1998; Naskar et al., 2002; Shareef et al., 1995; Urcola et al., 
2006), perhaps the simplest method, runs the risk that it might comprise venous 
drainage of the choroid and therefore induce retinal effects unrelated to the elevation 
of IOP. Other methods, such as episcleral vein sclerosis with hypertonic saline 
(method described in results section 4.22) (Morgan et al., 2006; Morrison et al., 1997; 
Nissirios et al., 2008) limit the outflow of aqueous at the level of the trabecular 
meshwork to produce stable and moderate elevations of IOP with a low risk of 
choroidal damage (Morrison, 2005). However, the injections can be technically 
challenging. As a result o f these considerations, alternative methods have been sought 
to induce experimental glaucoma in rodents. Laser occlusion of the episcleral vessels 
(Chiu et al., 2007; Levkovitch-Verbin et al., 2002; Martin et al., 2002; Pease et al., 
2008; Siu et al., 2002; WoldeMussie et al., 2001) can be effective but works best with 
albino animals and requires use of a laser facility. More recently, methods based on 
obstruction of the trabecular meshwork with microscopic beads have been used 
(Urcola et al., 2006), following successful application of this technique in primates 
(Weber and Zelenak, 2001). The injection of microbeads into the anterior chamber is 
straightforward, does not require specialist equipment and can be applied to a range of 
species with only minor modification. Furthermore, the IOP elevation can be 
modulated with subsequent injections. Unfortunately, the principal disadvantage is 
that beads can be difficult to retain following injection, and as a result, they can locate 
to the pupil and compromise visualisation of the retina.
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To address these issues, a novel technique for the induction of ocular hypertension 
using paramagnetic microbeads has been developed (see section 4.4). These beads 
have the advantage that they can be directed specifically to the iridocorneal angle in 
the rodent eye to optimise occlusion of the trabecular meshwork and facilitate 
visualisation of the fundus. Subsequent injections of beads can be given, as required, 
to further modulate the elevation in IOP.
4.1.2. OCT imaging studies: in vivo detection and monitoring of retinal damage 
in experimental glaucoma
The death of retinal ganglion cells axons is associated with thinning of the retinal 
nerve fiber layer (RNFL). RNFL thickness increases at the opening in the sclera, i.e. 
the optic disc. The edge of the disc carries axons that form the neuroretinal rim, while 
the centre of the disc is devoid of axons, forming a cup-shaped cavity recognised 
clinically as the optic disc cup (Elliot, 1917). The shape of the cup changes as a result 
of the degree of axonal loss in glaucoma; thinning of the neuroretinal rim occurs and 
the cup volume increases (Jonas et al., 1999).
According to recent studies, significant structural damage in the optic nerve head 
(ONH) and retinal nerve fiber layer (RNFL) may precede visual field loss. The 
Hypertension Treatment Study (OHTS) showed that disc changes preceded visual 
field abnormalities in more than 50% of patients diagnosed with glaucoma (Gordon et 
al., 2002). Therefore, many studies have focussed on the development of methods for 
improving the quantification of the RNFL. Over the last ten years, ONH and RNFL 
imaging has become widely used to diagnose early glaucoma and the disease 
progression (Li et al., 2010). The imaging technologies used to measure topographic 
parameters of the ONH and RNFL include confocal scanning laser ophthalmoscopy, 
scanning laser polarimetry and optical coherence tomography (OCT) (Ervin et al., 
2002; Mohammadi et al., 2004; Zangwill et al., 2005).
OCT was proposed as a powerful, noninvasive, cross-sectional imaging technique in 
1991 (Huang et al., 1991; Huang et al., 2010) In contrast to the methods described 
above, clinical OCT apparatus provides high-resolution cross-sectional images of the 
retinal nerve at the margin of the optic disc (Cense et al., 2004; Jaffe and Caprioli,
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2004). In this method, RNFL is measured relative to a reference plane, normally 
located at the margin of the optic disc. Although this geometric estimate of RNFL is 
improved compared to confocal or polarimetric techniques, it might be affected by 
optic disc tilt and deformations (Povazay et al., 2007b).
More recently, three-dimensional (3D) quantification of the RNFL became possible 
due to the development of very sensitive (Choma et al., 2003) fast frequency domain 
(spectral) OCT (FD-OCT) techniques (Cense et al., 2004; Leitgeb et al., 2004; 
Wojtkowski et al., 2004) coupled with ultrahigh-resolution OCT (Drexler, 2004). The 
imaging using this technique provides clear delineation of the RNFL relative to the 
scleral rim, an invariant retinal landmark (Povazay et al., 2007b). High-speed, 
ultrahigh-resolution OCT using spectral-Fourier domain detection offers several 
advantages for imaging the rat retina. The ultrahigh image resolution enables 
visualization of individual retinal layers while high-speed imaging enables acquisition 
of 3D-OCT data and high-definition OCT images (Srinivasan et al., 2006). Another 
important advantage of in vivo OCT imaging is that it allows an estimation of 
progressive glaucomatous changes within the same animals without the need for 
sacrificing them (i.e. within animal longitudinal studies).
The purpose of using OCT was to evaluate the changes in the RNFL thickness and 
optic nerve head in experimental glaucoma using frequency-domain optical coherence 
tomography imaging, operating either at 1050 nm (in vivo imaging) or 800 nm (ex 
vivo imaging). For in vivo imaging, the images were obtained from nine rats that were 
imaged before induction of experimental glaucoma by bead injection and up to two 
times after the induction of experimental glaucoma. 1050 nm was used for in vivo 
imaging because it performs better than 800nm in the event that the optical clarity of 
the anterior segment is compromised, as observed in the magnetic bead model, 
particularly in animals with high IOPs. For ex vivo imaging, the dissected retinas were 
imaged post mortem. In this case, ocular hypertension had been previously induced by 
injection of hypertonic saline.
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4.1.3. Experimental design
Calibration of a rebound tonometer is required for accurate measurement of IOP in rat 
eyes. Therefore, the Tonolab rebound tonometer was calibrated in cannulated rat eyes 
(see section 2.2.2). Following calibration, the tonometer was used to monitor IOP in 
awake rats following topical ocular anaesthesia (Wang et al., 2005). Elevated IOP, an 
important risk factor for glaucoma, was initially achieved by an injection of 
hypertonic saline into the limbal episcleral drainage vessels (see sections 2.2.3 &
4.2.2). However, due to some technical issues related to the generation of this model, 
we subsequently developed a novel technique for the induction of ocular hypertension 
using paramagnetic microbeads (see sections 2.2.4.1 & 4.2.3). It has been suggested 
that the injection of microbeads would be the best and simplest way to induce 
experimental glaucoma (Urcola et al., 2006; Weber and Zelenak, 2001). However, to 
preserve the clarity of the optic axis and to optimise location of the beads to the 
iridocorneal angle, magnetic beads were used. The size of the beads was selected 
based on the dimensions of the trabecular meshwork. Therefore, a bead diameter of 
5 pm was selected since this seemed most likely to occlude the spaces reported in the 
rodent trabecular meshwork (Smith et al., 2001).
IOP measurements were made using a Tonolab rebound tonometer under topical 
anaesthesia, which allowed non-invasive determination of IOP (Wang et al. 2005). 
The use of a topical anaesthetic prevents any hypotensive (Jia et al., 2000) or 
neuroprotective (Fujikawa, 1995; Ozden and Isenmann, 2004) effects that might have 
been observed with general anaesthesia. Rats were housed in constant low-level light 
to stabilise the circadian variation in IOP that would normal maximise during the dark 
phase (Johnson et al., 2007).
The IOP profiles were generated for both glaucoma models (4.2.2 & 4.2.3.1). For the 
magnetic bead model, retinas were prepared as wholemounts and stained with 
Hoechst (see section 2.3.2). The mean densities of cells in the retinal ganglion cell 
layer (RGCL) in control and glaucomatous retinas were compared to estimate cell loss 
(see section 4.2.3.2). In addition, RGCs were counted in the rats injected with BSS 
and those in which magnetic beads were not redirected. These controls were produced
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to assess the effect of BSS injection and the effect of using a magnet on the IOP
elevation in the magnetic bead model.
A frequency domain optical coherence tomography (FD-OCT) (Choma et al., 2003; 
de Boer et al., 2003; Fercher et al., 1995; Gerd and Michael Walter, 1998; Leitgeb et 
al., 2003; Nassif et al., 2004) was used to image rat retinas in vivo (section 4.2.4.1 & 
2.2.4.3). The system enables high-speed, high sensitivity and depth-resolved 
measurements of the retina due to analysis of the interference pattern in the optical 
frequency spectrum. The OCT data were processed for visualization using ImageJ. 
The steps involved: registration, filtering and reslicing. Manual segmentation was 
performed using custom-built Java code. Segmentation data were analysed and 
graphed using custom MATLAB code. Segmentation of the different layers was 
performed by distinguishing the texture of different layers and their interfaces. The 
retinal fibre layer (RNFL) thickness was segmented at the scleral rim (the inner 
limiting membrane, ILM, to the retinal pigment epithelium, RPE). The RNFL surface 
was easily identified in all images, and RNFL thickness was quantified from the OCT 
images of control and experimental eyes at different imaging times (before injection, 
7-10 days or 17-32 days post injection). Progressive glaucomatous changes in an 
experimental rat eye were observed before bead injection, 3 weeks and 4 weeks after 
injection in OCT images. The cell loss and IOP profiles were estimated for 6 and 9 
imaged rats, respectively.
The level of damage in experimental glaucoma induced by the injection of hypertonic 
saline was estimated by Optical Coherence Tomography ex vivo imaging (see section 
2.3.1 & 4.2.4.2). The samples were imaged ex vivo by two optical coherence 
tomography systems, a 1300 nm Thorlabs Swept Source OCT (SS-OCT) and an 800 
nm Three Dimensional Ultrahigh Resolution OCT (3D UHR-OCT). Three different 
types of retinal images were collected: 3D UHR OCT, enface OCT and UHR OCT 
depth profiles (cross sections of rat optic nerve head). The retinas were grouped from 
normal to advanced glaucoma according to the increasing integral IOP values. In 
addition, the OCT images from the rat CR308 were compared to the histological 
images of post mortem retinal sections from the same rat.
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4.2. Results
4.2.1. Calibration of the Tonolab rebound tonometer in cannulated rat eyes
Figure 4.1 shows the calibration curves obtained when the tonometer was tested on 
freshly enucleated, cannulated rat eyes. The measurements were taken at 1mm 
(Figures 4.1 A & B) and 3mm (Figure 4.1 C) probe-to-comea distances. The R- 
squared values showed good linearity (R2 = 0.90) at 3mm, suggesting that the 
rebound tonometer readings were proportional to the true IOP in rat eyes measured by 
a pressure transducer. However, the relationship between the true and measured IOP 
was less accurate (R2 = 0.67 -  0.88) when the tonometer was at 1mm distance from 
the cornea. Table 4.1 shows different parameters for calibration of the Tonolab 
rebound tonometer in cannulated rat eyes.
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Figure 4.1. Calibration of the Tonolab rebound tonometer in a cannulated rat eye. The 
relationship between IOP in the anterior chamber (measured using pressure transducer) and 
IOP reading obtained with the rebound tonometer. The measurements were taken at 1mm 
(Figures 4.1 A & B ) and 3mm (Figure 4.1 C) distance from tonometer probe to cornea. The 
parameters for these curves are presented in Table 4.1.
Calibration
experiment
Eye Distance 
(mm)a
R2 Pressure
1 1 1 0.84 decreasing
1 2 1 0.87 increasing
2 3 1 0.67 increasing
2 4 1 0.88 decreasing
3 5 3 0.90 decreasing
Table 4.1. Parameters for calibration of Tonolab rebound tonometer in cannulated rat 
eyes, a Distance from tonometer probe to cornea.
4.2.2. Intraocular pressure elevation in the hyperonic saline model
The IOP profiles following hypertonic saline injection could be classified either as a 
sustained increase in IOP (Figure 4.2B, 33% of eyes) or a fluctuating increase (Figure 
4.2A, 7.4% of eyes). A sustained IOP increase (defined as an elevation in IOP 5 
mmHg greater than the contralateral eye on at least 7 consecutive days) was obtained 
in 33% of rats. A fluctuating IOP increase (positive integral IOP increase) was 
obtained in 7.4% of rats. Overall, IOP increase was obtained in 40.4% of rats. 
Because of this low conversion rate, other methods were sought to increase IOP in a 
more consistent fashion (see section 4.2.3).
The mean IOP for all animals (n=27) was 24.9±1.2 mmHg in the injected eyes and 
24.7±0.6 mmHg in the contralateral untreated eyes. The mean and peak IOP increases 
were 0.2±1.1 mmHg and 18.5±2.5 mmHg, respectively, with a mean integral IOP 
change of -34.5±71.0 mmHg days. For the rats with sustained IOP increases, the mean 
IOP was 30.0±2.7 mmHg in the experimental eyes and 25.2±1.2 mmHg in the 
contralateral untreated eyes. The average and peak IOP increases for the sustained 
IOP increases were 8.7±3.5 mmHg and 31.7±2.6 mmHg, respectively, with a mean 
integral IOP increase of 128.7±186.1 mmHg days. The mean duration for the 
sustained IOP increase after a single injection was 17.8±3.4 days with a maximum 
duration of 40 days. Figure 4.3 shows the mean intraocular pressure (IOP) in 
experimental and contralateral eyes in the experimental rats injected with hypertonic 
saline during the whole experimental period. Table 4.2 is related to Figure 4.3 and 
shows the number of rats (right column) that had IOP measured during a certain 
number of days post-injection (left column). The mean number of days post-injection 
was 71.4±7.0, with the maximum duration of 150 days.
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Figure 4.2. Intraocular pressures (IOP) following a single injection of hypertonic saline in 
rat CR308 (A) and three injections rat CR303 (B). The arrows indicate times of injections. 
Error bars: standard deviations. Open symbols: glaucoma; closed symbols: control.
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Figure 4.3. The mean intraocular pressure (IOP) in the experimental rats injected with 
hypertonic saline during the experimental period. Open symbols: glaucoma; closed 
symbols: control. Error bars: standard error of the mean.
Days post-injection Number of rats
1-25 27
30 26
35 25
40 23
45-50 16
55-60 15
65 14
70-85 10
90 8
95-105 7
110 6
115 4
120 3
125-135 2
140-150 1
Table 4.2. The left column shows the number of days post injection and the right column 
shows the number of rats that had IOPs measured during these days. The values in the table 
are related to Figure 4.3.
4.2.3. Intraocular pressure elevation and cell loss in the magnetic bead model
4.2.3.I. Intraocular pressure elevation
Since the induction of glaucoma with the hypertonic saline resulted in a low 
proportion of rats with an IOP increase, other methods were sought to increase IOP in 
a more consistent fashion. To address this issue, we developed a novel technique for 
the induction of ocular hypertension using paramagnetic microbeads.
Microbead injections were made in 61 rats (section 2.2.4). Figure 4.4 demonstrates 
directing the microspheres to the iridocorneal angle with an external magnet. The 
typical bead distribution following injection and redirection with an external magnet 
is shown in Figure 4.5A and without redirection with an external magnet in Figure 
4.5B. With sufficient anterior chamber depth, the beads could easily be directed to 
provide uniform occlusion of the iridocorneal angle, a process facilitated by retention 
of the cannula tip in the anterior chamber during bead redistribution. Histological 
examination of the anterior segment of the eye following a single intraocular bead 
injection confirmed sequestration of the beads within the trabecular meshwork (Figure 
4.5C).
Microbead injections occupy the iridocorneal angle. Mirobeads were well tolerated 
and did not provoke a uveitic response. Localised iris haemorrhages were noted if the 
tip of the injection cannula damaged superficial vessels, but these were small and 
resolved within a few days. The IOP profiles following injection could be classified 
either as a sustained increase in IOP (Figure 4.6A, 64% of eyes) or a fluctuating 
increase (Figure 4.6B, 36% of eyes). A sustained IOP increase (defined as an 
elevation in IOP 5 mmHg greater than the contralateral eye on at least 7 consecutive 
days) was obtained in 64% of rats. The mean duration for the IOP increase after a 
single injection was 12.8±0.9 days with a maximum duration of 27 days.
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Figure 4.4. An image showing location of the magnet relative to the rat eye during 
redirection of magnetic beads with the magnet. The arrow indicates the magnet. Scale bar, 1 
cm.
A B
Figure 4.5. Rat anterior segment showing the distribution of paramagnetic beads 
immediately post injection with using a magnet (A) and without a magnet (B). The arrows 
indicate beads in the anterior chamber angle. (C) Cryosection of the anterior chamber 
injected with magnetic beads showing complete occlusion of the iridocorneal angle. 
AC=anterior chamber; TM=trabecular meshwork; MB=microbeads. Inset image shows 
higher magnification image of the angle with altered contrast to highlight the microbead 
distribution (indicated by arrows).
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Figure 4.6. Intraocular pressures (IOP) following single bead injections with using a 
magnet to direct beads to the anterior chamber angle in (A) rat CR352 and (B) rat CR355. 
Error bars: standard deviations. Open symbols rinjected eye; closed symbols: control eye. 
Intraocular pressures (IOP) following single bead injection without using a magnet in rat 
CR461 (C).
Up to 3 injections were made in any single animal. Fifty-one animals received 
injections with 20 pi, four with 10 pi and six with 15 pi. Injections were repeated to 
prevent the IOP falling to within 5 mmHg of the contralateral control eye. The typical 
injection period was 2-4 weeks (minimum 1 week). To compare the effects of 
different bead volumes on IOP profiles, eight additional rats were injected with lOul 
bead volumes. (Those rats were not included in the group analysis for IOP profiles 
and cell loss). Eyes injected with lOpl (N=12) or 20pl of beads (N=51) did not 
demonstrate a significant difference in either the mean IOP increase (6.0±1.5 vs 
6.2±1.2 mmHg) or peak IOP (31.05±2.0 mmHg vs 35.8±1.2 mmHg).
Since the IOP increase did not show a consistent relationship with injection volume, 
the results from all the animals have been pooled. The mean IOP for all the animals 
was 29.4±0.9 mmHg for injected eyes and 23.6±0.4 mmHg in the contralateral 
untreated eyes (P<0.001). The mean and peak IOP increases were 5.8±1.0mmHg and 
35.7±1.0 mmHg, respectively, with a mean integral IOP increase of 118.0±57.4 
mmHg days. The mean duration of an experimental period for all animals was 74±5.4 
days, ranging from 11 to 178 days.
For rats with sustained IOP increases, the mean IOP was 32.5±1.0 mmHg in the 
experimental eyes and 23.0±0.5 mmHg in the contralateral untreated eyes. The 
average and peak IOP increases were 9.5±1.1 mmHg and 37.8±1.0 mmHg, 
respectively, with a mean integral IOP increase of 323.1±55.3 mmHg days. The mean 
duration of an experimental period for rats with sustained IOP increases was 68±7.1 
days, ranging from 11 to 178 days. The mean duration for the sustained IOP increase 
after a single injection was 12.8±0.9 days with a maximum duration of 27 days. 
Figure 4.7 shows the mean intraocular pressure (IOP) in experimental and 
contralateral eyes in all experimental rats during the first 42 days after injection.
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Figure 4.7. The mean intraocular pressure (IOP) in the experimental rats injected with 
magnetic beads during the first 42 days after injection. Open symbols: injected eyes; 
closed symbols: control eyes. Error bars: standard error of the mean.
To investigate the effect of using a magnet on the IOP elevation in a magnetic bead 
model, rats were injected with magnetic beads without directing them to the 
iridocorneal angle using a magnet. Two rats were injected once with 10 jj.1 and two 
rats with 20 pi. One of the rats injected with 20 pi was killed soon after the injection 
due to severe haemorrhage and therefore was not included in the analysis of IOP 
profile. Following injection, the majority of beads settled on the inferior part of the 
anterior chamber, near the injection site (Figure 4.5B). The remaining beads were 
spread around the anterior chamber. Figure 4.6C shows the IOP profile for one of the 
injected rats. The mean IOP for the 3 injected rats was 27.0±1.6 mmHg for injected 
eyes and 24.3±2.3 mmHg in the contralateral untreated eyes. The mean and peak IOP 
increases were 2.7±1.7 mmHg and 24.1±2.7 mmHg, respectively, with a mean 
integral IOP increase of -0.6±33.6 mmHg days. The mean number of days with IOP 
increase above 5 mmHg was 2.33±0.3 days. The duration of the experimental period 
post injection was 20 days for all animals.
A vehicle control was produced to assess the effect of BSS injection on IOP elevation. 
Using the same technique as for the bead injection, a single rat received a vehicle 
injection of 10 pi BSS into the anterior chamber. The mean IOP for this rat was 
26.6±9.9 (SD) mmHg for the injected eye and 22.4±4.7 (SD) mmHg in the 
contralateral untreated eye. The mean and peak IOP changes were -4.2±7.2 (SD) 
mmHg and 4.8 mmHg, respectively. An IOP increase above 5 mmHg was not 
detected in the time before sacrifice.
4.2.3.2. Neuron quantification in the RGCL
Retinas were dissected out and prepared as wholemount preparations. The mean 
density of cells in the RGCL in control retinas was 4080±99 cells/mm2 and 2593±139 
cells/mm2 in glaucomatous retinas, accounting for 36.4±2.4% cell loss (P=0.002) 
(Table 4.3). Figure 4.8 shows the location of the imaged fields that were used for 
counting RGCs and sample images of the RGCL stained with Hoechst from control 
and injected eye. The RGCL neuronal populations were sampled in 21 animals with a 
mean IOP elevation of 7.7±1.4 mmHg and mean integral IOP increase of 194.5±87.5 
mmHg days. In a linear regression analysis, the relationship was not significant
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between the degree of cell loss relative to the contralateral control eye for the duration 
of IOP increase (r2= 0.18, P=0.56), peak or mean IOP increase or area under the IOP 
curve. A consistent difference in retinal regions was not observed when samples were 
taken at 1, 2 or 3 mm from the optic disc for the degree of loss (P=0.983 in One-way 
ANOVA).
Little change in RGC counts following bead injections was observed without 
magnetic redirection. When the RGC counts for animals receiving 10 or 20 pi 
injections were pooled, the mean density of cells in the RGCL in control eyes was 
3725.9±87.7 cells/mm2 compared with 3685.0± 190.4 cells/mm2 in bead injected eyes. 
For the rat injected with BSS, cell density in the RGCL in contralateral control eye 
was 3655.6 cells/mm2, compared with 3925.5 cells/mm2 in control retina injected with 
saline.
Discrete (<100um) retinal haemorrhages were observed in a peripapillary distribution 
in 5 of the 61 eyes. Comparison of the IOP profiles, either on the basis of peak IOP or 
integral IOP increase did not reveal a significant difference between eyes with or 
without haemorrhages (P>0.05).
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Eccentricity Cell density in 
control retinas 
(cell/mm2)
Cell count 
per field in 
control 
retinas
Cell density in 
glaucomatous 
retinas 
(cell/mm2)
Cell count per 
field in 
glaucomatous 
retinas
% Cell loss
1mm 4170 ± 104 471 ± 12 2 7 0 1 ± 128 305 ± 14 35.2 ±2.5
2mm 4327 ± 98 489 ± 11 2 6 9 9 ± 144 305 ± 16 37.6 ±2.3
3mm 3745 ± 96 423 ± 11 2 3 8 1 ± 145 269 ± 16 36.4 ± 2 .6
Mean 4080 ± 99 461 ± 11 2 5 9 3 ± 139 293 ± 16 36.4 ± 2 .4
Table 4.3
Cell density, mean number of cells counted per field and cell loss in the RGCL for 
control and glaucomatous retinas. Cell densities and cell counts are expressed as 
means (cells per mm2 ± SEM and cells ± SEM, respectively). Cell loss is expressed as 
a percentage relative to the contralateral (control) retina ± SEM.
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Figure 4.8. Schematic figure showing the location of the 12 sample areas that were 
imaged in the superior, inferior, temporal and nasal part o f a retina within the distances of 
1, 2 and 3mm from the optic disc (O). Double arrows indicate the distances of 1000 pm 
between the imaged areas (A). Sample images o f RGCL stained with Hoechst from control 
(B) and injected (C) eye from a rat injected with magnetic beads. Cells were counted using 
ImageJ plugin, Cell Counter. Pink dots indicate how the cells were picked out for 
counting. Scale bars, 100 pm.
4.2.4. OCT imaging
4.2.4.I. In vivo OCT imaging and quantification of RNFL thickness in a magnetic 
bead model
The mean IOP for the 9 rats imaged in vivo by OCT was 34.0±2.8 mmHg for injected 
eyes and 24.8±0.5 mmHg in the contralateral untreated eyes. The mean and peak IOP 
increases were 9.312.6 mmHg and 33.812.4 mmHg, respectively, with a mean 
integral IOP increase of 377.71115.9 mmHg days. The mean duration of an 
experimental period for all animals was 56.7±8.0 days, ranging from 15 to 73 days.
Figure 4.9A illustrates experimental subjects, dates of bead injection and OCT 
imaging. Rats were imaged once before injection and once (CR401, CR402, CR404, 
CR426) or twice (CR391, CR392, CR393, CR425, CR427) after injection. 
Summarized RNFL thickness trends in control and experimental eyes before bead 
injection, 7-10 days after injection and 17-32 days after injection are shown in Figure 
4.9B. Mean RNFL thicknesses of experimental eyes measured in OCT scans centred 
at the optic nerve head (ONH) were 363.63±11.43 pm before magnetic bead injection, 
325.60±20.38 pm 7-10 days after injection, and 247.40±28.32 pm 17-32 days after 
injection (Figure 4.10). RNFL thickness in experimental eyes was not significantly 
changed 7-10 days after injection compared to the RNFL thickness before injection. 
In contrast, there was a significant difference between the RFNL thickness of 
experimental eyes before injection and 17-32 days after injection (P<0.01). Mean 
RNFL thicknesses of control eyes were 358.28±11.41 pm before magnetic bead 
injection, 371.23±14.22 pm 7-10 days after injection and 347.13±8.58pm 17-32 days 
after injection. There were no significant changes in RFNL thickness in the untreated 
control eyes during the experimental period. The RFNL thickness of control eyes that 
were contralateral to the eyes imaged 17-32 days after injection was significantly 
different compared to the RFNL thickness of experimental eyes imaged 17-32 days 
after injection (P<0.01).
The average cell loss, estimated in the 5 out of 9 OCT imaged rats, was 
35.79±13.97%.
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Figure 4.11 demonstrates progressive glaucomatous changes in an experimental rat 
eye before bead injection, 3 weeks and 4 weeks after injection in OCT images. A 
cupping of the optic nerve head was clearly visible 3 weeks post injection and 
progressed to a very deep cupping 4 weeks post injection. Retinal layers were 
discernible before injection and 3 weeks after injection but not 4 weeks after injection. 
In contrast to the changes in the experimental eye, there were no glaucomatous 
changes in the control eye. High IOP elevation was observed in the injected eye of 
this experimental rat (Figure 4.11, below the images).
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Figure 4.9. (A) A plot showing experimental subjects, dates o f bead injection and OCT imaging. Rats were 
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Figure 4.11. OCT images showing extreme case o f glaucoma progression in rat CR427 before bead 
injection, 3 and 4 weeks after injection. Left column, control eye. Right column, injected eye. Below the 
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4.2.4.2. Evaluation of damage by ex vivo OCT imaging in hypertonic saline model
The retinas were grouped from normal to advanced glaucoma according to the 
increasing integral IOP increase values, namely 65.4, 400.2, 621.7 and 903.1 mmHg 
days for rats CR314, CR305, CR300 and CR308, respectively. The integral IOP 
increases were related to the level of glaucomatous damage observed in the OCT 
images. The retinas from the normal rat and from rat CR314 did not show any 
obvious glaucomatous damage (Figure 4.12). The RNFL and contour of the retina 
were observed, and the layers were well delineated. The retina from the rat CR305 
showed a moderate cupping with retinal detachments. In rat CR300, a very deep 
cupping was observed, and the retinal layers were difficult to recognise. The retina 
CR308 showed extensive damage through all layers with excessive cupping.
OCT images were consistent with histological images (Figure 4.13). The extensive 
damage in the retina from the experimental eye was observed in the OCT image 
(Figure 4.13A) as well as in vertical sections stained with Hoechst (Figure 4.13B) and 
imaged with Differential Interference Contrast (Nomarski) (DIC) method (Figure 
4.13C). There was no damage in the normal eye (Figure 4.13D-F).
115
NORMAL MODERATE GLAUCOMA ADVANCED GLAUCOMA
IOP p o s t ­
in jec tio n  
th ro u g h  
tim e
N orm al CR314 CR305 CR300 CR308
Figure 4.12. Summary chart showing IOP profiles, 3D volumes, enface images and depth profiles for the normal rat and the rats: CR314, CR305, CR300 and 
CR308. The red lines: IOPs in the injected (glaucomatous) eyes. The blue lines: IOPs in the contralateral eyes. Error bars: standard deviations. (Thanks to Alicia 
Charlton , Dr Boris Povazay and Prof Wolfgang Drexler).
OCT Histology
Figure 4.13 OCT images (A) & (B) were consistent with histological images (B)-(F). The extensive damage in the retina from the 
experimental eye from the rat CR308 was observed in the OCT image (A) as well as in vertical sections stained with Hoechst (B) and 
imaged with DIC method (C). There was no damage in the normal eye from the rat CR308 (D-F). GCL, ganglion cell layer; IPL, 
inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer.
4.3. Discussion
4.3.1. Evaluation of the Tonolab rebound tonometer
The applicability of a Tonolab rebound tonometer in measuring IOP in rats and mice 
has been evaluated by Wang et al. (2005). The study demonstrated that the Tonolab 
can precisely and reproducibly monitor IOP in rodents since the measured IOP values 
were comparable to the actual pressure in the eye.
It is considered likely that changes in the position of the tonometer relative to the eye 
will occur when measuring rats IOP in vivo (Prashar et al., 2007). The results showed 
that the relationship between the true and measured IOP was more accurate when the 
tonometer was at 3mm (R2 = 0.9) than at 1mm (R2 = 0.67 -  0.88) distance from the 
cornea. Calibrations obtained from chicken eyes suggested that the rebound tonometer 
was robust to varying probe-to-comea distances over 3 to 5 mm (Prashar et al., 2007).
During the calibration procedure, a number of problems related to taking tonometer 
measurements were encountered. The initial problem was the cannulation of the eye, 
which often caused leakage. The leakage occurred either immediately after 
cannulation or during the calibration procedure, not allowing measurements to be 
taken. In addition, error messages occurred when the probe did not move, did not 
touch the eye or when the probe speed was too low or too high.
To assess the effect o f other types of changes in the position of the tonometer relative 
to the eye, the calibration could be obtained with the tonometer laterally displaced 
from the centre of the cornea, and directed towards the centre of the cornea but at 
different angles to the visual axis (Prashar et al., 2007).
4.3.2. Hypertonic saline model
The induction of glaucoma with a hypertonic saline injection resulted in a relatively 
low proportion of rats with an IOP increase; a sustained IOP increase in a hypertonic 
saline model was obtained in 33% of rats, while a fluctuating IOP increase in 7.4% of 
rats.
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Hypertonic saline injection into aqueous humor outflow pathways to produce scarring 
of the tissue is a commonly used method for producing chronic experimental IOP 
elevation in rats (Morrison et al., 1997). A plastic ring is placed around the equator of 
the eye to restrict the injection to the limbus, resulting in a saline flow into Schlemm’s 
canal and across the trabecular meshwork. This leads to scarring of the meshwork and 
the anterior chamber angle due to inflammation. The level of the pressure rise is 
determined by the extent of scarring (Morrison et al., 2005).
The efficiency of the intraocular pressure induction depends on the extent and density 
of the resulting scarring of the anterior chamber angle. This is influenced by the 
anatomy of the limbal plexus and the effectiveness with which the ring confines the 
hypertonic saline to the limbus. Sustained IOP elevation usually occurs 7-10 days 
after injection, most probably when the scarring process matures and the 
inflammation drops, allowing continuation of normal production of aqueous humor 
(Morrison et al., 2005). Some investigators routinely perform a second injection in all 
animals (Chauhan et al., 2002) while others only do so if an IOP elevation does not 
occur within the first 2 weeks (Hanninen et al., 2002; Morrison et al., 1997). In the 
present study, the second injection was performed after an average 29.4±2.6 days.
The mean duration of sustained elevation was 17.8±3.4 days with a maximum 
duration of 40 days (53 days with 1 measurement of an IOP decrease within the 
period of increased IOP) with an elevated pressure when a rat was sacrificed. We have 
not attempted to maintain IOP elevation for a longer period due to the time-limitation 
of our experiments. Durations of elevated IOP with this method as long as 12 weeks 
have been reported (Hanninen et al., 2002; McKinnon et al., 2002). The IOP can 
potentially remain elevated for over 12 weeks if the rat is allowed to survive 
(Morrison et al., 2005). An important factor determining the duration of IOP elevation 
is the concentration of saline. 1.75 M saline was used in our experiments according to 
Morrison et al. (1997). The injection of a saline concentration more than 2.0 M 
generated a marked elevation that could remain highly elevated in a number of eyes 
for up to several months (Johnson et al., 2000; Morrison et al., 1997).
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It has been reported that for the hypertonic saline model, the extent of pressure 
elevation ranged between 1.3 x to 2 x normal (Chauhan et al., 2002; Hanninen et al., 
2002; McKinnon et al., 2002; Morrison et al., 1997; Morrison et al., 1998; Schlamp et 
al., 2001). Although in the present study, our mean IOP in injected eyes was the same 
as the mean IOP in contralateral eyes due to the low percentage of the animals with 
IOP elevation, the mean pressure elevation in rats with sustained IOP increase was 1.2 
x normal. That was similar to the 1.3 x normal described by other investigators 
(Chauhan et al., 2002; Morrison et al., 1997; Morrison et al., 1998; Schlamp et al., 
2001).
Following an initial period of successful experiments producing elevated IOP, several 
problems were encountered with the induction of increased IOP, resulting in only 
40.7% of rats with an IOP increase (sustained and fluctuating). It is possible that the 
use of a different ring (obtained from the Morrison’s lab) in the later experiments 
caused problems when trying to elevate IOP. If the ring was too tight the pressure 
from the ring may have forced aqueous to exit the eye resulting in an IOP decrease. 
However, if the ring was too loose, it might have confined the injection to the limbus 
insufficiently, not allowing for saline flow into Schlemm’s canal and across the 
trabecular meshwork. It is likely that the size of aqueous drainage veins of our rats 
was different from that of the rats from the Morrison’s lab. In addition, variability in 
vessel sizes was observed; in general the larger the animal, the larger the vessels.
Considering all the difficulties encountered during the experimental work with 
Morrison’s model, it was decided to develop an alternative, less technically 
challenging glaucoma model based on the injection of magnetic beads into the 
anterior chamber.
4.3.3. Magnetic bead model
A simple and effective method for the elevation of IOP in the rat was described. The 
technique is technically undemanding and provides a measure of control over the 
distribution of beads within the anterior segment. The beads can be drawn away from 
the visual axis and distributed around the iridocorneal angle to optimise occlusion of 
the trabecular meshwork and facilitate visualisation of the retina and optic disc. A
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sustained IOP increase was obtained in 64% of rats and a fluctuating increase in 36% 
of rats.
The principal finding of the present study is that fewer injections may be required to 
achieve a sustained increase in IOP compared with injections using non-magnetic 
beads. The data presented by others showed that the injection of latex microspheres, 
in combination with hydroxypropylmethylcellulose (HPM), or when given alone, 
required 6-9 weekly injections to achieve a sustained elevation in IOP (Urcola et al., 
2006). Similarly, 8-10 injections were necessary to produce a sustained IOP elevation 
that lasted up to 2 weeks in the primate (Weber and Zelenak et al., 2001); for more 
prolonged IOP elevation in the primate, as many as 20 bead injections were required 
to maintain significant occlusion of the iridocorneal angle. In the present study, a 
sustained IOP increase in 64% of animals following up to 3 injections was achieved, 
lasting on average 12.8±0.9 days. The mean IOP in injected eyes in our model, 
29.4±0.9 mmHg, was similar to the mean IOP seen in eyes injected with latex 
microspheres (28.1±0.7 mmHg) (Urcola et al., 2006). It was noted that the increase in 
IOP was not consistently related to the volume of the bead injection. One likely 
explanation is that the egress of aqueous seen following removal of the needle tended 
to normalise the IOP regardless of the injection volume. The present study used beads 
of approximately 5 pm diameter which was smaller than the 10pm beads used in 
previous studies (Urcola et al., 2006; Weber and Zelenak et al., 2001). Recently, the 
use of 15 pm beads has been reported to achieve sustained IOP elevations of up to 8 
weeks based on 2 injections in rats suggesting that the use of larger beads may be 
important in the long term induction of ocular hypertension (Sappington et al., 2010). 
In preliminary experiments, the use of beads in the range 1-2 pm did not produce a 
consistent increase in IOP and had the disadvantage that the beads were more difficult 
to guide in the anterior chamber. A critical technical point is that the carrier fluid in 
which the beads are packaged to minimise the introduction of potentially toxic agents 
into the anterior chamber was removed, using similar method to Weber and Zelenak 
et al. (2001). For animals in which beads were not redirected, a significant, sustained 
elevation in IOP was not observed. Furthermore, we did not facilitate the egress of 
carrier solution that was possible with magnetic redirection since this would have 
resulted in the loss of beads from the anterior chamber. Even in the animals injected
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with 20pl of beads, a significant reduction in RGCL cell density was not observed 
compared with animals with a sustained elevation in IOP as a result of redirecting the 
beads. Taken together, these observations suggest that the loss of cells in the RGCL 
results from the effects of sustained IOP increase, rather than from any transitory 
increase in IOP as a result o f injection. The lack of RGCL cell loss in the animal 
injected with BSS alone is consistent with this conclusion.
The degree of cell loss in our model is similar to that reported for other models. The 
use of (non magnetic) microbead occlusion in a rat glaucoma model produced a level 
of RGC loss (23.1±2.1%) (Urcola et al., 2006) similar to that seen in the present study 
(36.4±2.4%). Comparable RGC loss (40%) has also been reported with the hypertonic 
saline model (Hanninen et al., 2002; Morrison, 1998; Morrison et al., 1997) and the 
episcleral vein cautery model (30%-40 %) (Ahmed et al., 2001a; Ahmed et al., 2001b; 
Naskar et al., 2002; Neufeld et al., 1999). A consistent variation in the degree of cell 
loss as a function of retinal eccentricity in the sampled range 1-3 mm was not 
observed. A similar diffuse pattern of cell loss has been reported in the episcleral 
(hypertonic saline) vein occlusion model (Garrett et al., 1991). By contrast, clustered 
RGC loss has been reported in the rat vein cautery model (Mittag et al., 2000). Other 
studies have reported greater cell loss in the central compared with peripheral regions, 
but in animals with longer durations of IOP elevation (Laquis et al., 1998; Neufeld et 
al., 1999; Urcola et al., 2006). In addition, there was no significant relationship 
between the degree of cell loss relative to the contralateral control eye for the duration 
of IOP increase, peak or mean IOP increase or the IOP integral. Chauhan et al (2002) 
observed a strong negative correlation between peak AlOP and the proportion of 
surviving axons and between AIOP integral and the proportion of surviving axons.
4.3.4. OCT imaging
The use of OCT imaging validated the bead and hypertonic saline glaucoma models, 
revealing thickening o f the retinal fibre layer over time in vivo and optic nerve head 
cupping in vivo and ex vivo.
The objective of the study described in section 4.2.4.1 was to evaluate rat retinal fibre 
layer thickness changes over time in a magnetic bead glaucoma model. A protocol
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(section 2.2.4.3) for rat eye imaging, including preparation procedures such as 
methods of anaesthesia and positioning of the rat for imaging, has been successfully 
established. A spectral (Fourier domain) OCT system enabled visualisation of major 
intraretinal layers including retinal nuclear fibre layer (RNFL) and therefore 
evaluation o f RFNL thickness. The RNFL thickness in experimental eyes was not 
significantly changed 1 week after injection compared to the RNFL thickness before 
injection. However, RNFL thicknesses of experimental eyes before injection and 17- 
32 days after injection were significantly different. Also, there was a significant 
difference in RFNL thickness between experimental eyes imaged 17-32 days after 
injection and control eyes that were contralateral to the eyes imaged 17-32 days after 
injection. The observation of progressive changes in an extreme case of glaucoma 
revealed a progressive cupping of the optic nerve head 3 and 4 weeks post injection. 
In addition, the outer retinal layers looked normal, and the thinning of the RNFL 
agreed with the calculated cell loss.
RNFL thickness changes in a rat model of optic nerve crush have been estimated 
using an OCT system with a modified commercial time-domain OCT and a 
multiplexed two-superluminescent-diode (SLD) light source with 890 nm wavelength 
and a bandwith o f 150 nm. In this model, no changes in RNFL thickness were 
observed 1 week after the injury, but significant and progressive changes were evident 
after the second week. Consistent with our studies, there were no significant changes 
in the untreated control eyes during the experimental period (Nagata et al., 2009). 
Srinivasan et al. (2006) used a spectral-domain OCT to estimate RNFL thickness 
(which was approximately 30 pm) in normal Long-Evans rats. The RNFL thickness 
was also estimated in vivo by scanning laser ophthalmoscopy (SLO) that correlated 
well with the thickness assessed by histology. However, this method did not allow 
estimating absolute thickness or demonstrating cross-sectional images of RNFL 
(Kawaguchi et al., 2006). Therefore, OCT is more useful than SLO for RNFL 
thickness measurements. Using time-domain OCT, retinal thickness was measured to 
estimate retinal degeneration in mouse (Li et al., 2001). OCT imaging in the rodent 
eye is more challenging than in the human eye due to its smaller size and the thinner 
retina of the animal eye. The RNFL thickness measurements estimated by frequency- 
domain OCT imaging were highly reproducible in patients with glaucoma and normal 
subjects (Gonzalez-Garcia et al., 2009; Vizzeri et al., 2009).
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The objective of the study described in section 4.2.4.2 was to assess the damage in the 
retina by ex vivo OCT imaging and characterise the relationship between retinal 
damage and IOP elevation. There was an association between integral IOP increase 
and the glaucomatous damage (optic disc cupping and deterioration of retinal layers) 
visible in OCT images. Optic disc cupping, a hallmark of glaucoma, has been 
demonstrated in optic nerve sections in monkeys (Quigley et al., 1984) and rats with 
IOP elevation (Sawada and Neufeld, 1999). In rats, both cupping (as measured by 
scanning laser tomography) and electroretinography (ERG) changes were strongly 
linked to the peak IOP and integral IOP increase in the experimental eye as compared 
to the control eye (Chauhan et al., 2002).
4.4. Summary
In summary, the results from two different glaucoma models were presented. More 
satisfactory and reproducible data were obtained from the magnetic bead model, with 
64% of eyes showing sustained IOP increase, compared to hypertonic saline model 
with only 33% of eyes with a sustained IOP increase.
Injecting magnetic beads into the rodent eye is a simple method for the induction of 
experimental glaucoma. It has the principal advantages over non-magnetic microbead 
models that the visual axis is not obscured following injection and that complete 
occlusion of the iridocorneal angle can be achieved with a single injection. It is 
anticipated that it could be adapted with little modification for use in other species.
Optical coherence imaging enabled the observation of progressive glaucomatous 
changes in vivo and estimation of RNFL thickness before and after induction of 
elevated intraocular pressure. A significant reduction in RNFL thickness following 
induction of intraocular pressure was observed. In addition, OCT imaging was useful 
in the quantitative evaluation of glaucomatous damage ex vivo.
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Chapter 5: Dendrite morphology of RGCs in the 
control, glaucomatous and chABC/BDNF
treated retinas
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5.1. Introduction
Retinal ganglion cell dendrite remodelling and shrinkage is a feature of several 
experimental models of glaucoma (Morgan et al., 2006). To investigate the possibility 
that this could be reversed and act as a neural substrate for the recovery of vision in 
glaucoma, the perineuronal net (PNN) was modified in eyes in which the intraocular 
pressure (IOP) had been returned to its preglaucomatous level. It was assumed that 
digestion of the PNN would enhance the ability of retinal ganglion cell (RGC) 
dendrites to regenerate following removal of the effect of elevated IOP. Since 
chondroitinase ABC influences plasticity by enzymatic digestion of the PNN (Kwok 
et al., 2008), the enzyme was injected intravitreally to promote retinal ganglion cells 
(RGCs) regeneration in glaucoma. In addition, the effects of brain-derived 
neurotrophic (BDNF) factor on the preservation of the dendritic field complexity 
using the magnetic bead model of glaucoma were investigated.
The first aim of the present study was to explore the changes in RGCs in a rat 
magnetic bead model of glaucoma by comparing RGC dendrite morphology in control 
and glaucomatous retinas. The second aim was to explore the changes in RGC 
morphology in glaucomatous retinas which had been injected with digestive enzyme 
chondroitinase ABC, neurotrophic factor BDNF or a combination of these two agents.
Experimental design
A plan of the experiment (described in Methods Chapter in section 2.2.4.2) is 
summarised in Figure 5.1. Bead injection into the left rat eyes is described in sections 
2.2.4.1 and 4.4.1. The injections of either 3pl of lOmU/eye chondroitinase ABC, 1 pi 
of 1 pg/ml recombinant human BDNF or both agents (during the same procedure) into 
the vitreous of a glaucomatous, left rat eye were performed after a 3-4 weeks period 
of IOP elevation that was followed by a 1 week period of decreased IOP. 
Alternatively, 3pi of lOmU/eye chondroitinase ABC was injected into the normal rat 
eye. The right eye acted as an unoperated control. The animals were kept for two 
weeks after injection before being sacrificed. Subsequently, a retina was dissected and 
a gene gun was used to propel Dil-coated tungsten particles into wholemount rat 
retinal explants (Diolistics). Images of completely stained RGCs were collected by 
confocal microscopy (as described in section 2.3.2.1). Using the diolistic method,
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cells in the ganglion cell layer, both retinal ganglion cells and displaced amacrine 
cells, are stained randomly by the contact with tungsten particles. Ganglion cells were 
distinguished by the presence of an axon (Sun et al., 2002). The imaged cells were 
analysed using a Fast Sholl method (Gutierrez and Davies, 2007). RGC dendrite 
morphology in control and glaucomatous retinas was compared to the glaucomatous 
retinas injected with chABC, BDNF, chABC+BDNF and non-glaucomatous retinas 
injected with chABC. In addition, some retinas were stained with a fluorescent dye 
Hoechst and the images of retinal ganglion cell layer were collected from 12 retinal 
areas. RGCs were counted manually using ImageJ plugin Cell Counter. The number 
of RGCs in glaucomatous retinas injected with chABC or BDNF was compared to the 
number of RGCs in control retinas. Since not all retinas from the injected rats were 
labelled in a way that enabled analyses of RGC morphology (some retinas were 
under-labelled or over-labelled), the number of glaucomatous and control retinas used 
in the study varied slightly (section 5.2.1).
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Figure 5.1. A horizontal bar plot showing a plan of the experiment.
5.2 Results
5.2.1. IOP profiles
The IOP profile following first 43 days post-injection is shown in Figure 5.2. Thirty- 
two rats, whose glaucomatous or control (or both glaucomatous and control) retinas 
contributed to the study, were used to generate the IOP profiles. The mean IOPs for 
the rats (n=23) with glaucomatous retinas (including eyes injected with chABC, 
BDNF or chABC+BDNF) that were used to estimate dendrite morphology were 
30.56±1.53 mmHg for injected eyes and 24.27±0.57 mmHg in the contralateral 
untreated eyes. The mean and peak IOP increases were 6.29±1.43 mmHg and 
34.17±1.39 mmHg, respectively, with a mean integral IOP increase of 191.94±49.94 
mmHg days. The mean duration of the experimental post-injection period was 
58.83±4.02 days.
The mean IOPs for the rats (n=25) whose control retinas were used to estimate 
dendrite morphology were 29.96±1.36 mmHg for injected eyes and 23.74±0.60 
mmHg in the contralateral untreated eyes. The mean and peak IOP increases were 
6.22±1.45 mmHg and 35.88±1.52 mmHg, respectively, with a mean integral IOP 
increase of 177.43±47.49 mmHg days. The mean duration of the post-injection 
experimental period was 56.96±4.35 days.
The average number of cells analysed per retina was 5.17±0.62.
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Figure 5.2. The mean intraocular pressure (IOP) in the experimental rats whose 
glaucomatous or/and control retinas were included in the study (n=32) (A) and rats whose 
glaucomatous retinas were used in the study (n=23) (B) injected with magnetic beads 
during the first 43 days after injection. Open symbols: injected eyes; closed symbols: 
control eyes. Error bars: standard error of the mean.
5.2.2. Quantification of dendrite morphology
The injection of magnetic beads into the rat anterior chamber resulted in an induction 
of ocular hypertension (Figures 5.2 and section 4.2.3.1.). The diolistic method 
provided extensive labelling of RGCs. However, excessive labelling can reduce the 
number of cells in which the dendritic tree can be isolated and precisely reconstructed 
(Morgan et al., 2006). For this reason, only the cells with a dendritic tree clearly 
distinguishable from those of adjacent cells were analysed. The examples of Dil 
labelled RGCs from control and glaucomatous eyes are shown in Figure 5.3 while Dil 
labelled RGCs from glaucomatous eyes injected with chABC, BDNF, chABC+BDNF 
and RGC from control eye injected with chABC are shown in Figure 5.4.
RGCs (numbers shown in Table 5.1) from control (n=25 eyes), glaucomatous (n=9 
eyes), chABC-injected glaucomatous (n=4 eyes), BDNF-injected glaucomatous (n=5 
eyes), chABC+BDNF-injected glaucomatous (n=5 eyes) and non-glaucomatous 
chABC-injected retinas (n=3 eyes) were imaged and their dendritic trees analysed. 
The sholl plots, the total dendritic length, the number of branching points and the 
dendritic fields were estimated and compared among the groups as described below 
and in section 2.3.2.1.3, and are shown in Table 5.1.
The total number of intersections (i.e., the area under the Sholl curve) is directly 
proportional to the total metric length of the neuritic arbour (Gutierrez and Davies, 
2007). The total number of intersections per cell and the number of bifurcations were 
estimated by the Fast Sholl program. The total neurite length of 20 neurons was 
measured by manual tracing of dendrites in NeuronJ. As shown in Figure 5.5., the 
corresponding linear regression shows a strong correlation (R2 = 0.972, P<0.01) 
between actual length and the total number of intersections as estimated by Fast Sholl 
method. The resulting linear equation was subsequently used as a standard curve to 
derive the total (metric) length in micrometers of dendritic trees in experimental 
neurons. This calibration method was based on the method described by Gutierrez and 
Davies, 2007.
Statistical comparisons between the groups were performed in SPSS 16 using Mann- 
Whitney Test (for data that were not normally distributed) unless otherwise stated,
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with a significance level of p<0.05 (see Table 5.1, pg 144). The Sholl plots and bars in 
figures 5.6A, 5.7-5.10 represent mean values ± SEM.
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Figure 5.3. Dil labelled RGCs from control and glaucomatous eyes.
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Figure 5.4. Dil labelled RGCs from glaucomatous eyes injected with chABC, BDNF, 
chABC+BDNF and RGC from control eye injected with chABC.
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Figure 5.5. Correlation between the total estimated intersections per cell obtained by the 
Fast Sholl and the total length in micrometers of the dendritic arbours per cell as estimated 
by independent neurite tracing. Twenty individual neurons were sampled across the range of 
morphologies and the total number of estimated intersections derived according to the 
method described in the results section (vertical axis). Total dendritic length was measured 
by direct tracing of the dendrites (horizontal axis). The resulting linear equation can 
subsequently be used as a standard curve to calculate the total (metric) length in 
micrometers of dendritic arbours in experimental samples of neurons.
5.2.2.1. Dendrite morphology in glaucoma vs. control
A typical IOP plot for a magnetic bead model is shown in Figure 5.6B. In Figures 
5.6C&D, sample cells are shown from normal and glaucomatous retinas, respectively, 
indicating pruning of the dendritic tree with reduction in the complexity of the 
dendritic tree and overall dendritic area. The mean reduction in dendritic tree area for 
RGCs from the glaucomatous retinas was 33.0% compared with control retinas 
(76435.70±14171.26 pm2 vs. 114028.60±11122.86 pm2) (Figure 5.10). Sholl analysis 
revealed a 39.5% reduction in the number of intersections in glaucomatous retinas 
compared to control retinas (148.13±17.49 vs. 245.17±15.94, PO.OOl). The 
maximum number of intersections for control RGCs was 13.21 at 100 pm distance 
from soma while, for glaucomatous RGCs, 9.07 at 60 pm distance from soma. 
Beyond these distances, the number of intersections decreased until the last measured 
point, at 610 pm distance from soma for control and at 540 pm distance from soma 
for glaucomatous RGCs (Figure 5.6A). The total dendritic length, proportional to the 
number of intersections, was significantly decreased in glaucoma compared to 
controls (1807.12±198.99 pm vs. 2948.47±182.60 pm, PO.OOl) (Figure 5.8). The 
number of branching points was also significantly reduced in glaucoma compared to 
controls (11.96±1.85 vs. 28.88±1.74, PO.OOl) (Figure 5.9).
5.2.2.2. Dendrite morphology in the treated retinas vs. glaucomatous and control 
retinas
5.2.2.2.I. Sholl plots
Figure 5.7 shows Sholl analysis of RGC dendrites from control, glaucomatous, and 
either chABC-injected glaucomatous (Figure 5.7A), BDNF-injected glaucomatous 
(Figure 5.7B), chABC+BDNF-injected glaucomatous retinas (Figure 5.7C) and non- 
glaucomatous chABC-injected (Figure 5.7D).
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Figure 5.6. (A) Sholl analysis o f  RGC dendrites from control (white symbols) and glaucomatous retinas 
(black symbols) showing reduction in the number o f intersections relative to the distance from cell soma for 
RGCs from glaucomatous retinas. The radial distances were calculated and the corresponding 10 pm 
intervals assigned to each branching and/or terminal point. Error bars indicate SEM. (B) A typical IOP plot 
for a magnetic bead model. Intraocular pressures (IOP) following single bead injections in rat CR341. The 
arrow indicates time o f injections. Error bars: standard deviations. Open symbols: control; closed symbols: 
glaucoma. N indicates the number o f analysed cells. Dil labelled RGCs from (C) normal eye and (B) 
glaucomatous eye.
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Figure 5.7. Sholl analysis of RGC dendrites from control retinas (white symbols), 
glaucoma (black symbols), chABC-injected glaucomatous retinas (grey symbols) (A), 
BDNF-injected glaucomatous retinas (grey symbols) (B), chABC+BDNF-injected 
glaucomatous retinas (grey symbols) (C) and chABC-injected negative control retinas 
(grey symbols) (D). The radial distances were calculated and the corresponding 
10 |im intervals assigned to each branching and/or terminal point. Error bars indicate 
SEM. N indicates the number of analysed cells.
5.2.2.2.2. Dendrite morphology in chABC-injected glaucomatous eyes
Intravitreal injection of 10mU/3pl chABC after a 3-4 week period of IOP elevation 
resulted in a significant increase of the total dendritic length in chABC-injected 
glaucomatous retinas compared to untreated glaucomatous retinas (3199.94±326.97 
pm vs. 1807.11±198.99 pm, PO.OOl) (Figure 5.8A). In addition, the number of 
branching points was significantly increased in chABC-injected eyes with glaucoma 
compared to glaucomatous retinas (27.04±5.56 vs. 11.96±1.85, PO.Ol) (Figure 
5.9A). Both the total dendritic length and the number of branching points from 
chABC-treated glaucomatous eyes were not significantly different from control eyes 
(3199.94±326.97 pm vs. 2948.47±182.60 pm and 27.04±5.56 vs. 28.88±1.74, 
respectively) (Figures 5.8A & 5.9A). A significant increase in the dendritic field area 
was observed in chABC-injected eyes with glaucoma compared to untreated 
glaucomatous retinas (95866.53±8838.97 pm2 vs. 76435.70±14171.26 pm2, PO.Ol) 
(Figure 5.10A). However, the dendritic field area in these eyes was significantly 
reduced compared with controls (95866.53±8838.97 pm2 vs. 114028.60±11122.86 
pm2, PO.05) (Figure 5.10A).
5.2.2.2.3. Dendrite morphology in BDNF-injected glaucomatous eyes
Intravitreal injection of 1 pi of lpg/pl BDNF after 3-4 weeks of IOP elevation led to a 
significant increase in the number of branching points in BDNF-injected eyes with 
glaucoma compared to glaucomatous retinas (26.29±4.35 vs. 11.96±1.85, P<0.001) 
and was not significantly different to that in controls (28.88±1.74) (Figure 5.9B). In 
contrast, other morphological features such as the total dendritic length and the 
dendritic field area were not significantly increased in BDNF-injected glaucomatous 
eyes compared to glaucoma (2306.53±298.03 pm vs. 1807.11±198.99 pm and 
60029.35±9081.45 pm2 vs. 76435.70±14171.26 pm2, respectively). While the total 
dendritic length did not differ significantly from controls (2306.53±298.03 pm vs. 
2948.47±182.60 pm), the dendritic field area was significantly lower than in controls 
(60029.35±9081.45 pm2 vs. 114028.60±11122.86 pm2, P<0.05) (Figures 5.8B & 
5.10B).
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5.2.2.2.4. Dendrite morphology in chABC+BDNF-injected glaucomatous eyes
The combined treatment of 10mU/3pl chABC lp l and 1 jj.g/jj.1 BDNF following the 3- 
4 week period of IOP elevation resulted in a significant increase in the total dendritic 
length in chABC+BDNF-injected glaucomatous retinas compared to glaucomatous 
(4306.19±481.49 pm vs. 1807.12+198.99 pm, PO.OOl) and control retinas 
(4306.19±481.49 pm vs. 2948.47+182.60 pm, PO.OOl) (Figure 5.8C). In addition, 
the total length in chABC+BDNF-injected eyes was significantly higher than in 
BDNF-injected eyes (4306.19+481.49 pm vs. 2306.53+298.03 pm, PO.Ol) (Figure 
5.8B) but not significantly higher than in chABC-injected glaucomatous retinas 
(3199.94+326.97 pm) (Figure 5.8A). In addition, the dendritic field area in 
chABC+BDNF-injected glaucomatous retinas was significantly increased compared 
to glaucomatous retinas (264754.68+40080.85 pm2 vs. 76435.70+14171.26 pm2, 
PO.OOl) and to controls (264754.68+40080.85 pm2 vs. 114028.60+11122.86 pm2, 
PO.OOl) (Figure 5.10C). In contrast, chABC+BDNF-injected glaucomatous retinas 
had a slightly reduced number of branching points compared to glaucomatous retinas 
(13.61+2.23 vs. 11.96+1.85), and there was a significant reduction compared to 
control retinas (13.61+2.23 vs. 28.88+1.74, PO.OOl) (Figure 5.9C).
5.2.2.2.5. Dendrite morphology in non-glaucomatous chABC-injected eyes
Intravitreal injection of 10mU/3pl cliABC into the normal eyes led to a significant 
increase in the total dendritic length in RGCs of non-glaucomatous chABC-injected 
retinas compared to glaucomatous retinas (1929.95+196.74 pm vs. 1807.12+198.99 
pm) (Figure 5.8D). However, it was significantly lower than in controls 
(1929.95+196.74 pm vs. 2948.47+182.60 pm, PO.05) and chABC-injected 
glaucomatous retinas (1929.95+196.74 pm vs. 3199.94+326.97 pm, P<0.001, 
Independent T-Test) (Figure 5.8A). The number of branching points was significantly 
higher in RGCs of non-glaucomatous chABC-injected retinas than in glaucomatous 
retinas (17.71+2.21 vs. 11.96+1.85, P<0.05) but significantly lower than in controls 
(17.71+2.21 vs. 28.88+1.74, P<0.05) and not significantly different from chABC- 
injected glaucomatous retinas (27.04+5.56) (Figure 5.9A). Dendritic field area was 
not significantly different in RGCs of non-glaucomatous chABC-injected retinas 
compared to glaucomatous retinas (58010.32+7907.45 pm2 vs. 76435.70+14171.26
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pm2) but was significantly lower than in controls (58010.32±7907.45 um2 vs. 
114028.60±11122.86 jam2, P<0.05) (Figure 5.10C) and significantly lower than in 
chABC-injected glaucomatous retinas (58010.32±7907.45 pm2 vs. 95866.53±8838.97 
pm2, PO .Ol) (Figure 5.10A).
5.2.2.2.6. Summary of the results
Table 5.1 summarises the morphological features identified in retinal ganglion cells 
from eyes subjected to different treatments.
5.2.3. The presence of chABC generated epitopes in the retina after intravitreal 
injections
To confirm that the intravitreal injections of chABC digested chondroitin sulphate 
proteoglycans, immunohistochemistry was conducted (section 2.4.2.3) on a single, 
non-glaucomatous retina injected with cliABC. Incubation of retinal sections with a 
mixture of monoclonal antibodies specific for chondroitinase ABC-generated 
chondroitin-6-sulphate (3B3), chondroitin-4-sulphate (2B6) and chondroitin-0- 
sulphate (1B5) disaccharide epitopes demonstrated immunostaining throughout the 
retina that was detectable 24 hours following the intravitreal injection of chABC into 
the rat eye (Figure 5.11 A). The positive control section, which was also further 
digested by chABC directly on the slide, showed strong immunostaining throughout 
the retina that was the strongest in the photoreceptor layer (Figure 5.1 IB), indicating 
that not all epitopes had been exposed by the intravitreal injection. No 
immunostaining was detected in the section incubated without primary antibodies 
(Figure 5.11C).
5.2.4. RGC cell loss in the chABC and BDNF-treated retinas
In addition to examining changes in dendrite morphology following treatments with 
chABC and BDNF, RGCs of the treated glaucomatous and non-treated contralateral 
eyes from the same rats were counted to estimate the cell loss. RGC cell losses were 
40.9%±11.4 for BDNF-injected rats and 35.8%±1.9 for chABC-injected rats 
compared to the 36.4±2.4% RGC loss in the non-treated glaucomatous eyes (section 
4.4.2).
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Figure 5.8. The total dendritic length was compared among the groups. White bars indicate 
mean values for control retinas, black for glaucoma, grey for chABC-injected glaucomatous 
retinas (A), diagonal stripes for BDNF-injected glaucomatous retinas (B), grid for 
chABC+BDNF-injected glaucomatous retinas (C) and horizontal lines for chABC-injected 
negative control retinas (D). Error bars indicate SEM. * p<0.05, ** p<0.01, ***p<0.001. N 
indicates the number o f analysed cells.
Bo
c2&
35
30
25
20
15
10
5
0
i  r
Control
n=121
I
G laucom a
n=57
ChABC
n=25
42
co
Q.O)
uc£
-Q
30
25
20
15
10
5
Control Glaucoma BDNF
n=121 n=57 n=24
a
I  -
I  *
•I 25
c
c2
■Q
20
15
A 5E3 0
Control
n=121
i
Glaucoma
n=57
ChABC+
BDNF
n=23
42
co
Q.
O)cJSoc
2
-O>4—ok
<DJQ
E
* * *i---------- 1 r
I
Controls Glaucoma Control chABC
n=121 n=57 n=23
Figure 5.9. The number of branching points was compared among the groups. White bars 
indicate mean values for control retinas, black for glaucoma, grey for chABC-injected 
glaucomatous retinas (A), diagonal stripes for BDNF-injected glaucomatous retinas (B), 
grid for chABC+BDNF-injected glaucomatous retinas (C) and horizontal lines for chABC- 
injected negative control retinas (D). Error bars indicate SEM. * p<0.05, ** p<0.01, 
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Figure 5.10. The dendritic field areas were compared among the groups. White bars 
indicate mean values for control retinas, black for glaucoma, grey for chABC-injected 
glaucomatous retinas (A), diagonal stripes for BDNF-injected glaucomatous retinas (B), 
grid for chABC+BDNF-injected glaucomatous retinas (C) and horizontal lines for chABC- 
injected negative control retinas (D). Error bars indicate SEM. * p<0.05, ** p<0.01, 
***p<0.001. N indicates the number of analysed cells.
Total dendritic length fiim) Number of branches Dendritic field area (jim )
Control n=121
Mean 2948.47 28.88 114028.60
SEM 182.60 1.74 11122.86
Glaucoma n=57
Mean 1807.12 11.96 76435.70
SEM 198.99 1.85 14171.26
Vs Control p<0.001 pO.001 p>0.05
ChABC-injected glaucoma n=25
Mean 3199.94 27.04 95866.53
SEM 326.97 5.56 8838.97
Vs Control p>0.05 p>0.05 p<0.05
Vs Glaucoma p<0.001 p<0.01 p<0.01
BDNF-injected glaucoma n=24
Mean 2306.53 26.29 60029.35
SEM 298.03 4.35 9081.45
Vs Control p>0.05 p>0.05 p<0.05
Vs Glaucoma p>0.05 p<0.001 p>0.05
ChABC+BDNF glaucoma n=23
Mean 4306.19 13.61 264754.68
SEM 481.49 2.23 40080.85
Vs Control p<0.01 p<0.001 p<0.001
Vs Glaucoma p<0.001 p>0.05 p<0.001
ChABC-injected negative control n=24
Mean 1929.95 17.71 58010.32
SEM 196.74 2.21 7907.45
Vs Control p<0.05 p<0.05 p<0.05
Vs Glaucoma p>0.05 p<0.05 p>0.05
Table 5.1. Summary of the total dendritic length, the number of branching points and the dendritic fields were estimated and compared among 
the groups. Statistical analyses were performed using Mann-Whitney Test to determine significant differences between the groups.
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Figure 5.11. Rat retinal sections from a control adult rat eye injected intravitreally with 
chondroitinase ABC. Section incubated with a mixture of antibodies specific for chondroitin- 
O-sulphate (1B5), chondroitin-4-sulphate (2B6) and chondroitin-6-sulphate (3B3) 
demonstrated immunostaining throughout the retina that was detectable 24 hours following 
the intravitreal injection of chABC into the rat eye (A). Section digested with chondroitinase 
ABC directly on the slide prior to incubation with the antibodies 1B5, 2B6 and 3B3 showed 
a strong immunostaining throughout the retina that was the strongest in the photoreceptor 
layer (B). Section incubated without primary antibodies did not show immunostaining (C). 
Scale, 100 pm.
5.3. Discussion
5.3.1. Quantification of RGC dendritic morphology
The dendritic morphology of RGCs in control and glaucomatous retinas was 
quantified and compared to the dendritic morphology of RGCs in glaucomatous 
retinas injected with chABC, BDNF or chABC+BDNF and with non-glaucomatous 
retinas injected with chABC. The study showed, for the first time, morphological 
changes in RGCs in a magnetic bead model of glaucoma. The principal finding of the 
present study is that the treatment of glaucomatous retinas with chABC resulted in a 
significant change in all investigated morphological parameters of RGCs compared to 
RGCs of non-treated glaucomatous eyes, suggesting that chABC promoted recovery 
of RGC dendritic tree in adult glaucomatous eyes.
5.3.1.1. Dendritic morphology in experimental glaucoma
Morphological changes in RGCs of glaucomatous eyes in comparison to 
contralateral control eyes were observed in a magnetic bead model of glaucoma. 
Marked pruning of the dendritic tree of labelled RGCs in glaucomatous retinas was 
observed as compared to normal. There was a statistically significant reduction in 
total dendritic length and the number of branching points in glaucomatous retinas 
compared to controls (p<0.001). Dendritic field area was modestly (by 33%) but not 
significantly reduced in glaucomatous RGCs compared to controls. The dendritic field 
of control RGCs, 114028.60±11122.86 pm2, was larger compared to the dendritic 
field estimated by Sun et al (2002), ranging from 14306.63 to 75438.5 pm2 for 
different RGC types (the dendritic field was calculated from the dendritic field 
diameter shown in Table 1). However, larger cells have been reported, with a 
dendritic field of a few hundred micrometres (Gan et al., 2000).
Morphological changes of RGCs in experimental rat glaucoma have been 
demonstrated (Morgan et al., 2006). The reduction in the dendritic field diameter for 
RGCs of the glaucomatous retinas compared to controls was 25.7% (P<0.001) 
(Morgan et al., 2006). The complexity of the dendritic field, as a number of dendritic
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branches intersecting with each ring was reduced (Morgan et al., 2006). In 
experimental primate glaucoma, there was a reduction in the size of the RGC 
dendritic arborisation, with pruning of the terminal branches followed by a reduction 
in the size of the cell bodies and axons and eventual cell death (Weber et al., 1998). 
Similarly in cat retina, soma size, dendritic field, total dendritic length, and the 
number of branch bifurcations of dendrites was significantly reduced in glaucomatous 
eyes compared to normal eyes (Shou et al., 2003). These findings might be explained 
as the apparent selective loss of larger RGCs in glaucoma or by a reduction in RGC 
dendritic tree and cell soma area. The second explanation is in agreement with clinical 
psychophysical studies that failed to show selective damage to magnocellular or 
parvocellular retinogeniculate pathways in early glaucoma (Ansari et al., 2002; 
Graham et al., 1996).
In contrast to our findings and the above studies, Ahmed et al. (2001a) observed an 
increase in the soma and dendritic field diameter of dying RGCs in eyes with elevated 
IOP, suggesting the existence of plasticity in adult retina. These observations support 
the study performed on cat retina, demonstrating that the spaces vacated by dying 
cells allowed the remaining cells to increase their dendritic field and soma size (Kirby 
and Chalupa, 1986). Also, another study found that severe optic nerve damage caused 
50% RGC death in adult rats and the surviving cells increased their cell size within 15 
days (Rousseau et al., 1999). Ahmed et al. (2001a) suggested that the likely 
explanation for the increase in dendritic trees of the surviving RGCs might be the 
presence of free synaptic endings of bipolar and amacrine cells that could stimulate 
hypertrophy of the remaining ganglion cells. Consequently, there could be the 
formation of synaptic connections by these cells onto the remaining RGCs. However, 
there is no evidence to support this hypothesis (Ahmed et al, 2001a). The contrasting 
observations of the morphological neuronal changes in glaucoma in the studies 
showing an increase and the studies showing a reduction in the dendritic field and 
soma sizes might be due to the selectivity of measurement of individual labelled 
RGCs (Ahmed et al., 2001a).
It could be argued that the morphological changes observed in glaucoma were caused 
by severing of RGC axons during the retinal whole-mount preparation and by 
mechanical shock from the gene gun. Although this possibility cannot be ruled out
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completely, the degenerative changes described here for the glaucomatous retinas are 
highly representative and vary morphologically from normal retinas that were 
subjected to the same experimental approach. Moreover, 36.4±2.4% RGC death in 
glaucomatous eyes was observed for the magnetic bead model (Chapter 4.4.2). 
Overall, it is very unlikely that the morphological RGC changes in glaucoma were 
caused by factors other than an elevated IOP. However, considering the spiking IOPs 
in some rats (Chapter 4), there is a chance that some ischaemia was induced within 
the retina.
Another argument could be that the reduction in the dendritic field size is due to an 
inability to label distal processes of degenerating ganglion cells. However, the 
termination of label at the dendrite tips was consistent with a complete fill since Dil 
has been shown to label the complete dendritic field (Huxlin and Goodchild, 1997; 
Sun et al., 2002).
5.3.I.2. Dendritic morphology after chondroitinase ABC injection
The primary goal of this study was to determine whether the bacterial enzyme 
chondroitinase ABC, by digestion of the perineuronal net, might promote retinal 
ganglion cell remodelling in experimental rat glaucoma. The results showed that the 
intravitreal injection of chABC resulted in a significant increase in the total dendritic 
length compared to the glaucomatous non-treated retinas. The total dendritic length in 
the glaucomatous eyes treated with chABC was not significantly different from 
control retinas. Also, the number of branching points was significantly higher in 
chABC-treated injured eyes than in non-treated glaucomatous eyes but not 
significantly different than in control eyes. Additionally, there was a significant 
increase in the dendritic field area in chABC-treated glaucomatous retinas compared 
to non-treated retinas from rats with glaucoma. However, the dendritic field area 
remained significantly lower in chABC-injected glaucomatous eyes than in control 
eyes. These data indicate that chABC promoted recovery of RGCs dendritic tree from 
adult rats with glaucoma. The recovered dendritic complexity was very similar to the 
complexity of control RGCs, though the recovery was still only partial.
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5.3.1.2.1. Chondroitinase ABC-promoted plasticity
A number of studies have established that the chondroitinase ABC promotes 
functional recovery in the injured CNS by degrading inhibitory chondroitin sulphate 
glycosaminoglycan chains. For example, the enzyme promoted axonal regeneration 
and the reactivation of plasticity (Crespo et al., 2007). ChABC was found to reactivate 
ocular dominance plasticity in the adult visual cortex (Pizzorusso et al., 2002; 
Pizzorusso et al., 2006) by removing the perineuronal chondroitin sulphate 
proteoglycans. Tropea et al. (2003) showed that, following injury, chABC injections 
into the partially denervated superior colliculus increased sprouting of the remaining 
retinal ganglion cell axons into the collicular scotoma. Sprouting was enhanced by 
combining BDNF with chABC (Tropea et al., 2003). In the rat cerebellum, 
degradation of CS-GAG chains by injections of chABC promoted an outgrowth of 
Purkinje axons (Corvetti and Rossi, 2005). Moreover, axon regeneration in the adult 
rat nigrostriatal tract was enhanced by the treatment with chABC (Moon et al., 2001). 
Following spinal cord injury, treatment with chABC resulted in regrowth of axons 
into the denervated territory and recovery of motor and bladder function in rats 
(Bradbury et al., 2002; Caggiano et al., 2005). ChABC also enhanced plasticity of 
intact systems within the brainstem and spinal cord after spinal cord injury (Barritt et 
al., 2006). Additionally, chABC digestion of the perineuronal nets promoted a 
functional change directly linked to anatomical evidence of sprouting by spinal cord 
afferents (Massey et al., 2006). A recent study has shown that the combined use of 
chABC, growth factors and neural stem/progenitor cells (NPCs) promoted functional 
repair and plasticity of the chronically injured spinal cord in adult rats (Karimi- 
Abdolrezaee et al., 2010). In organotypic culture, treatment with chABC increased 
the motility of dendritic spines (Chierzi et al., 2005). Since the spines are much more 
dynamic in the immature CNS than in the adult, they might indicate the occurrence of 
plasticity (Grutzendler et al., 2002). Another study showed that chABC improved 
functional recovery after peripheral nerve injury by promoting plasticity in the spinal 
cord. Thus, enhanced plasticity in the spinal cord allowed the CNS to compensate for 
inaccurate motor and sensory re-innervation of the periphery (Galtrey et al., 2007).
It has been shown that the chABC treatment did not cause detrimental effects on 
neuronal survival, alterations of visual acuity, or abnormalities of receptive field size
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and spiking activity o f visual cortical neurons (Pizzorusso et al., 2002). Similar
conclusions related to the neuronal survival were drawn after comparing RGC loss 
from the non-treated glaucomatous rats with RGC loss from chABC-treated rats with 
glaucoma. The administration of chABC did not cause a significant change in the cell 
loss in the treated eyes compared to the non-treated glaucomatous eyes.
5.3.I.3. Dendritic morphology after BDNF injection
It has been demonstrated that glaucoma-related optic nerve injury leads to the 
degeneration of retinal ganglion cells which begins with the dendritic tree, suggesting 
an opportunity for reversing glaucomatous neuropathy by applying various 
neuroprotectants (Weber et al., 1998). Brain-derived neurotrophic factor (BDNF) is 
one of the most promising neuroprotective trophic factors that has been studied (Chen 
and Weber, 2001; Weber and Harman, 2008). In addition to enhancing RGC survival, 
BDNF can also help to preserve dendritic integrity. Optic nerve injury in cats resulted 
in a significant reduction in the soma, dendritic field size and dendritic complexity 
indicated by a decrease in number of branches, total dendritic length, and dendritic 
surface area. Intravitreal treatment of the eye with BDNF at the time of injury resulted 
in enhanced preservation of soma and dendritic morphology. BDNF treatment 
resulted also in enhanced visual responses relative to no treatment (Weber and 
Harman, 2008).
The focus of the present study was to examine whether the surviving RGCs retained 
their normal dendritic morphology, an essential step towards maintaining neuronal 
function after glaucomatous injury. In this investigation, intravitreal injection of 
BDNF into the glaucomatous eye resulted in a significant increase in the number of 
dendrite bifurcations in the treated eyes with ocular hypertension compared to the 
non-treated eyes, supporting the previous study (Weber and Harman, 2008). However, 
other dendritic features, namely the total dendritic length and the dendritic field area, 
were not significantly different in the BDNF-treated glaucomatous eyes compared to 
the glaucomatous non-treated eyes. The fafct that we observed a poorer effect of 
BDNF on the preservation of dendritic integrity than Weber & Harman (2008) might 
be due to the injection being made after a period of increased IOP and different 
injection dose. While rats in the study received a single, intravitreal injection of 1 jul
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of 1 (j.g/fj.1 BDNF after approximately 3-4 weeks of IOP elevation followed by the 
period of decreased IOP (approximately 1 week), Weber & Harman (2008) injected 
either 30 or 90 pi of lpg/pl BDNF into the cat eyes immediately after optic nerve 
crush. The injected dose for the rats was consistent with studies investigating patterns 
of RGC survival following BDNF-administration in hypertensive eyes (Ko et al., 
2001). It was reported that high doses of BDNF induced inflammation and reduced 
total RGC survival but saved the medium-sized, most severely affected neurons 
following nerve injury (Chen and Weber, 2001).
In the present study, BDNF injection did not reduce RGC death in the treated 
glaucomatous retinas (40.9% ± 11.4) as compared to RGC death in the non-treated 
glaucomatous retinas (36.4 ± 2.4%, Chapter 4). This was expected since the BDNF 
was administered after the increase in IOP. In the episcleral vein cauterisation rat 
model, BDNF enhanced RGC survival in moderately chronic hypertensive eyes after 
being injected into 3 groups which received from one to three injections of BDNF on 
days 5, 19 and 33 (Ko et al., 2001). Another study demonstrated that BDNF alone 
showed only slight neuroprotection to RGCs after 4 weeks of ocular hypertension 
when injections of BDNF were received once a week on days 0, 7, 14 and 21 (Fu et 
al., 2009).
5.3.I.4. Dendritic morphology after the combined injection of chABC and BDNF
Another objective of the experiments was to test the effects of the combined treatment 
with chABC and BDNF on the preservation and recovery of dendritic morphology in 
glaucoma. A previous study showed that the combined delivery of BDNF into the eye 
and injections of chABC into the superior, colliculus produced synergistic effects 
(Tropea et al., 2003). This indicates that the combination of a neurotrophic factor that 
stimulates cellular responses essential for neurite growth with agents that change the 
brain parenchyma into a more permissive environment is particularly effective in 
triggering processes of plastic reorganisation that are essential for the return of 
function after CNS injury. The synergistic action of BDNF and chABC could be 
explained by the fact that the chABC-mediated degradation of CSPGs increased the 
accessibility of BDNF via enhanced diffusion of the neurotrophin in the tissue
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parenchyma. These results suggest that chABC acts independently from BDNF, 
although it cannot be ruled out that BDNF signalling downstream of Trk activation is 
indirectly influenced by chABC (Tropea et al., 2003). TrkB accumulation and 
retrograde transport of BDNF is interrupted at the optic nerve in acute and chronic 
experimental glaucoma, suggesting that neurotrophin deprivation plays a role in the 
pathogenesis of RGC death in glaucoma (Pease et al., 2000).
A significant increase in the total dendritic length of the chABC+BDNF-injected 
glaucomatous retinas compared to non-treated glaucomatous and control retinas was 
observed in the present study. The combined treatment resulted in a significantly 
higher total length than by treatment with BDNF alone. However, the total length 
after the combined injection was not significantly different from the total length 
observed after chABC injection alone. This result suggests that the use of BDNF in 
isolation is insufficient to effect change. The PNN represents a substantial barrier for 
recovery which has to be addressed. Dendritic field area was also significantly 
increased in the chABC+BDNF injected retinas compared to the non-treated 
glaucomatous and control retinas. In contrast, the chABC+BDNF treatment did not 
result in an increased number of branching points compared to glaucomatous and 
control retinas. The possible explanation for the fact that, in contrast to the total 
dendritic length, the number of bifurcations was not significantly increased in the 
chABC+BDNF-treated glaucomatous retinas compared to the non-treated 
glaucomatous and control retinas could be that the population of the analysed neurons 
was relatively small (23 cells). Since several morphological subtypes of rat RGCs 
have been classified (Sun et al., 2002), it is possible that not all subtypes of RGCs 
were included in the analysis.
5.3.I.5. Dendritic morphology after chABC injection into a non-glaucomatous 
retina
The last part of this chapter was to examine the effects of chABC injection on the 
dendritic morphology in a normal rat eye. Therefore, applying the same experimental 
conditions as for the chABC injection into the glaucomatous eye, chABC was injected 
into a normal eye. The results showed that the total dendritic length, the number of
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branching points and the dendritic field area were significantly lower in the non- 
glaucomatous chABC-injected retinas than in control non-treated retinas. The number 
of bifurcations was the only morphological feature that was significantly increased in 
the control chABC-injected retinas compared to the glaucomatous retinas. These data 
were not consistent with the data obtained from chABC-injected glaucomatous eyes, 
where the morphological features varied significantly from the glaucomatous eyes. 
There is a possibility that due to more scarring present in glaucoma, it could be more 
difficult to digest PNN in glaucomatous than in control retinas.
5.3.2. The presence of chABC generated epitopes in the retina after intravitreal 
injections. Distribution of CSPGs in the eye
Immunohistochemical analysis confirmed the presence of chABC generated epitopes, 
(chondroitin-6-sulphate, chondroitin-4-sulphate and chondroitin-O-sulphate) in the 
retina 24 hours after intravitreal injections, meaning that chondroitinase ABC was 
present in the retina following intravitreal injection. Based on that, it was assumed 
that chABC injections resulted in the presence of chABC in all injected retinas. 
Further digestion o f the retinal section with chABC resulted in intense 
immunostaining throughout the retina; strongest in the photoreceptor layer, indicating 
that not all epitopes had been exposed by the intravitreal injection.
Previous studies demonstrated the distribution o f chondroitin sulphate proteoglycans 
in two regions o f the retina: nerve fibers, including the optic nerve, and the 
interphotoreceptor matrix (IPM), including the surface of retinal pigment epithelium 
(RPE) cells (Inatani and Tanihara, 2002). Antibody to CSPGs derived with bovine 
nasal cartridge was specific to the sclera, anterior uveal tract and endoneurium of the 
optic nerve (Poole et al., 1982) while an antibody to brain-derived chondroitin 
sulphate proteoglycans was immunoreactive with rat retinal ganglion cells (Aquino et 
al., 1984). In addition, proteoglycans were present in large quantities in the IPM and 
on the apical surface o f RPE cells (Varner et al., 1987). The presence of CSPGs was 
indicated by the staining o f filaments with Cupronic-Blue in human trabecular 
meshwork, and the staining, derived mainly from RPE cells, was eliminated by 
treatment with chABC (Tawara et al., 1989). Immunohistochemical analysis showed 
positive immunoreactivity with the antibodies against chondroitin-6-sulphate but not
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against chondroitin-O-sulphate or the chondroitin-4-sulphate in the IPM of human, rat, 
mice and bovine retinas (Hollyfield et al., 1999). Only in the Brown Norway rat retina 
IPM labelling with chondroitin-6-sulphate was observed in the absence of chABC 
predigestion. In contrast to immunohistochemical analysis, Western blot analysis 
indicated the presence o f some positive immunoreactivity against chondroitin-4- 
sulphate in IPM extracts from mouse and rat (Hollyfield et al., 1999).
5.3.3. Fast Sholl
Sholl analysis (Sholl, 1953) is a broadly applied method for quantifying the 
characteristic scaling properties o f dendritic arbors in vivo and neuritic arbors in vitro 
(Caserta et al., 1995; Davies et al., 1993; Duan et al., 2003; Gastinger et al., 2008; 
Gutierrez et al., 2004; Gutierrez et al., 2005; Haas et al., 2006; Inatani and Tanihara, 
2002; Ip et al., 2002; Isaacs et al., 1998; Kheirandish et al., 2005; Libersat and Duch, 
2002; Lowndes et al., 1990; Mizrahi and Libersat, 2002; Neale et al., 1993; Pante et 
al., 2005; Ristanovic et al., 2006; Robinson and Kolb, 1997; Shi et al., 2004; Spires et 
al., 2004; Wood et al., 2004; Zagrebelsky et al., 2005). This analysis shows the 
distribution o f neuritic segments at regular intervals from the soma. Although this 
method has been useful in quantifying neuronal morphology, it has the disadvantage 
of being a very time-consuming method that requires grouping the neurite intersection 
points in a series o f concentric circles centred on the cell soma. This leads to 
restrictions on the number o f neurons that can be conveniently analysed. Fast Sholl is 
an alternative method for obtaining the complete Sholl profile of a population of 
neurons from a reduced set o f sampled points (bifurcations and terminal points). This 
allows for simpler and faster analysis, permitting larger size of samples to be 
analysed, with a consequently more reliable statistical treatment of the data (Gutierrez 
and Davies, 2007).
In the Sholl analysis, the cumulative number of intersection points depends on the 
number of concentric circles, thus the larger number of concentric rings, the more 
precise the analysis but the greater analysis workload involved. In contrast to this type 
of Sholl analysis method, the total information in the Fast Sholl method is included in 
a set of counted points, bifurcation and terminal points. Therefore, the method allows 
an accurate estimation o f the entire number o f intersections without the direct
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counting used in the conventional Sholl analysis. In addition, the total length of the 
dendritic tree can be calculated from the obtained data set using a standard curve 
(Gutierrez and Davies, 2007).
The precision of the Fast Sholl method in estimating the pattern of intersections 
rests on the larger number of samples. For individual meandering processes that 
intersect the same circle more than once (or even extend back towards the cell body), 
this method can lead to a minor underestimation of the number of intersections for 
those processes and, consequently, adding an error to the analysis. However, 
analysing larger numbers o f neurons prevents the significance of the statistical impact 
of such relatively rare events on the overall growth pattern (Gutierrez and Davies, 
2007). Since the number o f analysed neurons from the treated retinas was 
considerably low, ranging from 23 to 25 RGCs, the possibility of an error resulting 
from the underestimation o f the number o f intersections for this particular type of 
processes cannot be ruled out. This problem might be resolved by including additional 
samples in the analysis.
Although automated systems for Sholl analysis are available, they require extremely 
good quality images, with high contrast and no background noise (Gutierrez and 
Davies, 2007). This is difficult to obtain using ‘Diolistic’ labelling method without 
separate manual tracing and extensive editing. Although Fast Sholl method permits 
marking and counting o f the bifurcations and terminal points without the requirement 
for manual tracing, some cells had to be traced (either from stack projection or from 
the stack of images) when the quality o f images was poor or when it was difficult to 
distinguish the dendritic tree from adjacent cells. Overall, this method proved to be 
useful and efficient in quantifying the morphological features of RGC dendrites.
5.4. Summary
In summary, the results showed the significant changes in the total dendritic length 
and the number of branching points in glaucomatous retinas compared to controls in 
the magnetic bead model o f glaucoma. O f all types of intravitreal injections studied, 
only RGCs o f  chABC-treated retinas displayed a highly significant increase with 
respect to all the morphological parameters measured compared to the RGCs of
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glaucomatous eyes. The preliminary data suggest that chABC injection might be 
useful in the recovery o f neuronal damage in glaucoma. This represents an important 
potential therapy for glaucoma and other neurogenerative diseases. However, the 
results from the injection o f chABC alone suggest that it should be used with caution. 
Since CSPGs are found mainly in the interphotoreceptor matrix (Hollyfield et al., 
1999), it is possible that the use of chABC may increase the risk of retinal damage, 
e.g. retinal detachment.
With respect to all types o f tested agents and their combinations, a more detailed, 
more statistically robust analysis is needed, including testing the effects of different 
doses and times o f injections.
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Chapter 6: Chondroitin sulphate proteoglycans 
(CSPGs) in young, old and glaucomatous retina
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6.1. Introduction
Retinal ganglion cell morphology in control and glaucomatous retinas was quantified 
and compared to glaucomatous retinas injected with chABC, BDNF, chABC+BDNF 
and negative control retinas injected with chABC (Chapter 5). The intravitreal 
injection of chABC resulted in digestion of CSPGs and generation of chondroitin 
sulphate stub epitopes as confirmed by immunohistochemistry (Chapter 5). Further 
digestion with chABC resulted in a strong immunostaining throughout the retina that 
was strongest in the photoreceptor layer, indicating that not all epitopes had been 
exposed by the intravitreal injection (Chapter 5). That led us to a question whether the 
tissue localisation o f CS-GAGs might be different in glaucomatous and young retinas. 
In addition, the localisation o f aggrecan core protein in the whole rat retina was 
examined.
In addition, in Chapter 5, the possibility that RGC dendrite remodelling and shrinkage 
could be reversed and act as a neural substrate for the recovery of vision in glaucoma 
was investigated. Since the perineuronal net (PNN) represents a substantial barrier for 
recovery, digestion o f the PNN to enhance the ability of RGCs to regenerate 
following the removal o f the effect of elevated IOP was attempted. The data from 
Chapter 5 suggested that chABC might be useful in the recovery of neuronal damage 
in glaucoma. However, this raises the concern o f whether chABC digestion may have 
a harmful effect on the retina.
PNNs are a highly condensed matrix surrounding the somas and proximal dendrites of 
some types o f neurons. They develop postnatally and finally emerge as net-like 
features on the cell surface as a consequence of extracellular matrix (ECM) materials 
deposited around synaptic endings, as well as in the space between neurons and 
astrocytic processes (Rhodes and Fawcett, 2004). There are several possibilities for 
the function o f PNNs: synaptic stabilisation and limitation of synaptic plasticity 
(Hockfield et al., 1990), neuroprotection (Morawski et al., 2004) or support of ion 
homeostasis in the region o f very active neurons (Hartig et al., 1999). Extracellular 
matrix is composed of (1) glycosaminoglycans (GAGs), either bound to proteins, as 
proteoglycans, or unbound in the form o f hyaluronan; (2) fibrous proteins (e.g., 
collagens and elastin); (3) adhesive glycoproteins (e.g., fibronectin, laminin and
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tenascin) and various secreted growth factors and other molecules, many of which 
bind with different affinities to GAGs and other ECM components (Galtrey et al., 
2007). In the CNS, unlike in other tissues, ECM contains a small quantity of fibrous 
proteins and a high quantity o f GAGs (Novak and Kaye, 2000) and is organised 
around certain neurons to produce specialised condensed ECM, i.e. PNNs 
(Yamaguchi, 2000). The main components o f the ECM in the CNS are hyaluronan, 
chondroitin sulphate proteoglycans (CSPGs), link protein and tenascin (Galtrey et al., 
2007).
A number of in vitro studies demonstrated inhibitory properties of CSPGs on neurite 
outgrowth, either via their CS chains or their core proteins (Dou and Levine, 1997; 
Dou and Levine, 1994; Friedlander et al., 1994). Moreover, large aggregating 
proteoglycans, such as aggrecan and versican, can indirectly inhibit neurite outgrowth 
by high-affmity binding to the cell adhesion molecules, N-CAM and Ng-CAM/Ll 
(Friedlander et al., 1994; Grumet et al., 1993). Most CSPGs are secreted from cells 
and contribute to the formation o f extracellular matrix (ECM) (Galtrey and Fawcett,
2007). Extracellular matrix changes, predominantly the formation of CSPG- 
containing perineuronal nets, restrict plasticity after the end of critical periods. 
Enzymatic removal o f chondroitin sulphate (CS) chains with chondroitinase ABC has 
been shown to promote axonal regeneration and plasticity (Pizzorusso et al., 2002).
Experimental design
The aim of the present study was to investigate and compare the presence of 
chondroitin sulphate glycosaminoglycans (CS-GAGs) and aggrecan core protein 
epitopes in young, old and glaucomatous retinas. This was to enhance the 
understanding o f the changes that occur in the extracellular matrix in glaucoma and 
aging. Therefore, the molecular weight distribution and immunohistochemical tissue 
localisation of GAGs in young, old and glaucomatous retinas were investigated 
(sections 2.4 & 6.2). Monoclonal antibodies [(Mab): 2B6, 3B3 and 1B5 specific to 
chondroitinase-generated chondroitin-4-sulphate (C4S), chondroitin-6-sulphate (C6S), 
chondroitin-0-sulphate (COS) disaccharide epitopes (Caterson et al., 1983; Caterson et 
al., 1985; Caterson et al., 2000; Caterson et al., 1990; Ilic et al., 1992)] were 
employed. The COS, C4S and C6S epitopes are located proximal to the 
tetrasaccharide bridge (glucuronic acid-galactose-galactose-xylose) that connects the
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chondroitin GAG chain to the consensus serine residues of proteoglycan core 
proteins. Chondroitinase ABC removes all repeating chondroitin sulphate 
disaccharide units, leaving the hexasaccharide attached to serine (Hollyfield et al., 
1999).
Other monoclonal antibodies used in the study were specific to aggrecan core protein
IgD domain (394EPEEPFTFAPEI405) (6B4) (Ilic et al., 1992; Little et al., 2002;
♦.
Maeda et al., 1992), an epitope shared by both the globular 1 (G l) and the chondroitin 
sulphate (CS) attachment domains on aggrecan (7D1) (Calabro et al., 1992), the new 
C-terminus (FVDIPEN) on aggrecan degradation products produced by the 
proteolytic action o f matrix metalloproteinases (BC-4) (Hughes et al., 1995), and the 
C-terminal neoepitope sequence (NITEGE) generated after ‘aggrecanase’ catabolism 
at the same site within the aggrecan IGD (BC-13) (Caterson et al., 2000).
The core protein o f the large human cartilage proteoglycan aggrecan consists of six 
distinct domains: globular 1 (G l), interglobular, globular 2 (G2), keratan sulphate 
attachment, chondroitin sulphate (CS) attachment, and globular 3 (G3) (Hughes et al., 
1995) (Figure 6.1).
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Figure 6.1. Diagrammatic representation o f  the structural epitopes and catabolic neoepitopes on 
aggrecan (native and deglycosylated) and link protein (copied from Haye et al., 2008).
Retinas used for biochemical analysis were obtained from young normal (3 weeks 
old), old normal and old glaucomatous rat eyes (old eyes were over 6 months old) 
(section 2.4.1.1). Immunohistochemical analysis was conducted on retinal sections 
obtained from young (8 weeks old), old normal and old glaucomatous rat eyes (old 
eyes were over 6 months old) (see section 2.4.2.1).
6.2. Results
6.2.1. Western blotting
Positive immunoreactivity with 6B4 and 2B6 mAbs for GAGs was present in rat 
retina (Figures 6.2 & 6.3). All 6B4 bands appeared to increase in intensity during 
aging, however the staining was reduced in bands from glaucomatous retinas (Figure
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6.2). The multiple bands indicated the presence of highly degraded aggrecan (i.e. 
aggrecan metabolites); most predominant bands were at 60 kDa and 40 kDa. Non­
specific labelling (IgG) was detected at 50 kDa and 25 kDa. The 60 kDa band seemed 
to be lost in glaucoma. 2B6 bands had the same intensity in young and old retinas but 
slighty decreased in glaucoma (Figure 6.3). Most predominant bands were below 75 
kDa, with very weak staining of higher molecular weight. The multiple bands 
containing C4S were most predominant at 55 and 40 kDa.
6.2.2. Immunohistochemistry
Rat retinal sections from young (8 weeks old) normal rat retinas, old normal and old 
glaucomatous retinas (old eyes were over 6 months old) were digested with 
chondroitinase ABC and incubated with antibodies specific for chondroitinase ABC 
generated chondroitin-sulphate stubs (1B5, 2B6, 3B3, 6B4) (Figure 6.4), aggrecan 
core protein domains (7D1, BC4, BC13) ajid no primary antibodies (Figure 6.5). 
Overall, the staining was weaker in glaucomatous than in old normal eyes for the 
antibodies specific for chondroitin sulphate epitopes and slightly weaker for 
antibodies specific to aggrecan core protein domain or neoepitopes. 1B5 staining was 
weak throughout the retinas in young, slightly increased in old and reduced in 
glaucomatous retinas. 2B6 labelling was seen in the photoreceptor layer and weakly 
throughout the retina in young retinas; it was restricted to the photoreceptor layer in 
normal retinas and was not present in glaucomatous retinas. Very intense 6B4 staining 
was seen throughout the young retina with slightly weaker staining in the 
photoreceptor layer. In contrast, 6B4 immunoreactivity in glaucomatous and normal 
retinas was again detected throughout the retina, however stronger in RGC and 
photoreceptor layer. 3B3 immunolabeling was restricted to the photoreceptor layer in 
young, glaucomatous and normal retinas but stronger in the inner segments in young 
retinas. 7D1 immunoreactivity was detected throughout the retina, with stronger 
staining in photoreceptor layer in young and old retinas. In glaucomatous retinas, 
stronger 7D1 staining was present in the retinal ganglion cell and photoreceptor 
layers. BC-4 immunostaining was present throughout the retina with stronger staining 
in the photoreceptor layer in old and glaucomatous retinas. No staining was present in
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that were not incubated with primary antibodies.
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Figure 6.2. Western blot analysis of GAGs from old, young (3 weeks old), old normal and 
old glaucomatous rat retinas. 6B4 recognises aggrecan and aggrecan metabolites. Bands 
from old normal retinas were stained more intensely than those from old glaucomatous 
eyes. The weakest staining intensity was present in a track with bands from young retinas. 
Molecular weight standards are shown on the left hand side of the gel. Non-specific bands, 
50 and 25 kDa, are marked by red oval lines.
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Figure 6.3. Western blot analysis of GAGs from old, young (3 weeks old), old normal and 
old glaucomatous rat retinas. 2B6 recognises chondroitinase-generated chondroitin-4- 
sulphate (C4S). Molecular weight standards are shown on the left hand side of the gel. 
Non-specific bands, 50 and 25 kDa, are marked by red oval lines.
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Figure 6.4. Rat retinal sections from 8 weeks old, old normal and old glaucomatous eyes 
(both over 6 months old) were incubated with antibodies specific for chondroitin-O- 
sulphate (1B5), chondroitin-4-sulphate (2B6), chondroitin-6-sulphate (3B3) and aggrecan 
core protein IgD domain (6B4). The (+) notation indicates that the sections were 
predigested with chondroitinase ABC to expose the stub epitopes prior to incubation with 
1B5, 2B6 and 3B3 antibodies.
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Figure 6.5. Rat retinal sections from 8 weeks old, old normal and old glaucomatous eyes 
(both over 6 months old) were incubated were incubated with antibodies specific for 
(7D1), (BC-4), (BC-13) and no primary antibodies (No 1°).
6.3. Discussion
In the current study, molecular weight distribution and immunohistochemical tissue 
localisation of chondroitin sulphate proteoglycans and aggrecan core proteins were 
compared in young, old normal and old glaucomatous rat retinas.
The 6B4 and 2B6 bands appeared to increase in intensity during aging, however the 
staining was reduced in bands from glaucomatous retinas. The 6B4 bands indicated 
highly degraded aggrecan while 2B6 bands indicated the presence of chondroitin-4- 
sulphate proteoglycans. MAb anti-IGD (6B4) recognises a specific linear amino acid 
sequence EPEEPFTFAPEI present in the interglobular domain (IGD) of human and 
bovine aggrecan but not other animal species (Hayes et al., 2008). However, our 
results showed the presence of 6B4 epitopes in rat retina. The fact that the reduced 
staining intensity was observed in bands from glaucomatous retinas indicates a 
possible reduction in aggrecan content in glaucoma. The presence of aggrecan in a rat 
spinal cord was previously investigated using Western blot analysis, showing similar 
findings to what was observed in rat retina. Namely, aggrecan species were similar in 
the developing and adult spinal cord; ho\vever, adult spinal cord injury led to 
significant reduction in aggrecan content (Lemons et al., 2001).
An interesting finding of the study is that immunoreactivity of the antibodies specific 
to chondroitin sulphate epitopes (1B5, 2B6 and 3B3) was strongest in the 
photoreceptor layer of the retina, while immunoreactivity of the antibodies specific to 
aggrecan core protein IGD domain (6B4), neoepitope sequence (BC-4) and an epitope 
shared by both the Gl and the CS attachment domains on aggrecan (7D1) was found 
throughout the retina in the inner retina, including the INL, the IPL, and the RGCL. 
This indicates that chondroitin sulphate proteoglycans are mainly localised to the 
interphotoreceptor matrix (IPM), whilst aggrecan core protein to the inner retina. This 
might also imply that the CS-GAG attachment regions of aggrecan have been 
removed. Aggrecan usually has many CS epitopes, therefore weak co-localisation 
with 6B4 outside the IPM is unusual. It would appear that these aggrecan 6B4 
fragments do not contain detectable CS epitopes. Also, Western blotting analysis 
indicates that aggrecan was highly digested, but the reason is unknown. It could be 
that the aggrecan breakdown is needed for a normal retinal function. In addition,
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Western blotting analysis of 2B6 implies some aggrecan fragments have C4S but the 
staining was weak.
Since BC-4 antibody is specific to aggrecan degradation products generated by 
metalloproteinases while BC-13 to aggrecan degradation products generated by 
aggrecanases, the fact that only BC-4 staining was observed might imply that retinal 
aggrecan is digested predominantly by metalloproteinases. These findings raise the 
possibility that neuronal plasticity in the RGCL could be enhanced by digestion with 
enzymes other than chondroitinase ABC. Since the CS-PGS are involved in retinal 
attachment, digestion with ABC could cause retinal detachments. There is a 
possibility that an upregulation of metalloproteinases in the inner retina might prevent 
outer retinal damage.
Hollyfield et al. (1999) investigated the distribution of chondroitin-type proteoglycans 
in interphotoreceptor matrix (IPM) of Brown Norway rat retinas and aimed to identify 
the chondroitin-type proteoglycan core proteins present in IPM samples. According to 
Hageman et al. (1991), “The interphotoreceptor matrix (IPM) occupies the 
extracellular space between the photoreceptors of the retina and the apical surface of 
the retinal pigmented epithelium”. A great proportion of the IPM consists of aqueous- 
insoluble glycoconjugates, including chondroitin sulphate-containing proteoglycans 
(Hageman et al., 1991). Immunohistochemical analysis showed intense staining 
against chondroitin-6-sulphate (3B3) in IPM in both digested and undigested retinas 
with chondroitinase ABC. This is consistent with our results as no labelling was 
observed in the IPM stained with the chondroitin-O-sulphate (unsulphated) (1B5) or 
the chondroitin-4-sulphate (2B6) antibodies before or after chondrotinase ABC 
digestion. In contrast, we detected 1B5 and 2B6 immunoreactivity in the 
photoreceptor layer and weakly throughout the normal retina and 2B6 
immunoreactivity in young retinas. However, 1B5 immunoreactivity was absent in 
young and glaucomatous retinas, and 2B6 immunoreactivity was absent in 
glaucomatous retinas. Hollyfield et al. (1999) observed some scleral labelling in 
chondrotinase ABC treated samples with all three antibodies that was eliminated after 
double digestion with chondrotinase ABC and chondrotinase AC II. In Western blots 
using 2B6 antibody, two prominent immunoreactive bands were observed, one at 
approximately 230 kDa and the other at approximately 150 kDa in chondroitinase
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ABC treated IPM samples. These results were different from our findings, showing 
multiple 2B6 bands most predominant at 100, 75, 70 kDa.
Degradation of cartilage is characteristic to arthropathies and involves proteolytic 
cleavage of its main structural elements, i.e. aggrecan and type II collagen. As an 
early event in cartilage degeneration, proteolysis and subsequent loss of the GAG rich 
region of aggrecan from cartilage occur (Cawston et al., 1998). Although there was a 
degradation of aggrecan within the retina, no consequent damage to the retina was 
observed. Thus, the function of aggrecan in retina remains unknown.
6.4. Chapter summary
The present study confirmed the existence of a perineuronal net in the rat retina and 
demonstrated the distribution of CS-GAGs and aggrecan core proteins in young, old 
and glaucomatous retinas. Our preliminary, results indicate that molecular weight 
distribution and immunohistochemical tissue localisation of glycosaminoglycans 
might vary in younger, older and glaucomatous rat retinas. Chondroitin sulphate 
proteoglycans were mainly localised to the photoreceptor layer, while aggrecan core 
protein to the inner retina. Aggrecan was highly degraded in young, old and 
glaucomatous retinas. Future study could involve further investigation on molecular 
weight distribution and immunohistochemical tissue localisation of 
glycosaminoglycans in younger, older and glaucomatous rat retinas.
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Chapter 7: General discussion
7.1. Summary
Glaucoma is the second leading cause of vision loss in the world (Thylefors et al., 
1995; Quigley, 1996). In the commonest form of the disease, chronic open angle 
glaucoma, increased intraocular pressure (IOP) is associated with accelerated death of 
retinal ganglion cells (RGCs) and consequent loss of visual field. Although lowering 
IOP can stop or slow the progression of glaucoma, currently there is no treatment to 
recover lost vision. Neuroplasticity is the ability for a neural system to remodel and 
repair following injury. If surviving damaged tissue could be regenerated on the basis 
of its intrinsic plasticity in glaucomatous eye, visual impairment associated with 
glaucoma might be potentially reversed. The principal aim of the project was to 
determine if RGC remodelling in glaucoma could be driven by the combined 
therapeutic intervention of IOP reduction and manipulation of retinal perineuronal 
nets.
There are conflicting opinions about the events that occur prior to RGC cell death in 
glaucoma. While some early studies suggested that larger RGCs were more 
susceptible to the effects of increased intraocular pressure (Quigley et al., 1989; 
Quigley et al., 1987), more recent studies showed that RGCs actually shrink (Morgan 
et al., 2000; Morgan 2002; Shou et al., 2003; Weber and Harman, 2005; Weber and 
Harman, 2008; Weber et al., 1998) prior to cell death. These later observations 
suggested that morphological changes can occur in RGCs that would affect cell 
function some time before cell death (Weber and Harman, 2005). Therefore, there is a 
possibility that there is a window opportunity for the administration of 
neuroprotective agents in order to prevent RGC death. It also raises a question about 
how the reduction in the number of RGCs would affect the dendrodendritic 
interactions that delimit the size of the dendritic tree. The loss of RGC caused by the 
elevated IOP is known to result in an expansion of adjacent dendritic trees to fill 
regions vacated by the dendritic trees of dead cells (Ahmed et al., 2001a), similar to 
what was previously observed in the developing retina (Perry and Linden, 1982). This 
neuroplastic response, when combined with the administration of neurotrophic agents, 
could potentially lead to the restoration of cellular morphology (Weber and Harman,
2008). Such a neuroplastic response in adult tissue could be exploited by the 
coadministration of agents (such as chondroitinase ABC) that disrupt the
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glycosaminoglycan perineuronal net that limits the extent to which adult neurons can 
recover from injury. The manipulation of the perineuronal ECM can promote 
plasticity with beneficial effects on neuronal structure and function (Crespo et al., 
2007; Fawcett, 2009; Pizzorusso et al., 2002). To evaluate the extent to which retinal 
neuroplasticity and retinal neuronal survival can be enhanced to permit visual 
recovery in experimental glaucoma, both in vivo (Chapters 4, 5 & 6) and ex vivo 
(Chapter 3) models of glaucoma were employed.
The purpose of the initial part of the study was to establish an in vitro model of 
glaucoma to analyse morphological changes of RGCs over a period of time (Chapter 
3). Retinal explant cultures serve as a highly suitable model of glaucoma since the 
explanation of the retina requires the severing of all axons within the optic nerve and 
the consequential degeneration of RGCs; axonal damage is the chief suspect in the 
development of glaucoma. This system is particularly useful for experiments that 
cannot be performed in vivo due to limitations involving tissue access, confounding 
systemic factors, or control over microenvironment (Johnson and Tomarev, 2010). To 
establish retinal explant culture, culture conditions and biolistic transfection 
parameters were optimised. During the course of experiments, it was established that 
the helium pressure for the gene gun, the pore size of the filter used to protect from 
the shock wave and the age of animals were critical to the survival and the successful 
transfection. Once the conditions were optimised, further experiments were conducted 
using a broad-spectrum caspase inhibitor and BDNF to study their effects on neuronal 
survival and the formation of axonal growth cones. Broad-spectrum caspase inhibitor 
enhanced RGC survival and the number of axons in the proximity of the optic disc 
whereas exogenous BDNF enhanced the number of growth cones on the axons of 
RGCs. The present observations showing that caspase inhibitor had an effect on the 
survival of RGCs in culture are consistent with previous studies (Manabe et al., 2002; 
Oshitari and Adachi-Usami et al., 2003). The findings from this in vitro study implied 
that the regrowth of RGC axons could potentially be stimulated in the adult retina, 
encouraging further investigation with the use of in vivo rat models of glaucoma.
The main part of the project was conducted using two rat glaucoma models, induced 
by either injection of hypertonic saline into the episcleral veins to sclerose the 
trabecular meshwork (Morrison et al., 1997) or injection of paramagnetic microbeads
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into the anterior chamber (Chapter 4). Since the induction of glaucoma with 
hypertonic saline resulted in a low rate of rats with a sustained increase in IOP (33%), 
we developed a novel technique for the induction of ocular hypertension using 
paramagnetic microbeads (Chapter 4). Glaucoma models based on obstruction of the 
trabecular meshwork with microscopic beads have been used both in rats (Urcola et 
al., 2006) and in primates (Weber and Zelenak, 2001). The injection of paramagnetic 
microbeads into the anterior chamber was technically undemanding and provided a 
measure of control over the distribution of bqads within the anterior segment. Using a 
handheld magnet, the beads could be drawn away from the visual axis and distributed 
around the iridocorneal angle to optimise occlusion of the trabecular meshwork and 
facilitate visualisation of the retina and optic disc. A sustained IOP increase was 
obtained in 64% of rats and a fluctuating increase in 36% of rats. The degree of cell 
loss in our model (36.4%) was similar to that reported for other models (Ahmed et al., 
2001a; Ahmed et al., 2001b; Naskar et al., 2002; Neufeld et al., 1999). The use of 
Optical Coherence Tomography validated the bead and hypertonic saline glaucoma 
models, by revealing a thinning of the retinal fibre layer over time in vivo as well as 
optic nerve head cupping in vivo and ex vivo (Chapter 4).
Following the successful development of a magnetic bead model (Chapter 4), it was 
time to determine whether dendritic tree morphology of RGCs in glaucoma could be 
influenced by the administration of agents that have previously been shown to 
promote plasticity in the CNS. Since chondroitinase ABC (chABC) influences 
plasticity by enzymatic digestion of the PNN (Kwok et al., 2008), the enzyme was 
injected intravitreally to promote retinal ganglion cells regeneration in glaucoma 
(Chapter 5). In addition, the effect of brain-derived neurotrophic factor on the 
preservation of the dendritic field complexity (Weber and Herman, 2008) was also 
investigated. The combined treatment of BDNF and chABC had effects on axon 
growth and synapse formation by the sprouting axons, implying the potential of this 
approach in therapies for the repair of the damaged adult CNS (Tropea et al., 2003).
Our results indicated that chABC promoted recovery of RGCs dendritic tree, when 
used alone or in combination with BDNF. Only treatment with chABC demonstrated 
a significant increase with respect to all the morphological parameters measured 
compared to the RGCs of glaucomatous eyes (Chapter 5). This represents an
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important potential therapy for glaucoma and other neurogenerative diseases. 
However, the results from the injection of chABC alone suggest that it should be used 
with caution (Chapter 5). Since chondroitin sulphate proteoglycans (CS-PGs) are 
found mainly in the interphotoreceptor matrix (Hollyfield et al., 1999; Inatani and 
Tanihara, 2002) (Chapter 6), it is possible that the use of chABC may increase the risk 
of retinal damage, e.g. retinal detachment.
CS-PGs have been demonstrated to have inhibitory properties on neurite outgrowth, 
either via their CS chains or their core proteins (Dou and Levine, 1997; Dou and 
Levine, 1994; Friedlander et al., 1994). Moreover, large aggregating proteoglycans, 
such as aggrecan and versican, can indirectly inhibit neurite outgrowth by high- 
affinity binding to the cell adhesion molecules, N-CAM and Ng-CAM/Ll 
(Friedlander et al., 1994; Grumet et al., 1993). The intravitreal injection of chABC 
resulted in digestion of CSPGs and generation of chondroitin sulphate stub epitopes as 
confirmed by immunohistochemistry (Chapter 5). Further digestion with chABC 
resulted in a strong immunostaining throughout the retina that was strongest in the 
photoreceptor layer, indicating that not all epitopes had been exposed by the 
intravitreal injection (Chapter 5). That led us to question whether the tissue 
localisation of CS-GAGs might be different in glaucomatous, old and young retinas. 
In addition, the localisation of aggrecan core protein in the whole rat retina was 
examined. Our study confirmed the existence of a perineuronal net in the rat retina 
and indicated that the molecular weight distribution and immunohistochemical tissue 
localisation of glycosaminoglycans varied in young, old and glaucomatous rat retinas 
(Chapter 6). Chondroitin sulphate proteoglycans were mainly localised to the 
photoreceptor layer, while aggrecan core protein was limited to the inner retina 
(Chapter 6). An interesting finding was that the positive staining with BC-4 but not 
BC-13 antibody suggested that aggrecan is digested predominantly by 
metalloproteinases, raising the possibility that neuronal plasticity in the RGCL could 
be enhanced by digestion with enzymes other than chondroitinase ABC (Chapter 6). 
This alternative approach might reduce likelihood of retinal detachment that could be 
caused by chondroitinase ABC digestion of CS-PGs, since CS-PGs are specifically
involved in retinal attachment. Aggrecan was highly degraded in young, old and
glaucomatous retinas, without any consequent damage to the tissue, leaving an 
unanswered question about its role in retina.
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7.2. Future work
In Chapter 3, we have magnified the potential for increased RGC survival and the 
number of axons in the proximity to the optic disc in explants treated with caspase 
inhibitor. In addition, the number of growth cones was increased in explants treated 
with BDNF. It will be interesting to see if we can observe axonal and dendritic 
changes in RGCs in retinal explants over a period of time following the use of 
chondroitinase ABC and BDNF.
In Chapter 4, we introduced and evaluated a novel model of induction of experimental 
glaucoma using paramagnetic microspheres. The model could be further improved by 
testing different sizes of magnetic beads and different hand-held magnets to prolong 
the period of an elevated IOP following a single injection. Also, further investigation 
using Optical Coherence Tomography should be conducted to evaluate changes in the 
retinal fibre layer over a period of time in vivo.
Of all the types of intravitreal injections studied in Chapter 5, treatment with chABC 
demonstrated the most significant results. RGCs of chABC-treated retinas displayed a 
highly significant increase in all of the morphological parameters measured as 
compared to the RGCs of glaucomatous eyes. With respect to all types of tested 
agents and their combinations, a more detailed, more statistically robust analysis is 
needed, including testing the effects of different doses and times of injections.
We have characterised the tissue localisation and protein expression of CS-GAGs and 
aggrecan core proteins in young, aged and glaucomatous retinas 
immunohistochemical and western-blotting analyses (Chapter 6). Further experiments 
should be conducted to confirm these results and to further characterise protein 
expression in these groups of retinas. Also, the role of aggrecan in retina should be 
further examined.
7.3. Conclusion
In conclusion, the study led to the development of a novel rat glaucoma model and, 
more importantly, demonstrated potential for dendritic regeneration of RGCs in 
glaucoma.
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